PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	WE	SC	GA	UT	PM	OA	HC	HP	DA
J	Lisi, DM				Lisi, Donna M.			Pros and Cons of Pharmacy Compounding	US PHARMACIST			English	Article									[Lisi, Donna M.] Hackensack Meridian Hlth, Eatontown, NJ USA		Lisi, DM (通讯作者)，Hackensack Meridian Hlth, Eatontown, NJ USA.						AlphaScrip Inc, PROS CONS COMP MED; Bell EA, 2012, BENEFITS RISKS COMPO; FDA, COMP LAWS POL; FDA, FD C ACT PROV APPL H; FDA, DIFF STRENGTH EXPR P; FDA, COMP INSP REC OTH AC; FDA, FACTS CURR GOOD MAN; FDA, COMP RISK AL; Glassgold J., 2013, COMPOUNDED DRUGS; Gudeman J, 2013, DRUGS R&D, V13, P1, DOI 10.1007/s40268-013-0005-9; Jackson LM, 2020, COMPOUNDED TOPICAL P, P4; Janusziewicz AN, 2021, AM J HEALTH-SYST PH, V78, P1438, DOI 10.1093/ajhp/zxab176; Kainer Marion, 2012, Morbidity and Mortality Weekly Report, V61, P839; Le P, 2011, J GENERIC MED, V8, P210; McLernon LM, DRUG COMPOUNDING HEL; McPherson T, 2016, J MANAG CARE SPEC PH, V22, P172, DOI 10.18553/jmcp.2016.22.2.172; Mohiuddin AK, 2018, IP INT J COMPREHENSI, P3124; National Association of Boards of Pharmacy, 2015, FDA ISS GUID ADV EV; Pew Charitable Trusts, MARK COMP DRUGS NEED; Piatek OI, 2020, AM J HEALTH-SYST PH, V77, P1778, DOI 10.1093/ajhp/zxaa228; Todorova A, 2016, IAIM, V3, P45; U.S. Department of Health and Human Services/U.S. Food and Drug Administration/Center for Drug Evaluation and Research (CDER)/ Office of Compliance/OUDLC, COMP DRUG PROD AR ES; U.S. Food & Drug Administration, 2017, FDAS HUM DRUG COMP P; United States Pharmacopoeia, PROP UPD USP GEN CHA; Watson CJ, 2021, J MED TOXICOL, V17, P197, DOI 10.1007/s13181-020-00814-3	25	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	NOV	2021	46	11					8	12					5	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	XB5IC	WOS:000721361900001					2022-04-28	
J	Dellarocca, MA				Dellarocca, Mena Alrais			Key Updates From the 2020 AHA Pediatric Basic Life Support Guidelines	US PHARMACIST			English	Article							HEART-ASSOCIATION GUIDELINES; CARDIOPULMONARY-RESUSCITATION; CHEST COMPRESSIONS; BRADYCARDIA	The American Heart Association (AHA) guidelines for pediatric basic and advanced life support and the International Liaison Committee on Resuscitation (ILCOR) treatment recommendations were updated in 2020. In terms of basic life support for pediatric patients, the AHA guidelines continue to emphasize high-quality cardiopulmonary resuscitation (CPR)-i.e., chest compressions of adequate rate and depth, full chest recoil with each compression, minimal interruptions, and avoidance of excessive ventilation. In infants and children receiving CPR who have an advanced airway in place or who have a pulse but are undergoing rescue breathing, a key update is the recommendation to increase the respiratory rate to 20 to 30 breaths per minute (one breath every 2-3 seconds). Pharmacists should be aware of these important changes from previous guidelines, as a growing body of pediatric-specific evidence supports these new recommendations.	[Dellarocca, Mena Alrais] Univ Southern Calif, Sch Pharm, Pharm Practice, Los Angeles, CA 90007 USA		Dellarocca, MA (通讯作者)，Univ Southern Calif, Sch Pharm, Pharm Practice, Los Angeles, CA 90007 USA.						Berg MD, 2010, CIRCULATION, V122, pS862, DOI 10.1161/CIRCULATIONAHA.110.971085; Berg RA, 2001, CIRCULATION, V104, P2465, DOI 10.1161/hc4501.098926; Donoghue A, 2009, PEDIATRICS, V124, P1541, DOI 10.1542/peds.2009-0727; Donoghue AJ, 2020, PEDIATR EMERG CARE, V36, P267, DOI 10.1097/PEC.0000000000002109; Duff JP, 2019, CIRCULATION, V140, pE904, DOI 10.1161/CIR.0000000000000731; Edelson DP, 2020, CIRCULATION, V141, pE933, DOI 10.1161/CIRCULATIONAHA.120.047463; Kern KB, 2002, CIRCULATION, V105, P645, DOI 10.1161/hc0502.102963; Khera R, 2019, CIRCULATION, V140, P370, DOI 10.1161/CIRCULATIONAHA.118.039048; Kleinman ME, 2010, CIRCULATION, V122, pS876, DOI 10.1161/CIRCULATIONAHA.110.971101; Maconochie IK, 2020, RESUSCITATION, V156, pA120, DOI 10.1016/j.resuscitation.2020.09.013; Nolan JP, 2020, CIRCULATION, V142, pS2, DOI 10.1161/CIR.0000000000000890; Sutton RM, 2019, CRIT CARE MED, V47, P1627, DOI 10.1097/CCM.0000000000003898; Topjian AA, 2020, CIRCULATION, V142, pS469, DOI 10.1161/CIR.0000000000000901	13	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	AUG	2021	46	8					HS2	HS9					8	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	UB4JE	WOS:000685813400004					2022-04-28	
J	[Anonymous]				[Anonymous]			Device Detects Skin Disorders Based on Tissue Stiffness	US PHARMACIST			English	News Item																		0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	AUG	2021	46	8					36	37					2	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	UB4JE	WOS:000685813400012					2022-04-28	
J	Pal, S				Pal, Somnath			Patterns of Vaccination in Infants and Toddlers	US PHARMACIST			English	Editorial Material									[Pal, Somnath] St Johns Univ, Coll Pharm & Hlth Sci, Pharm Adm, Jamaica, NY 11439 USA		Pal, S (通讯作者)，St Johns Univ, Coll Pharm & Hlth Sci, Pharm Adm, Jamaica, NY 11439 USA.							0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	APR	2021	46	4					14	14					1	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	SE9UN	WOS:000652412200008					2022-04-28	
J	[Anonymous]				[Anonymous]			COVID-19 Vaccines	US PHARMACIST			English	Editorial Material													Ndwandwe, Duduzile/L-2296-2013	Ndwandwe, Duduzile/0000-0001-7129-3865				0	0	0	1	2	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	FEB	2021	46	2											2	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	QU8YE	WOS:000627563600006					2022-04-28	
J	Davidson, R				Davidson, Robert			COVID-19 Conferring Worse Stroke Outcomes	US PHARMACIST			English	Editorial Material												rdavidson@uspharmacist.com						0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	JAN	2021	46	1					3	3					1	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	PY9CO	WOS:000612338200001					2022-04-28	
J	DeRuiter, J; Holston, PL				DeRuiter, Jack; Holston, Pamela L.			Review of Selected NMEs 2021	US PHARMACIST			English	Article								New molecular entities (NMEs) are defined by the FDA as new drug products containing a chemical substance marketed for the first time in the United States as their active ingredient. The following descriptions of NMEs approved in 2020-2021 (TABLE 1) detail the basic pharmacologic and clinical profile for each new drug, as well as key precautions and warnings. Also included is a brief summary of selected pharmacokinetic, adverse reaction, drug interaction and dosing data submitted to the FDA in support of the manufacturer's new drug application. The information for each NME was obtained primarily from sources published prior to FDA approval. Experience clearly demonstrates that many aspects of a new drug's therapeutic profile, not detected in premarketing studies, emerge after the drug is used in the population in general. For example, "new" adverse reactions for many NMEs often emerge within 2 to 3 years of their first becoming available. Some of these drugs may eventually acquire black box warnings for serious adverse drug reactions or be withdrawn from the market for safety reasons that were not recognized at the time of approval. Therefore, while this review offers an initial assessment of newly approved drugs, it is essential that practitioners become aware of changes in a drug's therapeutic profile as reported in the pharmaceutical literature and by patients.	[DeRuiter, Jack] Auburn Univ, Harrison Sch Pharm, Dept Drug Discovery & Dev, Auburn, AL 36849 USA; [Holston, Pamela L.] Keystone Peer Review Org, Harrisburg, PA USA		DeRuiter, J (通讯作者)，Auburn Univ, Harrison Sch Pharm, Dept Drug Discovery & Dev, Auburn, AL 36849 USA.						[Anonymous], 2021, ZEGALOGUE DASIGLUCAG; [Anonymous], 2021, TEPMETKO TEPOTINIB P; [Anonymous], 2020, MARGENZA MARGETUXIMA; [Anonymous], 2021, VEKLURY REMDESIVIR P; [Anonymous], 2021, ZYNLONTA LONCASTUXIM; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Caimi PF, 2021, LANCET ONCOL, V22, P790, DOI 10.1016/S1470-2045(21)00139-X; Hovelmann U, 2019, DIABETES OBES METAB, V21, P601, DOI 10.1111/dom.13562; Paik PK, 2020, NEW ENGL J MED, V383, P931, DOI 10.1056/NEJMoa2004407; Rugo HS, 2021, JAMA ONCOL, V7, P573, DOI 10.1001/jamaoncol.2020.7932	10	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	OCT	2021	46	10					HS1	HS10					10	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	WI6KL	WOS:000708466800003					2022-04-28	
J	[Anonymous]				[Anonymous]			Managing Complications of Cystic Fibrosis	US PHARMACIST			English	Editorial Material																	Beck RW, 2017, JAMA-J AM MED ASSOC, V317, P371, DOI 10.1001/jama.2016.19975; Welsh JB, 2019, DIABETES TECHNOL THE, V21, P128, DOI 10.1089/dia.2018.0374	2	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	JUL	2021	46	7											3	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	TP3SU	WOS:000677515000006					2022-04-28	
J	Bookwalter, CM				Bookwalter, Christina M.			Dispensing Proper Asthma Inhaler Education to Pediatric Patients	US PHARMACIST			English	Article								Over 5.5 million children in the United States have a diagnosis of asthma, but children have high rates of poor inhaler technique. Inhaled therapy is the backbone of asthma treatment, necessitating that inhaler-technique education be incorporated at all points of care. Children require individualized teaching to meet appropriate developmental needs. The teach-back method, print and video resources, and interactive technology are options to meet individual learning needs. Dispensing pharmacists are often the last healthcare provider to come in contact with a child before independent inhaler administration, consequently making it imperative for pharmacists to take responsibility for providing developmentally targeted inhaler-technique education.	[Bookwalter, Christina M.] Womack Army Med Ctr, Ft Bragg, NC 28310 USA		Bookwalter, CM (通讯作者)，Womack Army Med Ctr, Ft Bragg, NC 28310 USA.						Abraham Olufunmilola, 2017, J Pediatr Pharmacol Ther, V22, P412, DOI 10.5863/1551-6776-22.6.412; Allergan, LEARN US YOUR AEROCH; Allergy and Asthma Network, CHOOS RIGHT ASTHM DE; American Academy of Allergy Asthma and Immunology, DRY POWD INH DEF; American Association for Respiratory Care, 2017, PAT GUID AER MED DEL; American College of Chest Physicians, 2006, US YOUR MDI SPAC MAS; Anderson P., 2006, INT J CHRONIC OBSTR, V1, P251; Axtell Samantha, 2017, J Pharm Pract, V30, P195, DOI 10.1177/0897190016628961; Centers for Disease Control (CDC), MOST REC NAT ASTHM D; El-Rachidi Sarah, 2017, Hosp Pharm, V52, P124, DOI 10.1310/hpj5202-124; Gillette C, 2016, ACAD PEDIATR, V16, P605, DOI 10.1016/j.acap.2016.04.006; Global Initiative for Asthma, 2019, GLOB STRAT ASTHM MAN; MassDiGl, WIZD PETS; Mickel CF, 2017, J SCH NURS, V33, P189, DOI 10.1177/1059840516659912; Mistry N., APP REV PEDIAT ASTHM; Montefiore Applications LLC, 2020, ASTHMAXCEI ADV; National Heart Lung and Blood Institute, GUID NAT ASTHM ED PR; Pai A., 2015, CHILDRENS HLTH LAUNC; Postelnicu L, 2019, NEW APP USES GAMIFIC; Teachbacktraining.org, 2020, ALW US TEACH BACK US; van Aalderen WM, 2015, NPJ PRIM CARE RESP M, V25, DOI 10.1038/npjpcrm.2014.88; Wilson EAH, 2010, PATIENT EDUC COUNS, V80, P393, DOI 10.1016/j.pec.2010.07.011	22	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	APR	2021	46	4					40	45					6	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	SE9UN	WOS:000652412200015					2022-04-28	
J	Sucher, A; Daigle, M; Truex, M				Sucher, Allana; Daigle, Melissa; Truex, Michael			Review of Treatment of Healthcare-Associated Ventriculitis and Meningitis in Adults	US PHARMACIST			English	Review								Healthcare-associated ventriculitis and meningitis is a serious infection that most commonly has a bacterial etiology, including Gram-positive and Gram-negative microorganisms. According to guidelines released by the Infectious Diseases Society of America, the recommended empiric antimicrobial treatment for these types of infections is vancomycin in combination with an antipseudomonal beta-lactam-either cefepime, ceftazidime, or meropenem. Therapy should be modified and directed toward the identified pathogen, with a typical treatment duration of 10 to 14 days. Pharmacists are in a key position to understand the diagnostic challenges and recommend appropriate empiric and directed antimicrobial treatment for the management of these infections.	[Sucher, Allana] Regis Univ, Sch Pharm, Pharm Practice, Denver, CO 80221 USA; [Daigle, Melissa; Truex, Michael] Regis Univ, Sch Pharm, Denver, CO USA		Sucher, A (通讯作者)，Regis Univ, Sch Pharm, Pharm Practice, Denver, CO 80221 USA.							0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	APR	2021	46	4											5	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	SE9UN	WOS:000652412200007					2022-04-28	
J	Davidson, R				Davidson, Robert			Scientists Isolate New, Potent Antibody Against SARS-CoV-2	US PHARMACIST			English	Editorial Material												rdavidson@uspharmacist.com						0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	OCT	2021	46	10					4	4					1	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	WI6KL	WOS:000708466800001					2022-04-28	
J	Pal, S				Pal, Somnath			Breastfeeding Trends in Infants	US PHARMACIST			English	Editorial Material									[Pal, Somnath] St Johns Univ, Pharm Adm, Coll Pharm & Hlth Sci, Jamaica, NY 11439 USA		Pal, S (通讯作者)，St Johns Univ, Pharm Adm, Coll Pharm & Hlth Sci, Jamaica, NY 11439 USA.							0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	AUG	2021	46	8					14	14					1	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	UB4JE	WOS:000685813400006					2022-04-28	
J	[Anonymous]				[Anonymous]			Most Patients Find Teledermatology Appointments Suitable	US PHARMACIST			English	News Item																		0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	AUG	2021	46	8					34	34					1	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	UB4JE	WOS:000685813400009					2022-04-28	
J	Viswanath, N; Lee, CS				Viswanath, Nishanth; Lee, Chung-Shien			Contemporary Developments in MET-Selective Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer	US PHARMACIST			English	Article								Mesenchymal epithelial transition (MET) alterations are noted in up to 5% of non-small-cell lung cancer (NSCLC) cases and can present as either a MET exon 14 skipping mutation or MET amplifications. MET-selective kinase inhibitors have become available for the treatment of NSCLC in recent years and have displayed remarkable efficacy in clinical studies to date. Capmatinib and tepotinib are both approved for the treatment of MET-dysregulated advanced NSCLC, and savolitinib and glumetinib are currently under investigation for their application in the MET-mutated environment.	[Viswanath, Nishanth; Lee, Chung-Shien] St Johns Univ, Coll Pharm & Hlth Sci, Queens, NY 11439 USA; [Viswanath, Nishanth; Lee, Chung-Shien] Donald & Barbara Zucker Sch Med Hofstra Northwell, Northwell Hlth Canc Inst, Div Med Oncol & Hematol, Lake Success, NY USA		Viswanath, N (通讯作者)，St Johns Univ, Coll Pharm & Hlth Sci, Queens, NY 11439 USA.							0	0	0	2	4	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	JUL	2021	46	7					36	42					7	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	TP3SU	WOS:000677515000011					2022-04-28	
J	[Anonymous]				[Anonymous]			What Is Prenatal Care?	US PHARMACIST			English	Editorial Material								Prenatal care is healthcare that you get while you are pregnant. Receiving early and regular care during your pregnancy is one of the best ways to improve your chances of a healthy pregnancy. Prenatal visits usually include a physical exam, weight checks, and checking your urine. They may also include blood tests and ultrasound exams. If you are pregnant or think you are pregnant, schedule an appointment with your doctor as soon as you can.										0	0	0	1	2	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	JUL	2021	46	7					22	22					1	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	TP3SU	WOS:000677515000008					2022-04-28	
J	Davidson, R				Davidson, Robert			Men's Blood Contains More Enzyme That Helps COVID-19 Infect Cells	US PHARMACIST			English	Editorial Material												rdavidson@uspharmacist.com						0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	JUN	2021	46	6					1	1					1	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	SR7UE	WOS:000661251200001					2022-04-28	
J	Pope, H				Pope, Hannah			Making a case for IV KENGREAL (R) (cangrelor)	US PHARMACIST			English	Editorial Material																		0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	OCT	2021	46	10					24	25					2	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	WI6KL	WOS:000708466800009					2022-04-28	
J	Saljoughian, M				Saljoughian, Manouchehr			The Benefits and Limitations of Telehealth	US PHARMACIST			English	Article									[Saljoughian, Manouchehr] Alta Bates Summit Med Ctr, Dept Pharm, Berkeley, CA 94705 USA		Saljoughian, M (通讯作者)，Alta Bates Summit Med Ctr, Dept Pharm, Berkeley, CA 94705 USA.						Croymans D, 2020, NEJM CATALYST; Dorsey ER, 2016, NEW ENGL J MED, V375, P154, DOI 10.1056/NEJMra1601705; Lee JY, 2018, DIABETES TECHNOL THE, V20, P492, DOI 10.1089/dia.2018.0098; Liaw WR, 2019, J AM MED INFORM ASSN, V26, P420, DOI 10.1093/jamia/ocy182; Mermelstein H., 2017, J TECHNOL BEHAV SCI, V2, P5, DOI [10.1007/s41347-017-0010-x, DOI 10.1007/S41347-017-0010-X]; Nieman CL, 2020, ANN INTERN MED, V173, P831, DOI 10.7326/M20-1322; Office of the National Coordinator for Health Information Technology, WHAT IS TEL DIFF TEL; Ong MK, TELEMEDICINE ADULTS; Ramirez AV, 2021, OTOLARYNG HEAD NECK, V164, P91, DOI 10.1177/0194599820947667; Weinstein RS, 2014, AM J MED, V127, P183, DOI 10.1016/j.amjmed.2013.09.032	10	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	AUG	2021	46	8					5	8					4	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	UB4JE	WOS:000685813400002					2022-04-28	
J	Alrais, M				Alrais, Mena			Implications of COVID-19 for the Mental Health of Pharmacists	US PHARMACIST			English	Article								Coronavirus disease 2019 ( COVID-19) has had a detrimental impact on the mental health of healthcare workers ( HCWs). As frontline workers, pharmacists have experienced an escalation in many areas of responsibility, often increasing their burden, frustration, and stress and negatively impacting their mental health and well-being. Although most stress symptoms are temporary, normal, and will resolve on their own, HCWs are likely to benefit from access to mental-health resources that can address sources of anxiety and distress. Awareness of the warning signs of emotional distress and developing practices to alleviate stress may help. Pharmacist managers can encourage self- care and provide pharmacy staff with resources to help them better cope.	[Alrais, Mena] Univ Southern Calif, Sch Pharm, Pharm Practice, Los Angeles, CA 90007 USA		Alrais, M (通讯作者)，Univ Southern Calif, Sch Pharm, Pharm Practice, Los Angeles, CA 90007 USA.							0	0	0	1	1	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	JUN	2021	46	6					25	29					5	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	SR7UE	WOS:000661251200009					2022-04-28	
J	Davidson, R				Davidson, Robert			Pandemic Fomenting Familial Mental Health Challenges	US PHARMACIST			English	Editorial Material												rdavidson@uspharmacist.com						0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	MAY	2021	46	5					1	1					1	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	SE9UV	WOS:000652413000001					2022-04-28	
J	Mithawala, P; Davis, DM				Mithawala, Priyam; Davis, Daijah M.			Underlying Body Dysmorphic Disorder in Patients With Zoom Dysmorphia	US PHARMACIST			English	Editorial Material								The coronavirus 2019 pandemic has caused dramatic changes in daily life, primarily in terms of social connections. Many people are using videoconferencing via Zoom and similar programs as a means of communication for work, school, and social events. As a result, Zoom dysmorphia-which can potentially cause or worsen body dysmorphic disorder (BDD)-is a growing concern. Owing to the lack of FDA-approved agents for BDD, treatment involves psychosocial and pharmacologic therapies that target the underlying issues. It is important to identify underlying BDD in Zoom-dysmorphic patients and to use published guidelines, multimodal treatment strategies, and individual patient response to determine the best approach for effective BDD management.	[Mithawala, Priyam] Presbyterian Coll Sch Pharm, Pharm Practice, Clinton, SC 29325 USA; [Davis, Daijah M.] Presbyterian Coll Sch Pharm, Clinton, SC 29325 USA		Mithawala, P (通讯作者)，Presbyterian Coll Sch Pharm, Pharm Practice, Clinton, SC 29325 USA.							0	0	0	0	3	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	MAY	2021	46	5					HS1	HS6					6	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	SE9UV	WOS:000652413000008					2022-04-28	
J	Mithawala, PK; Thomas, NM				Mithawala, Priyam K.; Thomas, Natai M.			Managing Social Anxiety Disorder	US PHARMACIST			English	Article							PLACEBO	Anxiety disorders, which are the most common psychiatric illnesses, often go undiagnosed or undertreated. Social anxiety disorder (SAD) involves the persistent, intense fear of being observed or judged in social situations, such as public speaking or interactive settings, and affects a person's quality of life by impacting relationships, work or school, and social activities. Common comorbidities in patients with SAD include cardiovascular, neurologic, gastrointestinal, respiratory, autoimmune, and endocrine disorders. Psychological and pharmacologic approaches are used to treat SAD. It is important to consider treatment guidelines and patient-related factors in choosing the best therapy for a patient with SAD, and pharmacists' comprehensive knowledge of drugs and ability to evaluate drug therapy are essential in treatment management.	[Mithawala, Priyam K.] Presbyterian Coll Sch Pharm, Pharm Practice, Clinton, SC 29325 USA; [Thomas, Natai M.] Presbyterian Coll Sch Pharm, Clinton, SC 29325 USA		Mithawala, PK (通讯作者)，Presbyterian Coll Sch Pharm, Pharm Practice, Clinton, SC 29325 USA.						American Psychiatric Association, DSM HIST; [Anonymous], 2020, PHARM J, DOI DOI 10.1016/J.AGEE.2020.107141; Baldwin DS, 2014, J PSYCHOPHARMACOL, V28, P403, DOI 10.1177/0269881114525674; Bandelow B, 2017, DIALOGUES CLIN NEURO, V19, P93; Blanco C, 2002, BIOL PSYCHIAT, V51, P109, DOI 10.1016/S0006-3223(01)01294-X; Boyers GB, 2017, COGN BEHAV THERAPY, V46, P507, DOI 10.1080/16506073.2017.1338310; Craske MG, 2016, LANCET, V388, P3048, DOI 10.1016/S0140-6736(16)30381-6; Eaves S, 2020, J AM PHARM ASSOC, V60, pS11, DOI 10.1016/j.japh.2020.04.017; Farzam K, 2020, BETABLOCKERS; Frick A, 2021, CURR PHARM TEACH LEA, V13, P608, DOI 10.1016/j.cptl.2021.01.027; Garakani A, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.595584; Griffin CE, 2013, OCHSNER J, V13, P214; Hormone Health Network, WHAT IS SER; Koyuncu Ahmet, 2019, Drugs Context, V8, P212573, DOI 10.7573/dic.212573; Liebowitz MR, 2005, ARCH GEN PSYCHIAT, V62, P190, DOI 10.1001/archpsyc.62.2.190; Marazziti D, 2014, CLIN NEUROPSYCHIATR, V11, P91; Martin EI, 2009, PSYCHIAT CLIN N AM, V32, P549, DOI 10.1016/j.psc.2009.05.004; Melton ST, 2020, PHARMACOTHERAPY PATH, V11th; National Collaborating Centre for Mental Health (UK), 2013, NICE CLIN GUID; National Institute for Health and Care Excellence, 2021, CLIN GUID; Sartori SB, 2019, PHARMACOL THERAPEUT, V204, DOI 10.1016/j.pharmthera.2019.107402; Schneier FR, 2006, NEW ENGL J MED, V355, P1029, DOI 10.1056/NEJMcp060145; Sills GJ, 2006, CURR OPIN PHARMACOL, V6, P108, DOI 10.1016/j.coph.2005.11.003; Sobnosky JL, 2014, US PHARM, V39, P56; Steenen SA, 2016, J PSYCHOPHARMACOL, V30, P128, DOI 10.1177/0269881115612236; Stein MB, 2008, LANCET, V371, P1115, DOI 10.1016/S0140-6736(08)60488-2; Substance Abuse and Mental Health Services Administration, 2016, DSM 5 CHANG IMPL CHI; Vaishnavi S, 2007, PROG NEURO-PSYCHOPH, V31, P1464, DOI 10.1016/j.pnpbp.2007.06.027; VanAmeringen M, 1996, J AFFECT DISORDERS, V39, P115, DOI 10.1016/0165-0327(96)00030-4; Williams T, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001206.pub3	30	0	0	2	2	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	MAY	2021	46	5					23	27					5	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	SE9UV	WOS:000652413000013					2022-04-28	
J	[Anonymous]				[Anonymous]			Pneumonia	US PHARMACIST			English	Editorial Material																		0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	APR	2021	46	4					15	16					2	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	SE9UN	WOS:000652412200009					2022-04-28	
J	DeMaagd, G				DeMaagd, George			An Introduction to Hypnic Headache	US PHARMACIST			English	Article								Hypnic headache (HH) is a rare primary headache disorder that occurs most commonly in persons older than age 50 years and awakens the patient from sleep. The first case of HH was not identified until 1988, and the rarity of this disorder has resulted in limited data on diagnosis and management. The pain, duration, and frequency of HH can present in variable fashion, but the defining factor is waking from sleep at roughly the same time each night. Case reports and anecdotal evidence suggest that potential treatments are limited to pharmacologic options including caffeine, lithium, indomethacin, melatonin, amitriptyline, and some anticonvulsants. Nonpharmacologic management options for HH may be helpful, but they require further evaluation.	[DeMaagd, George] Union Univ, Acad Affairs, Coll Pharm, Jackson, TN 38305 USA		DeMaagd, G (通讯作者)，Union Univ, Acad Affairs, Coll Pharm, Jackson, TN 38305 USA.							0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	JAN	2021	46	1					17	20					4	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	PY9CO	WOS:000612338200005					2022-04-28	
J	Smith, C; Neumiller, JJ				Smith, Connor; Neumiller, Joshua J.			Nonalcoholic Fatty Liver Disease Primer for Pharmacists	US PHARMACIST			English	Article							INSULIN-RESISTANCE; PIOGLITAZONE; MANAGEMENT; DIAGNOSIS	Nonalcoholic fatty liver disease (NAFLD) is a condition that affects nearly a quarter of the U.S. population. Nonalcoholic steatohepatitis, the more severe form of NAFLD, is associated with an increased risk for cirrhosis and poor health outcomes. NAFLD is a common comorbidity in patients with type 2 diabetes and/or obesity, but it often remains undiagnosed. There are currently no FDA-approved medications for the treatment of NAFLD. Weight loss is the cornerstone of management through lifestyle interventions and the use of pharmacologic and/or surgical treatments to promote weight loss in appropriate patients. Research with select glucose-lowering medications is ongoing.	[Smith, Connor; Neumiller, Joshua J.] Washington State Univ, Dept Pharmacotherapy, Coll Pharm & Pharmaceut Sci, Spokane, WA 99202 USA		Smith, C (通讯作者)，Washington State Univ, Dept Pharmacotherapy, Coll Pharm & Pharmaceut Sci, Spokane, WA 99202 USA.						[Anonymous], 2019, DIABETES CARE, V42, pS1, DOI [10.2337/dc19-SINT01, 10.2337/dc19-Sint01]; Armstrong MJ, 2016, LANCET, V387, P679, DOI 10.1016/S0140-6736(15)00803-X; Belfort R, 2006, NEW ENGL J MED, V355, P2297, DOI 10.1056/NEJMoa060326; Bhatt HB, 2015, HEPATOL SURG NUTR, V4, P101, DOI 10.3978/j.issn.2304-3881.2015.01.03; Bril F, 2018, CLIN GASTROENTEROL H, V16, P558, DOI 10.1016/j.cgh.2017.12.001; Bril F, 2017, DIABETES CARE, V40, P419, DOI 10.2337/dc16-1787; Budd J, 2020, AM J MED, V133, P536, DOI 10.1016/j.amjmed.2020.01.007; Chalasani N, 2018, HEPATOLOGY, V67, P328, DOI 10.1002/hep.29367; Choi DH, 2018, ENDOCRINOL METAB, V33, P387, DOI 10.3803/EnM.2018.33.3.387; Cusi K, 2016, ANN INTERN MED, V165, P305, DOI 10.7326/M15-1774; Cusi K, 2009, CLIN LIVER DIS, V13, P545, DOI 10.1016/j.cld.2009.07.009; Eriksson JW, 2018, DIABETOLOGIA, V61, P1923, DOI 10.1007/s00125-018-4675-2; Gaggini M, 2013, NUTRIENTS, V5, P1544, DOI 10.3390/nu5051544; Inoue M, 2019, J DIABETES INVEST, V10, P1004, DOI 10.1111/jdi.12980; Itani T, 2018, OBES SCI PRACT, V4, P477, DOI 10.1002/osp4.294; Kuchay MS, 2020, DIABETOLOGIA, V63, P2434, DOI 10.1007/s00125-020-05265-7; Kuchay MS, 2018, DIABETES CARE, V41, P1801, DOI 10.2337/dc18-0165; Mathurin P, 2009, GASTROENTEROLOGY, V137, P532, DOI 10.1053/j.gastro.2009.04.052; Musso G, 2012, DIABETOLOGIA, V55, P885, DOI 10.1007/s00125-011-2446-4; National Institute of Diabetes and Digestive and Kidney Diseases, DEF FACTS NAFLD NASH; Newsome PN, 2021, NEW ENGL J MED, V384, P1113, DOI 10.1056/NEJMoa2028395; Saponaro C, 2015, CURR DIABETES REP, V15, DOI 10.1007/s11892-015-0607-4; Shimizu M, 2019, DIABETES OBES METAB, V21, P285, DOI 10.1111/dom.13520; Soccio RE, 2014, CELL METAB, V20, P573, DOI 10.1016/j.cmet.2014.08.005; Spengler EK, 2015, MAYO CLIN PROC, V90, P1233, DOI 10.1016/j.mayocp.2015.06.013; Tomah Shaheen, 2020, Clin Diabetes Endocrinol, V6, P9, DOI 10.1186/s40842-020-00097-1; Younossi ZM, 2020, DIABETES CARE, V43, P283, DOI 10.2337/dc19-1113	27	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	OCT	2021	46	10					HS11	HS16					6	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	WI6KL	WOS:000708466800004					2022-04-28	
J	Panesar, K				Panesar, Kiran			Investigational Antivirals for Managing COVID-19	US PHARMACIST			English	Article							AZITHROMYCIN	The COVID-19 pandemic has presented the global research community with the greatest challenge of its generation. Safe and effective therapeutic agents are limited, and there are hundreds of ongoing clinical trials. Remdesivir is the only antiviral that is currently FDA approved for the management of COVID-19. This article discusses the mode of action of current investigational antiviral agents, the evidence of their effectiveness, and clinical trials that are currently being conducted in the United States.									Abd El-Aziz TM, 2020, INFECT GENET EVOL, V83, DOI 10.1016/j.meegid.2020.104327; Al-Horani RA, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12101092; [Anonymous], 2017, PLAQ PACK INS; [Anonymous], 2016, KAL PACK INS; [Anonymous], 2020, VEKL PACK INS; [Anonymous], STROM PACK INS; [Anonymous], 2011, COP PACK INS; [Anonymous], 2017, AR PACK INS; [Anonymous], 2016, AL PACK INS; Arshad S, 2020, INT J INFECT DIS, V97, P396, DOI 10.1016/j.ijid.2020.06.099; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Cai QX, 2020, ENGINEERING-PRC, V6, P1192, DOI 10.1016/j.eng.2020.03.007; Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787; Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282; Cavalcanti AB, 2020, NEW ENGL J MED, V383, P2041, DOI 10.1056/NEJMoa2019014; Cennimo D., 2020, MEDSCAPE; Chen C, FAVIPIRAVIR VERSUS A, V2020, DOI [10.1101/2020.03.17.20037432, DOI 10.1101/2020.03.17.20037432]; Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658; Coomes EA, 2020, J ANTIMICROB CHEMOTH, V75, P2013, DOI 10.1093/jac/dkaa171; Elfiky AA, 2020, LIFE SCI, V248, DOI 10.1016/j.lfs.2020.117477; Furtado RHM, 2020, LANCET, V396, P959, DOI 10.1016/S0140-6736(20)31862-6; Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410; Goldman JD, 2020, NEW ENGL J MED, V383, P1827, DOI 10.1056/NEJMoa2015301; Horby PW, 2020, LANCET, V396, P1345, DOI 10.1016/S0140-6736(20)32013-4; Kelleni MT, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104874; Khalili JS, 2020, J MED VIROL, V92, P740, DOI 10.1002/jmv.25798; Li YP, 2020, MED-CAMBRIDGE, V1, P105, DOI 10.1016/j.medj.2020.04.001; Lian N, 2020, CLIN MICROBIOL INFEC, V26, P917, DOI 10.1016/j.cmi.2020.04.026; Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0; Lythgoe MP, 2020, TRENDS PHARMACOL SCI, V41, P363, DOI 10.1016/j.tips.2020.03.006; NIH, COVID 19 TREATM GUID; Prudon, 2020, EFFECT HYDROXYCHLORO, DOI [10.1101/2020.07.15.20151852, DOI 10.1101/2020.07.15.20151852]; Rafter JC, 2020, CHEST; ROCCO P, 2021, EUR RESPIR J, DOI DOI 10.1183/13993003.03725-2020; Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630; Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019; Schoergenhofer C, 2020, ANN INTERN MED, V173, P670, DOI 10.7326/M20-1550; Spinner CD, 2020, JAMA-J AM MED ASSOC, V324, P1048, DOI 10.1001/jama.2020.16349; Wang DY, 2020, J INFECT PUBLIC HEAL, V13, P1405, DOI 10.1016/j.jiph.2020.07.004; Wang X, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0169-8; Wang ZL, 2020, CLIN INFECT DIS, V71, P769, DOI 10.1093/cid/ciaa272; WHO Solidarity Trial Consortium, 2021, NEW ENGL J MED, V384, P497, DOI 10.1056/NEJMoa2023184	42	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	FEB	2021	46	2					29	35					7	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	QU8YE	WOS:000627563600010					2022-04-28	
J	[Anonymous]				[Anonymous]			Age Affects Gender-Related Heart Attack	US PHARMACIST			English	Editorial Material																		0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	FEB	2021	46	2					43	44					2	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	QU8YE	WOS:000627563600013					2022-04-28	
J	De la Cruz, A; Imran, A; Thai, R				De la Cruz, Austin; Imran, Aroge; Thai, Raymond			Pharmacist Review of Loperamide Abuse	US PHARMACIST			English	Review								Loperamide is a common OTC antidiarrheal medication, also known as Imodium, that has been targeted as a drug of abuse by those seeking to relieve opioid withdrawal symptoms or achieve a euphoric high. Loperamide is a synthetic opioid agonist that lacks central nervous system effects when taken as directed. When taken at supratherapeutic doses, however, loperamide can cross the blood-brain barrier and lead to a variety of adverse effects, including cardiovascular-related complications. A concerning rise in overdose cases and fatalities associated with loperamide overdose has prompted the FDA to limit the amount of loperamide available in OTC packages. Pharmacists should be aware of the patterns of loperamide abuse and diversion and understand how to implement effective measures to prevent patient harm within their practice setting.	[De la Cruz, Austin; Imran, Aroge; Thai, Raymond] Univ Houston, Coll Pharm, Houston, TX 77030 USA		De la Cruz, A (通讯作者)，Univ Houston, Coll Pharm, Houston, TX 77030 USA.							0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	DEC	2021	46	12					43	56					14	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	XY4CD	WOS:000736921600010					2022-04-28	
J	Hilas, O				Hilas, Olga			A Pharmacist's Primer on Prescription Discount Cards	US PHARMACIST			English	Article								According to recent data, approximately 49% of individuals in the United States use at least one prescription medication monthly, making the affordability of prescription medications a key consideration in patient care. Prescription discount cards, most of which are available at no cost, offer savings to patients who may lack insurance or adequate coverage for their brand or generic medication costs. Numerous programs that provide such cost savings are available, and these cards can be used at many pharmacies across the U.S. The actual savings can vary from pharmacy to pharmacy and card to card. It is important for pharmacists to understand how these discount cards work in order to help patients manage their prescription expenses and to address potential adherence issues related to financial barriers.	[Hilas, Olga] St Johns Univ, Coll Pharm & Hlth Sci, Queens, NY 11439 USA		Hilas, O (通讯作者)，St Johns Univ, Coll Pharm & Hlth Sci, Queens, NY 11439 USA.						[Anonymous], AM J MANAG CARE; Doherty K., GOODRX BUY PERELMANS; Feke T., BEST PRESCRIPTION DI; Hernandez I, 2020, JAMA-J AM MED ASSOC, V323, P854, DOI 10.1001/jama.2020.1012; Kirzinger A, KFF HLTH TRACKING PO; Moriates C., ADDRESSING AFFORDABI; National Center for Health Statistics, THER DRUG US; Sagall RJ, DRUG DISCOUNT CARDS	8	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	OCT	2021	46	10					21	23					3	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	WI6KL	WOS:000708466800008					2022-04-28	
J	Renaud, A; Mahdavian, S; Smith, UD; Larose-Pierre, M; Carter, C; Honeywell, M				Renaud, Amy; Mahdavian, Soheyla; Smith, Ukamaka Dike; Larose-Pierre, Margareth; Carter, Chenita; Honeywell, Marlon			The Dexcom G6 Continuous Glucose Monitoring System	US PHARMACIST			English	Editorial Material							INSULIN INJECTIONS		[Renaud, Amy] Florida A&M Univ, Coll Pharm & Pharmaceut Sci, Tallahassee, FL 32307 USA; [Mahdavian, Soheyla; Smith, Ukamaka Dike; Honeywell, Marlon] Florida A&M Univ, Coll Pharm & Pharmaceut Sci, Pharm Practice, Tallahassee, FL 32307 USA; [Larose-Pierre, Margareth; Carter, Chenita] Florida A&M Univ, Coll Pharm & Pharmaceut Sci, Pharm Practice, Crestview, FL USA		Renaud, A (通讯作者)，Florida A&M Univ, Coll Pharm & Pharmaceut Sci, Tallahassee, FL 32307 USA.						Abbott Diabetes Care Inc, LIBRELINKUP FAQS; Amer Diabet Assoc, 2010, DIABETES CARE, V33, pS11, DOI 10.2337/dc10-S011; [Anonymous], Dexcom CLARITY; Beck RW, 2017, ANN INTERN MED, V167, P365, DOI 10.7326/M16-2855; Beck RW, 2017, JAMA-J AM MED ASSOC, V317, P371, DOI 10.1001/jama.2016.19975; Centers for Disease Control and Prevention (CDC), 2020, NATL DIAB STAT REP 2; Dexcom, 2020, DAT FIL; Dexcom Inc., DEXC G6 CONT GLUC MO; Dexcom Inc, 2020, DEXC CARE; FDA, 510 K PREM NOT DEXC; Puhr S, 2019, DIABETES TECHNOL THE, V21, P155, DOI 10.1089/dia.2018.0359; Reddy M, 2018, DIABETIC MED, V35, P483, DOI 10.1111/dme.13561; Welsh JB, 2019, DIABETES THER, V10, P751, DOI 10.1007/s13300-019-0571-0; Welsh JB, 2019, DIABETES TECHNOL THE, V21, P128, DOI 10.1089/dia.2018.0374	14	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	OCT	2021	46	10					18	20					3	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	WI6KL	WOS:000708466800007					2022-04-28	
J	Etzel, JV; Ambizas, EM				Etzel, Joseph V.; Ambizas, Emily M.			Pharmacist's Role in Prenatal Care and Safe Medication Use	US PHARMACIST			English	Editorial Material									[Etzel, Joseph V.; Ambizas, Emily M.] St Johns Univ, Coll Pharm & Hlth Sci, Queens, NY 11439 USA; [Ambizas, Emily M.] Walgreens Pharm, Whitestone, NY USA		Etzel, JV (通讯作者)，St Johns Univ, Coll Pharm & Hlth Sci, Queens, NY 11439 USA.							0	1	1	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	JUL	2021	46	7					18	21					4	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	TP3SU	WOS:000677515000007					2022-04-28	
J	Shipley, S; Bryant, C; Darais, D				Shipley, Scott; Bryant, Casey; Darais, Dallin			Sphingosine-1 Phosphate Receptor Modulators in the Treatment of Multiple Sclerosis	US PHARMACIST			English	Article								Multiple sclerosis (MS) is an autoimmune disease that attacks the central nervous system, affecting nearly 1 million people in the United States. Recently, two new sphingosine-1 phosphate (SIP1) receptor modulators, siponimod and ozanimod, were FDA-approved for the treatment of clinically isolated syndrome, relapsing-remitting MS (RRMS), and secondary progressive MS (SPMS). In clinical trials, ozanimod was found to significantly reduce the annualized relapse rate in patients with RRMS compared with interferon. Siponimod was compared against placebo in patients with SPMS and showed a statistically significant decrease in disability progression at 3 months. A review of newly approved SIP1 therapy illustrates further advancements and therapy options for decreased relapse rate and progression in adult MS patients.	[Shipley, Scott] Roseman Univ Hlth Sci, Pharm Practice, Henderson, NV 89014 USA; [Bryant, Casey; Darais, Dallin] Utah Valley Hosp, Provo, UT USA		Shipley, S (通讯作者)，Roseman Univ Hlth Sci, Pharm Practice, Henderson, NV 89014 USA.							0	0	0	4	4	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	JAN	2021	46	1					HS1	HS5					5	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	PY9CO	WOS:000612338200003					2022-04-28	
J	Sucher, A; Heinrich, A; Ramsey, S				Sucher, Allan; Heinrich, Amy; Ramsey, Sydnee			Treatment and Prevention of Community-Acquired Bacterial Meningitis	US PHARMACIST			English	Article								Bacterial meningitis is a serious infection that requires immediate treatment. Recommended empiric antimicrobial therapy is based upon the most likely pathogen, according to a patient's age and immune status. Antimicrobial therapy should be modified after identification of the causative microorganism and results of susceptibility tests. Preventive measures include the use of vaccines that target Neisseria meningitidis, Haemophilus influenzae, and Streptococcus pneumoniae, as well as the use of chemoprophylaxis in selected situations. Pharmacists are in a key position to recommend appropriate antimicrobial therapy for the treatment and prophylaxis of bacterial meningitis and to ensure that patients are receiving recommended vaccinations.	[Sucher, Allan; Heinrich, Amy; Ramsey, Sydnee] Regis Univ, Sch Pharm, Denver, CO 80221 USA		Sucher, A (通讯作者)，Regis Univ, Sch Pharm, Denver, CO 80221 USA.							0	0	0	1	2	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	JAN	2021	46	1					HS6	HS12					7	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	PY9CO	WOS:000612338200010					2022-04-28	
J	Mathew, DS; Ng, KE; Jacob, EC				Mathew, Daniya S.; Ng, Kimberly E.; Jacob, Elsen C.			Management of Euglycemic Diabetic Ketoacidosis	US PHARMACIST			English	Article							INHIBITORS	Euglycemic diabetic ketoacidosis (EDKA) is a rare, acute, life-threatening emergency that is characterized by euglycemia, metabolic acidosis, and ketoacidosis. Unlike DKA, the diagnosis of EDKA is often overlooked because of the absence of hyperglycemia. The mechanism behind EDKA involves a general state of starvation that results in ketosis while normoglycemia is maintained. EDKA may be associated with precipitating factors, including sodium-glucose cotransporter 2 inhibitors, starvation, pregnancy, alcohol use, surgery, and drug-induced intoxication. A stepwise approach is used in the management of EDKA. Pharmacists can assist the medical team in preventing EDKA and can play a role in the management of EDKA.	[Mathew, Daniya S.] St Johns Univ, Coll Pharm & Hlth Sci, New York, NY 11439 USA; [Ng, Kimberly E.; Jacob, Elsen C.] St Johns Univ, Coll Pharm & Hlth Sci, Dept Clin Hlth Profess, New York, NY USA		Mathew, DS (通讯作者)，St Johns Univ, Coll Pharm & Hlth Sci, New York, NY 11439 USA.						Abu-Abed Abdin Asma, 2016, Case Rep Crit Care, V2016, P4275651, DOI 10.1155/2016/4275651; American Diabetes Association, 2018, STAND MED CAR DIAB 2; [Anonymous], 2016, INVOKANA CANAGLIFLOZ; [Anonymous], 2020, FARXIGA DAPAGLIFLOZI; Blau JE, 2017, DIABETES-METAB RES, V33, DOI 10.1002/dmrr.2924; Bonora BM, 2020, CURR DIABETES REP, V20, DOI 10.1007/s11892-020-01307-x; Burge MR, 2001, METABOLISM, V50, P171, DOI 10.1053/meta.2001.20194; Chauhan S P, 1996, J Perinatol, V16, P173; Diaz-Ramos A, 2019, INT J EMERG MED, V12, DOI 10.1186/s12245-019-0240-0; Erondu N, 2015, DIABETES CARE, V38, P1680, DOI 10.2337/dc15-1251; FDA, FDA WARNS SGLT2 INHI; Handelsman Y, 2016, ENDOCR PRACT, V22, P753, DOI 10.4158/EP161292.PS; Jaber JF, 2019, CASE REP CRIT CARE, V2019; Kitabchi AE, 2009, DIABETES CARE, V32, P1335, DOI 10.2337/dc09-9032; Larroumet A, 2020, NUTRITION, V72, DOI 10.1016/j.nut.2019.110668; METZGER BE, 1982, LANCET, V1, P588; Muneer M, 2021, ADV EXP MED BIOL, V1307, P85, DOI 10.1007/5584_2020_545; MUNRO JF, 1973, BRIT MED J, V2, P578, DOI 10.1136/bmj.2.5866.578; Nakamura K, 2014, INTERNAL MED, V53, P1071, DOI 10.2169/internalmedicine.53.1791; Nasa P, 2021, WORLD J DIABETES, V12, P514, DOI 10.4239/wjd.v12.i5.514; Nathan DM, 2017, NEW ENGL J MED, V377, P2390, DOI 10.1056/NEJMe1711296; Owen D, 2008, INTENS CARE MED, V34, P971, DOI 10.1007/s00134-007-0950-2; Perry RJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08466-w; Peters AL, 2015, DIABETES CARE, V38, P1687, DOI 10.2337/dc15-0843; Plewa MC, 2021, STATPEARLS; Prater J, 2015, AACE CLIN CASE REP, V1, P388; Pujara S, 2017, J INVEST MED HIGH IM, V5, DOI 10.1177/2324709617710040; Rawla P, 2017, ENDOCRINOL DIAB META, DOI 10.1530/EDM-17-0081; Rosenstock J, 2015, DIABETES CARE, V38, P1638, DOI 10.2337/dc15-1380; Sarnyai Z, 1998, NEUROENDOCRINOLOGY, V68, P334, DOI 10.1159/000054382; Sinha Nupur, 2014, Case Rep Crit Care, V2014, P906283, DOI 10.1155/2014/906283; Svart MV, 2015, CLIN DIABETES, V33, P37; Tahrani AA, 2013, LANCET DIABETES ENDO, V1, P140, DOI 10.1016/S2213-8587(13)70050-0	33	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	NOV	2021	46	11					HS1	HS6					6	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	XB5IC	WOS:000721361900002					2022-04-28	
J	[Anonymous]				[Anonymous]			Prediabetes	US PHARMACIST			English	Editorial Material																		0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	NOV	2021	46	11					15	16					2	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	XB5IC	WOS:000721361900005					2022-04-28	
J	Lisi, DM				Lisi, Donna M.			Addressing Medication Overload	US PHARMACIST			English	Article								Medication overload, another term for polypharmacy, is ubiquitous especially among older adults. It is estimated that two-thirds of those aged 65 years and older use five or more medications, including prescription, OTC, and supplements, daily. The Lown Institute published a national action plan in which it addresses the issue of medication overload and outlines five categories of interventions and 11 recommendations. Among the strategies identified in the action plan are implementing a prescription checkup, raising awareness about medication overload, improving information on deprescribing at the point of care, educating and training healthcare professionals on deprescribing, and reducing pharmaceutical-industry influence in the prescribing process.	[Lisi, Donna M.] Hackensack Meridian Hlth, Eatontown, NJ 07724 USA		Lisi, DM (通讯作者)，Hackensack Meridian Hlth, Eatontown, NJ 07724 USA.							0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	JUL	2021	46	7					23	28					6	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	TP3SU	WOS:000677515000009					2022-04-28	
J	[Anonymous]				[Anonymous]			Activity Is Good; Varied Activity Is Better	US PHARMACIST			English	News Item																		0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	MAY	2021	46	5					8	8					1	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	SE9UV	WOS:000652413000006					2022-04-28	
J	[Anonymous]				[Anonymous]			Pervasive, With Wide-Ranging Symptoms	US PHARMACIST			English	Editorial Material								Persistent low mood, low energy, and loss of interest in activities and hobbies-these are the hallmark symptoms of depression-a significant and growing public health issue. It is estimated that as many as one in five individuals in the United States will experience a major depressive disorder in their lifetime. Depression is associated with a wide range of psychological, emotional, and even physical symptoms. If left unmanaged, it may cause problems at work and in relationships with others. At its most extreme, depression can lead to suicide-the 10th leading cause of death in the U.S.										0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	MAY	2021	46	5					15	16					2	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	SE9UV	WOS:000652413000011					2022-04-28	
J	[Anonymous]				[Anonymous]			Researchers Look for Drugs That Keep HIV Latent	US PHARMACIST			English	News Item																		0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	MAY	2021	46	5					40	40					1	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	SE9UV	WOS:000652413000018					2022-04-28	
J	Allen, LV				Allen, Loyd V., Jr.			Fentanyl 25 mcg/0.1 mL Nasal Spray	US PHARMACIST			English	Editorial Material									[Allen, Loyd V., Jr.] Univ Oklahoma, Coll Pharm, Oklahoma City, OK 73117 USA		Allen, LV (通讯作者)，Univ Oklahoma, Coll Pharm, Oklahoma City, OK 73117 USA.						Allen Loyd V Jr, 2019, Int J Pharm Compd, V23, P299; Allen Loyd V Jr, 2019, Int J Pharm Compd, V23, P211; [Anonymous], 2021, US PHARM NAT FORM; Maheswaran R, 2021, HDB PHARM EXCIPIENTS, P670; Quinn ME, 2021, HDB PHARM EXCIPIENTS, P878; Quinn ME, 2021, HDB PHARM EXCIPIENTS, V9th, P867; Reynolds JEF, 2014, MARTINDALE EXTRA PHA; Watters M., 2021, HDB PHARM EXCIPIENTS, P945	8	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	APR	2021	46	4					60	61					2	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	SE9UN	WOS:000652412200018					2022-04-28	
J	Opitz, B; Ostroff, J				Opitz, Brandon; Ostroff, Jared			Prioritizing Drug Security in Hospital Pharmacies	US PHARMACIST			English	Editorial Material									[Opitz, Brandon; Ostroff, Jared] Baystate Hlth, Dept Acute Care Pharm Serv, Springfield, MA 01199 USA		Opitz, B (通讯作者)，Baystate Hlth, Dept Acute Care Pharm Serv, Springfield, MA 01199 USA.							0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	APR	2021	46	4											1	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	SE9UN	WOS:000652412200006					2022-04-28	
J	Wu, A				Wu, Amy			Best Practices for Preventing Drug Diversion	US PHARMACIST			English	Editorial Material																		0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	APR	2021	46	4											1	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	SE9UN	WOS:000652412200005					2022-04-28	
J	[Anonymous]				[Anonymous]			COVID-19 NEWS DIGEST	US PHARMACIST			English	Editorial Material																		0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	SEP	2021	46	9					18	20					3	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	UT3BM	WOS:000697994900006					2022-04-28	
J	[Anonymous]				[Anonymous]			Balanced Diet May Reduce Skin, Joint Inflammation	US PHARMACIST			English	News Item																		0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	AUG	2021	46	8					35	36					2	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	UB4JE	WOS:000685813400011					2022-04-28	
J	Allen, LV				Allen, Loyd V., Jr.			Ketoconazole 2% Nasal Spray	US PHARMACIST			English	Editorial Material									[Allen, Loyd V., Jr.] Univ Oklahoma, Coll Pharm, Oklahoma City, OK 73106 USA		Allen, LV (通讯作者)，Univ Oklahoma, Coll Pharm, Oklahoma City, OK 73106 USA.						Allen Loyd V Jr, 2019, Int J Pharm Compd, V23, P299; Allen Loyd V Jr, 2019, Int J Pharm Compd, V23, P211; [Anonymous], 2021, US PHARMACOPEIA NATL; CDC, FUNG INF PROT YOUR H FUNG INF PROT YOUR H; RxList, KET KET; Uri N, 2003, OTOLARYNG HEAD NECK, V129, P372, DOI 10.1016/S0194-5998(03)01304-4; Weber KS, 2020, HDB PHARM EXCIPIENTS, V9th, P769	7	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	JUL	2021	46	7					58	59					2	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	TP3SU	WOS:000677515000014					2022-04-28	
J	Caliendo, T; Hiles, O				Caliendo, Tina; Hiles, Olga			Biologic Therapy for Eosinophilic Asthma	US PHARMACIST			English	Article								Eosinophilic asthma (EA) is a severe subphenotype of asthma. Patients with EA historically suffer from frequent and severe asthma exacerbation, declining lung function, and oral-steroid dependency, as well as decreased quality of life and the risk for poor health outcomes. Biologic therapies target the eosinophil inflammatory response, and they have been found to reduce asthma exacerbations and hospitalizations, decrease oral-corticosteroid use, improve lung function, and result in better overall quality of life for these refractory patients.	[Caliendo, Tina; Hiles, Olga] St Johns Univ, Coll Pharm & Hlth Sci, Queens, NY 11439 USA		Caliendo, T (通讯作者)，St Johns Univ, Coll Pharm & Hlth Sci, Queens, NY 11439 USA.							0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	JUL	2021	46	7					43	47					5	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	TP3SU	WOS:000677515000012					2022-04-28	
J	Laisure, M; Covill, N; Ostroff, ML; Ostroff, JL				Laisure, Mackenzie; Covill, Nicole; Ostroff, Marissa L.; Ostroff, Jared L.			Summarizing the 2021 Updated GOLD Guidelines for COPD	US PHARMACIST			English	Article								Chronic obstructive pulmonary disease ( COPD) is a complex disease that requires differential diagnosis and proper classification to identify appropriate therapy. Nonpharmacologic therapy and preventative measures should be utilized to prevent worsening of disease, symptoms, and complications. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines classify a patient's COPD and provide recommendations for first-line treatment. The 2021 update included information regarding the use of e-cigarettes as nicotine replacement, triple therapy, and how the SARS-CoV-2 virus impacted patients with COPD. This article will focus on the diagnosis, classification, and treatment of COPD, as well as recently updated information regarding the use of e-cigarettes and the impact of COVID-19.	[Laisure, Mackenzie; Covill, Nicole] Western New England Univ, Coll Pharm & Hlth Sci, Springfield, MA 01119 USA; [Ostroff, Marissa L.] Western New England Univ, Coll Pharm & Hlth Sci, Dept Pharm Practice, Springfield, MA USA; [Ostroff, Jared L.] Baystate Hlth, Dept Acute Care Pharm Serv, Springfield, MA USA		Laisure, M (通讯作者)，Western New England Univ, Coll Pharm & Hlth Sci, Springfield, MA 01119 USA.							0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	JUL	2021	46	7					30	35					6	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	TP3SU	WOS:000677515000010					2022-04-28	
J	[Anonymous]				[Anonymous]			Low Testosterone and Male Hypogonadism	US PHARMACIST			English	Editorial Material																		0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	JUN	2021	46	6											2	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	SR7UE	WOS:000661251200007					2022-04-28	
J	Barlow, A				Barlow, Ashley			Cytomegalovirus Management in Allogeneic Hematopoietic Stem Cell Transplant Recipients	US PHARMACIST			English	Article								Cytomegalovirus (CMV) continues to be a major complication in allogeneic hematopoietic cell transplant (aHCT) recipients. Either of two approaches may be used to mitigate the development of CMV after aHCT: preemptive initiation of antiviral treatment upon evidence of viral replication or a primary prophylaxis strategy. Both methods are equally effective, and the strategy employed is based on the patient's specific risks for CMV disease. Given the drugs presently available, both preemptive and prophylactic strategies have shortcomings in terms of toxicity, drug interactions, or costs. The pharmacist has an important role in the selection, dosing, monitoring, and management of CMV therapies in aHCT recipients.	[Barlow, Ashley] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA		Barlow, A (通讯作者)，Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.							0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	APR	2021	46	4											8	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	SE9UN	WOS:000652412200004					2022-04-28	
J	Davidson, R				Davidson, Robert			Will COVID-19 Vaccines Require Regular Updates?	US PHARMACIST			English	Editorial Material												rdavidson@uspharmacist.com						0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	APR	2021	46	4					1	1					1	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	SE9UN	WOS:000652412200001					2022-04-28	
J	Renaud, A; Mahdavian, S; Honeywell, M				Renaud, Amy; Mahdavian, Soheyla; Honeywell, Marlon			Inspire Upper Airway Stimulation System	US PHARMACIST			English	Editorial Material									[Renaud, Amy] Apalachee Ctr Inc, Tallahassee, FL 32308 USA; [Mahdavian, Soheyla; Honeywell, Marlon] Florida A&M Univ, Coll Pharm & Pharmaceut Sci, Pharm Practice, Tallahassee, FL 32307 USA		Renaud, A (通讯作者)，Apalachee Ctr Inc, Tallahassee, FL 32308 USA.							0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	APR	2021	46	4					46	48					3	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	SE9UN	WOS:000652412200016					2022-04-28	
J	Davidson, R				Davidson, Robert			Pregnant Women Fare Well With COVID Vaccine, Survey Finds	US PHARMACIST			English	Editorial Material									[Davidson, Robert] Jobson Med Informat LLC, 395 Hudson St,3rd Floor, New York, NY 10014 USA		Davidson, R (通讯作者)，Jobson Med Informat LLC, 395 Hudson St,3rd Floor, New York, NY 10014 USA.	rdavidson@uspharmacist.com						0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	SEP	2021	46	9					4	4					1	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	UT3BM	WOS:000697994900001					2022-04-28	
J	LaPreze, J; Montgomery, E				LaPreze, Jennifer; Montgomery, Ellen			The Johnson & Johnson COVID-19 Vaccine, Women, and VITT	US PHARMACIST			English	Article								The COVID-19 virus has posed a serious threat to the health of individuals globally. In just over a year since the official declaration of the global pandemic, the FDA has issued emergency-use authorization of three vaccines against SARS-CoV-2, the virus responsible for COVID-19, in the United States. The third vaccine to receive this designation was from Johnson & Johnson, a single-dose adenovirus vector vaccine indicated for individuals aged 18 years and older for protection against COVID-19 infection. Since approval, the Johnson & Johnson vaccine has been associated with life-threatening thrombosis, requiring a 10-day halt in vaccine administration in April 2021. Case reports have indicated that women aged 18 to 49 years are at the highest risk for experiencing this rare but serious adverse event. Patients who experience vaccine-induced thrombotic thrombocytopenia (VITT) should be treated with nonheparin anticoagulants and IV immunoglobulin while avoiding heparincontaining products and platelet transfusions.	[LaPreze, Jennifer] Atrium Hlth, Ft Mill, SC 29715 USA; [Montgomery, Ellen] Univ N Carolina, Eshelman Sch Pharm, Chapel Hill, NC 27515 USA		LaPreze, J (通讯作者)，Atrium Hlth, Ft Mill, SC 29715 USA.							0	0	0	2	3	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	SEP	2021	46	9					HS2	HS6					5	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	UT3BM	WOS:000697994900003					2022-04-28	
J	Shue, J; LaPreze, J				Shue, Jessica; LaPreze, Jennifer			Pediatric Food Allergy Update	US PHARMACIST			English	Article							AMERICAN ACADEMY; PREVENTION; IMMUNOLOGY; GUIDELINES; ASTHMA	Multiple risk factors predispose infants to develop food allergies. Food allergies are categorized as IgE-mediated, non-IgE-mediated, and mixed reactions, and each varies by clinical presentation, allergens associated with its development, and diagnostic criteria. Multiple strategies exist to prevent food allergies, but only a few are backed by evidence and proven to reduce the risk of development. The primary treatment for both IgE-mediated and non-IgE-mediated reactions is complete avoidance of the specific food allergen known to elicit the response. The first-line treatment for anaphylactic IgE-mediated reactions is epinephrine. Novel treatment modalities aiming to eliminate food allergies or help speed up the desensitization process are currently being used or investigated.	[Shue, Jessica] Novartis Pharmaceut, Rutgers Inst Pharmaceut Ind Fellowships, US Oncol Med Informat, E Hanover, NJ 07936 USA; [LaPreze, Jennifer] Atrium Hlth, Ft Mill, SC USA		Shue, J (通讯作者)，Novartis Pharmaceut, Rutgers Inst Pharmaceut Ind Fellowships, US Oncol Med Informat, E Hanover, NJ 07936 USA.						[Anonymous], 2016, EP INJ USP AUT PACK; AUVI-Q, 2017, AUVI Q PACK INS; Calvani M, 2020, ACTA BIOMED, V91; Cianferoni A, 2020, CURR PEDIATR REV, V16, P95, DOI 10.2174/1573396315666191031103714; Cosme-Blanco W, 2020, PEDIATR REV, V41, P403, DOI 10.1542/pir.2019-0037; Dupixent, DUP DUP PACK INS; EpiPen, 2016, EPIPEN EPIPEN JR PAC; Fleischer DM, 2021, J ALLER CL IMM-PRACT, V9, P22, DOI 10.1016/j.jaip.2020.11.002; Greer FR, 2019, PEDIATRICS, V143, DOI 10.1542/peds.2019-0281; Huang YJ, 2017, J ALLERGY CLIN IMMUN, V139, P1099, DOI 10.1016/j.jaci.2017.02.007; Meyer R, 2020, ALLERGY, V75, P14, DOI 10.1111/all.13947; Mitre E, 2018, JAMA PEDIATR, V172, DOI 10.1001/jamapediatrics.2018.0315; Nadeau KC, 2011, J ALLERGY CLIN IMMUN, V127, P1622, DOI 10.1016/j.jaci.2011.04.009; Omalizumab, DRUGDEX SYST MICR 2; Pajno GB, 2018, ALLERGY, V73, P799, DOI 10.1111/all.13319; Sampson HA, 2014, J ALLERGY CLIN IMMUN, V134, P1016, DOI 10.1016/j.jaci.2014.05.013; Sampson HA, 2011, J ALLERGY CLIN IMMUN, V127, P1309, DOI 10.1016/j.jaci.2011.01.051; Spergel Jonathan M, 2006, Allergy Asthma Clin Immunol, V2, P78, DOI 10.1186/1710-1492-2-2-78; Stephen-Victor E, 2020, IMMUNITY, V53, P277, DOI 10.1016/j.immuni.2020.07.025; Togias A, 2017, J ACAD NUTR DIET, V117, P788, DOI 10.1016/j.jand.2017.03.004; Xolair, XOL OM PACK INS	21	0	0	1	1	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	AUG	2021	46	8					44	54					11	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	UB4JE	WOS:000685813400016					2022-04-28	
J	Prasad-Reddy, L; Ghazer, M				Prasad-Reddy, Lalita; Ghazer, Marina			Clinical Approaches to the Management of Obesity	US PHARMACIST			English	Article							WAIST CIRCUMFERENCE; PRACTICE GUIDELINES; WEIGHT-MANAGEMENT; AMERICAN-COLLEGE; BODY-WEIGHT; OVERWEIGHT; ASSOCIATION; STATEMENT; ORLISTAT; ADULTS	In the United States and worldwide, obesity is a major public-health concern. Obesity is associated with a higher risk of morbidity and mortality, and it significantly increases patients' risk of developing cancer, cardiovascular disease, and diabetes; however, it remains underassessed and frequently undiagnosed. Health-promoting behaviors, lifestyle modifications, pharmacotherapy, and bariatric surgery are all potential treatment modalities that can be considered, as appropriate, for patients who are overweight or obese. Clinicians should consult current guidelines and routinely assess patients for the presence of obesity and associated diseases, and pharmacists should initiate counseling interventions when obesity is identified.	[Prasad-Reddy, Lalita] Chicago State Univ, Coll Pharm, Student Affairs, Chicago, IL 60628 USA; [Prasad-Reddy, Lalita] Chicago State Univ, Coll Pharm, Pharm Practice, Chicago, IL 60628 USA; [Prasad-Reddy, Lalita] Rush Univ, Med Ctr, Pharmacol, Chicago, IL 60612 USA; [Prasad-Reddy, Lalita] Rush Univ, Med Ctr, Internal Med, Chicago, IL 60612 USA; [Ghazer, Marina] Chicago State Univ, Coll Pharm, Chicago, IL USA		Prasad-Reddy, L (通讯作者)，Chicago State Univ, Coll Pharm, Student Affairs, Chicago, IL 60628 USA.; Prasad-Reddy, L (通讯作者)，Chicago State Univ, Coll Pharm, Pharm Practice, Chicago, IL 60628 USA.; Prasad-Reddy, L (通讯作者)，Rush Univ, Med Ctr, Pharmacol, Chicago, IL 60612 USA.; Prasad-Reddy, L (通讯作者)，Rush Univ, Med Ctr, Internal Med, Chicago, IL 60612 USA.						Anderson JW, 2006, ANN PHARMACOTHER, V40, P1717, DOI 10.1345/aph.1H234; [Anonymous], 2020, VICTOZA LIRAGLUTIDE; [Anonymous], 2000, NIH PUBLICATION, V4084; [Anonymous], 2007, ALLI ORLISTAT PACKAG; [Anonymous], 2012, QSYMIA PHENTERMINE T; [Anonymous], 2014, CONTRAVE NALTREXONE; [Anonymous], 2014, SAXENDA LIRAGLUTIDE; [Anonymous], 2013, XENICAL ORLISTAT PAC; Apovian CM, 2015, J CLIN ENDOCR METAB, V100, P342, DOI 10.1210/jc.2014-3415; Butryn ML, 2011, PSYCHIAT CLIN N AM, V34, P841, DOI 10.1016/j.psc.2011.08.006; CDC, BOD MASS IND CONS PR BOD MASS IND CONS PR; CDC, AD OB FACTS; Center for Disease Control, CHILDH OB FACTS; Centers for Disease Control and Prevention (CDC), DEF AD OV OB; Cornier MA, 2011, CIRCULATION, V124, P1996, DOI 10.1161/CIR.0b013e318233bc6a; Darsini D, 2020, J PUBLIC HEALTH RES, V9, P94, DOI 10.4081/jphr.2020.1811; Dobbs R, 2014, OVERCOMING OBESITY I; FDA, FDA REQ WITHDR WEIGH FDA REQ WITHDR WEIGH; Filippatos TD, 2008, DRUG SAFETY, V31, P53, DOI 10.2165/00002018-200831010-00005; Freedman DS, 2002, JAMA-J AM MED ASSOC, V288, P1758, DOI 10.1001/jama.288.14.1758; Fruhbeck G, 2019, OBESITY FACTS, V12, P131, DOI 10.1159/000497124; Gadde KM, 2011, LANCET, V377, P1341, DOI 10.1016/S0140-6736(11)60205-5; Garvey WT, 2016, ENDOCR PRACT, V22, P842, DOI 10.4158/EP161356.ESGL; Heck AM, 2000, PHARMACOTHERAPY, V20, P270, DOI 10.1592/phco.20.4.270.34882; Hollander P, 2013, DIABETES CARE, V36, P4022, DOI 10.2337/dc13-0234; Jensen MD, 2014, CIRCULATION, V129, pS102, DOI 10.1161/01.cir.0000437739.71477.ee; Klein S, 2007, DIABETES CARE, V30, P1647, DOI 10.2337/dc07-9921; Lonneman David J Jr, 2013, P T, V38, P446; Ma J, 2009, ARCH INTERN MED, V169, P313, DOI 10.1001/archinternmed.2008.582; McKinney L., 2013, DIAGNOSIS MANAGEMENT; Pasanisi F, 2001, NUTR METAB CARDIOVAS, V11, P401; Pi-Sunyer X, 2015, NEW ENGL J MED, V373, P11, DOI 10.1056/NEJMoa1411892; Pi-Sunyer X, 2009, POSTGRAD MED, V121, P21, DOI 10.3810/pgm.2009.11.2074; Piercy KL, 2018, JAMA-J AM MED ASSOC, V320, P2020, DOI 10.1001/jama.2018.14854; Ruban A, 2019, CLIN MED, V19, P205, DOI 10.7861/clinmedicine.19-3-205; Ryan DH, 2018, MED CLIN N AM, V102, P49, DOI 10.1016/j.mcna.2017.08.006; Ryan DH, 2017, CURR OBES REP, V6, P187, DOI 10.1007/s13679-017-0262-y; Sherman Matthew M, 2016, P T, V41, P164; Whitten JS, 2016, AM FAM PHYSICIAN, V94, P161	39	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	JUL	2021	46	7					48	55					8	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	TP3SU	WOS:000677515000013					2022-04-28	
J	Delgado, E; Harrington, L				Delgado, Elina; Harrington, Lydia			Breast Cancer: Not Just a Female Disease	US PHARMACIST			English	Article								Male breast cancer (MBC) comprises less than 1% of breast carcinomas in the United States, but the incidence has been slowly rising. Despite lower incidence rates, male patients present with more progressive disease and face higher mortality rates compared with female breast cancer (FBC) patients. Although treatment strategies for MBC are largely derived from therapeutic trials involving FBC, new evidence is being used to guide clinical decisions for MBC. Pharmacist recognition of the clinical signs and symptoms of MBC may lead to earlier detection and improved patient outcomes. Additionally, the pharmacist can counsel on therapies and side-effect management. In the health-system setting, the highest priority is to optimize treatment and minimize adverse drug events.	[Delgado, Elina] William Carey Univ, Sch Pharm, Pharm, Dept Pharm Practice, Biloxi, MS 39532 USA; [Harrington, Lydia] William Carey Univ, Sch Pharm, Dept Pharm Practice, Biloxi, MS USA		Delgado, E (通讯作者)，William Carey Univ, Sch Pharm, Pharm, Dept Pharm Practice, Biloxi, MS 39532 USA.							0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	JUN	2021	46	6					HS11	HS16					6	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	SR7UE	WOS:000661251200005					2022-04-28	
J	Pal, S				Pal, Somnath			Hypercholesterolemia Trends	US PHARMACIST			English	Editorial Material									[Pal, Somnath] St Johns Univ, Coll Pharm & Hlth Sci, Pharm Adm, Jamaica, NY 11439 USA		Pal, S (通讯作者)，St Johns Univ, Coll Pharm & Hlth Sci, Pharm Adm, Jamaica, NY 11439 USA.							0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	FEB	2021	46	2					14	14					1	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	QU8YE	WOS:000627563600005					2022-04-28	
J	Allen, LV				Allen, Loyd V., Jr.			5-Aminosalicylic Acid 1.2 g and 2.5 g Enemas	US PHARMACIST			English	Editorial Material									[Allen, Loyd V., Jr.] Univ Oklahoma, Coll Pharm, Oklahoma City, OK 73019 USA		Allen, LV (通讯作者)，Univ Oklahoma, Coll Pharm, Oklahoma City, OK 73019 USA.						Allen Loyd V Jr, 2019, Int J Pharm Compd, V23, P299; Allen Loyd V Jr, 2019, Int J Pharm Compd, V23, P211; Allen LV, 2020, HDB PHARM EXCIPIENTS, V9th, P665; [Anonymous], 2021, US PHARM NAT FORM CU; Kibbe AH., 2020, HDB PHARM EXCIPIENTS, V9th, P116; Shah HC., 2020, HDB PHARM EXCIPIENTS, V9th, P1129	6	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	DEC	2021	46	12					58	59					2	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	XY4CD	WOS:000736921600011					2022-04-28	
J	Davidson, R				Davidson, Robert			Digesting COVID's Impact on Gut Health	US PHARMACIST			English	Editorial Material												rdavidson@uspharmacist.com						0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	DEC	2021	46	12					1	1					1	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	XY4CD	WOS:000736921600001					2022-04-28	
J	Sucher, A; Biehle, L; Smith, A; Tran, C				Sucher, Allana; Biehle, Lauren; Smith, Alexandria; Tran, Charlene			Updated Clinical Practice Guidelines for C difficile Infection in Adults	US PHARMACIST			English	Article								Guidelines for the management of adults with Clostridioides difficile infection (CDI) were recently published by the American College of Gastroenterology, followed by a focused update by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America (IDSA-SHEA). Recommended treatment is based on the type of episode ( primary or recurrent) as well as the number of previous recurrences and/or presence of fulminant infection. The IDSA-SHEA guidelines suggest fidaxomicin as the preferred agent for treating initial CDI, with oral vancomycin considered an acceptable alternative. For a first recurrence, standard or extended-pulsed dosing of fidaxomicin is suggested, with oral vancomycin considered an acceptable alternative. Pharmacists are in a key position to recommend appropriate antimicrobial therapy and preventive measures for CDI management.	[Sucher, Allana] Regis Univ, Sch Pharm, Pharm Practice, Denver, CO 80221 USA; [Biehle, Lauren] Univ Wyoming, Sch Pharm, Pharm Practice, Laramie, WY 82071 USA; [Smith, Alexandria; Tran, Charlene] Regis Univ, Sch Pharm, Denver, CO USA		Sucher, A (通讯作者)，Regis Univ, Sch Pharm, Pharm Practice, Denver, CO 80221 USA.							0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	DEC	2021	46	12					HS10	HS16					7	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	XY4CD	WOS:000736921600004					2022-04-28	
J	Saljoughian, M				Saljoughian, Manouchehr			COVID-19: A Closer Look	US PHARMACIST			English	Editorial Material									[Saljoughian, Manouchehr] Alta Bates Summit Med Ctr, Dept Pharm, Berkeley, CA 94705 USA		Saljoughian, M (通讯作者)，Alta Bates Summit Med Ctr, Dept Pharm, Berkeley, CA 94705 USA.						AlTakarli NS, 2020, DUBAI MED J, V3, P44, DOI 10.1159/000508448; CDC, COVID 19 SPREADS; CDC, SCI BRIEF EM SARS CO; Godoy M., 2021, SHOTS HLTH NEWS NPR; Johnson CY, 2021, WASHINGTON POST; Knoll MD, 2021, LANCET, V397, P72, DOI 10.1016/S0140-6736(20)32623-4; McIntosh K, 2019, CORONOVIRUS DIS 2019; Patel A, 2020, MMWR-MORBID MORTAL W, V69, P140, DOI 10.15585/mmwr.mm6905e1; Sax PE, 2021, NEJM	9	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	APR	2021	46	4					4	7					4	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	SE9UN	WOS:000652412200002					2022-04-28	
J	Saljoughian, M				Saljoughian, Manouchehr			Emotional Eating and Binge Eating Disorder	US PHARMACIST			English	Editorial Material							PSYCHOLOGICAL TREATMENTS		[Saljoughian, Manouchehr] Alta Bates Summit Med Ctr, Dept Pharm, Berkeley, CA 94705 USA		Saljoughian, M (通讯作者)，Alta Bates Summit Med Ctr, Dept Pharm, Berkeley, CA 94705 USA.						Brownley KA, 2016, ANN INTERN MED, V165, P409, DOI 10.7326/M15-2455; Brownley KA, 2015, DRUGS, V75, P9, DOI 10.1007/s40265-014-0327-0; Da Porto A, 2020, DIABETES METAB SYND, V14, P289, DOI [10.1016/j.dsx2020.03.009, 10.1016/j.dsx.2020.03.009]; Kass AE, 2013, CURR OPIN PSYCHIATR, V26, P549, DOI 10.1097/YCO.0b013e328365a30e; Lee DY, 2015, BMB REP, V48, P209, DOI 10.5483/BMBRep.2015.48.4.275; Sysko R, 2020, BINGE EATING DISORDE; Wilson GT, 2010, ARCH GEN PSYCHIAT, V67, P94, DOI 10.1001/archgenpsychiatry.2009.170	7	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	FEB	2021	46	2					36	38					3	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	QU8YE	WOS:000627563600011					2022-04-28	
J	[Anonymous]				[Anonymous]			PATIENT EDUCATION	US PHARMACIST			English	Editorial Material								Chronic obstructive pulmonary disease (COPD) is a preventable and treatable lung disease. It is a condition where there is chronic inflammation and swelling in your lungs. It gets worse over time, making it harder to breathe.										0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	NOV	2021	46	11					56	56					1	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	XB5IC	WOS:000721361900010					2022-04-28	
J	Allen, LV				Allen, Loyd V., Jr.			Azstarys in Ora-Blend Single Dose	US PHARMACIST			English	Editorial Material									[Allen, Loyd V., Jr.] Univ Oklahoma, Coll Pharm, Oklahoma City, OK 73106 USA		Allen, LV (通讯作者)，Univ Oklahoma, Coll Pharm, Oklahoma City, OK 73106 USA.						[Anonymous], 2021, US PHARM NAT FORM; [Anonymous], 2021, AZST SERD DEXM PACK; [Anonymous], 2021, ORA BLEND PRODUCT IN	3	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	OCT	2021	46	10					60	61					2	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	WI6KL	WOS:000708466800014					2022-04-28	
J	Barlow, A; Barlow, B				Barlow, Ashley; Barlow, Brooke			Optimizing Polycystic Ovary Syndrome Outcomes	US PHARMACIST			English	Article								Polycystic ovary syndrome (PCOS) is a heterogeneous endocrine disorder that primarily affects women of reproductive age. PCOS is also a very complex disorder, and although it is common, many women remain undiagnosed. The syndrome is characterized by a defect in the hypothalamic-pituitary-ovarian axis that results in a triad of hyperandrogenism, anovulation, and ovarian cysts that carries a myriad of metabolic and reproductive consequences. Symptoms of PCOS manifest as obesity, insulin resistance resulting in acanthosis nigricans, acne, hirsutism, and infertility; PCOS can also result in significant patient morbidity, such as cardiovascular diseases and type 2 diabetes mellitus. The goals of pharmacologic and nonpharmacologic management are aimed at restoring ovulation, alleviating symptoms, and improving quality of life. Pharmacologic treatments are targeted at improving insulin resistance with agents such as metformin, regulating hormonal disturbances with oral contraceptives, or managing infertility with ovulation agents. Pharmacists play a critical role in the management of patients with PCOS, and this article aims at providing a comprehensive review of the syndrome, its presentation, diagnosis, and key management strategies to optimize patient outcomes.	[Barlow, Ashley] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Barlow, Brooke] UF Hlth Shands Hosp, Gainesville, FL USA		Barlow, A (通讯作者)，Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.							0	0	0	1	2	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	SEP	2021	46	9					50	58					9	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	UT3BM	WOS:000697994900013					2022-04-28	
J	Behrend, BA; Liu, AN; Ambizas, EM				Behrend, Benjamin A.; Liu, Amy N.; Ambizas, Emily M.			Prostate Health	US PHARMACIST			English	Editorial Material							EPIDEMIOLOGY; HYPERPLASIA; MANAGEMENT; MEN		[Behrend, Benjamin A.; Liu, Amy N.] St Johns Univ, Coll Pharm & Hlth Sci, Queens, NY 11439 USA; [Ambizas, Emily M.] St Johns Univ, Coll Pharm & Hlth Sci, Experiential Pharm Educ, Queens, NY USA; [Ambizas, Emily M.] Walgreens Pharm, Whitestone, NY USA		Behrend, BA (通讯作者)，St Johns Univ, Coll Pharm & Hlth Sci, Queens, NY 11439 USA.						Abrams P, 2003, UROLOGY, V61, P37, DOI 10.1016/S0090-4295(02)02243-4; Alawamlh OA, 2018, MED CLIN N AM, V102, P301, DOI 10.1016/j.mcna.2017.10.005; Coker TJ, 2016, AM FAM PHYSICIAN, V93, P114; Holt JD, 2016, AM FAM PHYSICIAN, V93, P290; Jones C, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c2354; Krieger JN, 2008, INT J ANTIMICROB AG, V31, pS85, DOI 10.1016/j.ijantimicag.2007.08.028; Lim KB, 2017, ASIAN J UROL, V4, P148, DOI 10.1016/j.ajur.2017.06.004; Lokeshwar SD, 2019, TRANSL ANDROL UROL, V8, P529, DOI 10.21037/tau.2019.10.01; McVary KT, 2011, J UROLOGY, V185, P1793, DOI 10.1016/j.juro.2011.01.074; National Institute of Diabetes and Digestive and Kidney Diseases, PROST PROBL; Parsons JK, 2010, CURR BLADDER DYSFUNC, V5, P212, DOI 10.1007/s11884-010-0067-2; Rawla P, 2019, WORLD J ONCOL, V10, P63, DOI 10.14740/wjon1191; Roehrborn Claus G, 2005, Rev Urol, V7 Suppl 9, pS3; Ryu YW, 2015, UROL INT, V94, P187, DOI 10.1159/000366521; Siu AL, 2016, ANN INTERN MED, V164, P279, DOI 10.7326/M15-2886; Sokeland J, 2000, BJU INT, V86, P439, DOI 10.1046/j.1464-410X.2000.00776.x; Surveillance Epidemiology and End Results Program, CANC PROST CANC STAT; Tacklind J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001423.pub3; Zhang SJ, 2013, ASIAN J ANDROL, V15, P116, DOI 10.1038/aja.2012.127	20	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	SEP	2021	46	9					34	37					4	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	UT3BM	WOS:000697994900009					2022-04-28	
J	Sarbacker, GB; Smith, A; Bond, H; Ellis, KD				Sarbacker, G. Blair; Smith, Amanda; Bond, Haley; Ellis, Katie D.			Managing Atopic Dermatitis in Children	US PHARMACIST			English	Article							GUIDELINES; MANAGEMENT; CARE; EFFICACY; ECZEMA	Atopic dermatitis, or eczema, is a chronic inflammatory skin disease that is common in the pediatric population, with 90% of patients experiencing an eruption by age 5 years. Atopic dermatitis is identified by its hallmark pruritic rash and involves a cycle of flare-up and remission. Management with nonpharmacologic and pharmacologic options can lessen the symptoms of atopic dermatitis and improve the patient's quality of life.The mainstay of treatment is topical agents, but more severe cases may require additional therapies. Pharmacists are highly accessible and therefore are positioned to assist parents and caregivers in learning about treatment options for pediatric atopic dermatitis.	[Sarbacker, G. Blair; Smith, Amanda; Bond, Haley; Ellis, Katie D.] Presbyterian Coll Sch Pharm, Pharm Practice, Clinton, SC 29325 USA		Sarbacker, GB (通讯作者)，Presbyterian Coll Sch Pharm, Pharm Practice, Clinton, SC 29325 USA.						[Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; [Anonymous], 2020, EUCR CRIS PACK INS; [Anonymous], 2014, EL PIM PACK INS; [Anonymous], 2021, DUP DUP PACK INS; Bath-Hextall FJ, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005205.pub3; Boyle RJ, 2009, CLIN EXP ALLERGY, V39, P1117, DOI 10.1111/j.1365-2222.2009.03305.x; Chopra R, 2017, ANN ALLERG ASTHMA IM, V119, P435, DOI 10.1016/j.anai.2017.08.289; Cline Abigail, 2020, J Clin Aesthet Dermatol, V13, pS33; Eichenfield LF, 2014, J AM ACAD DERMATOL, V71, P116, DOI 10.1016/j.jaad.2014.03.023; Eichenfield LF, 2014, J AM ACAD DERMATOL, V70, P338, DOI 10.1016/j.jaad.2013.10.010; Lyons JJ, 2015, IMMUNOL ALLERGY CLIN, V35, P161, DOI 10.1016/j.iac.2014.09.008; Maged M, 2009, J DERMATOL SCI, V54, P76, DOI 10.1016/j.jdermsci.2009.02.002; Ohtsuki M, 2018, J DERMATOL, V45, P936, DOI 10.1111/1346-8138.14501; Paller AS, 2020, J AM ACAD DERMATOL, V83, P1282, DOI 10.1016/j.jaad.2020.06.054; Paller AS, 2016, J AM ACAD DERMATOL, V75, P494, DOI 10.1016/j.jaad.2016.05.046; Rawlings A V, 2004, Dermatol Ther, V17 Suppl 1, P49, DOI 10.1111/j.1396-0296.2004.04S1006.x; Sidbury R, 2014, J AM ACAD DERMATOL, V71, P1218, DOI 10.1016/j.jaad.2014.08.038; Sidbury R, 2014, J AM ACAD DERMATOL, V71, P327, DOI 10.1016/j.jaad.2014.03.030; Tollefson MM, 2014, PEDIATRICS, V134, pE1735, DOI 10.1542/peds.2014-2812; Vaughn AR, 2019, J ALTERN COMPLEM MED, V25, P567, DOI 10.1089/acm.2018.0363; Wollenberg A, 2018, J EUR ACAD DERMATOL, V32, P657, DOI 10.1111/jdv.14891	21	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	AUG	2021	46	8					28	33					6	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	UB4JE	WOS:000685813400008					2022-04-28	
J	[Anonymous]				[Anonymous]			COVID-19 Pandemic Impacting Global Mental Health	US PHARMACIST			English	Editorial Material																		0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	APR	2021	46	4					8	12					5	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	SE9UN	WOS:000652412200003					2022-04-28	
J	Alrais, M				Alrais, Mena			Improving Statin Adherence in Patients at Risk for Cardiovascular Disease	US PHARMACIST			English	Article								Lipid-lowering medications have been shown to be efficacious, but adherence can be challenging in patients who are at risk for cardiovascular disease. It is critical for pharmacists to utilize tools in their practice to help patients attain better adherence outcomes, as nonadherence to evidence-based pharmacotherapy has been associated with excess morbidity and mortality. Pharmacists can work toward a better understanding of the factors affecting treatment adherence and interact compassionately with patients to determine the reasoning behind their actions. Furthermore, the pharmacist can identify the specific cause of nonadherence, address this with effective tools and resources in collaboration with the patient and physician, and distinguish nonadherence from drug-treatment ineffectiveness.	[Alrais, Mena] Univ Southern Calif, Sch Pharm, Pharm Practice, Los Angeles, CA 90007 USA		Alrais, M (通讯作者)，Univ Southern Calif, Sch Pharm, Pharm Practice, Los Angeles, CA 90007 USA.							0	0	0	0	1	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	FEB	2021	46	2					6	12					7	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	QU8YE	WOS:000627563600002					2022-04-28	
J	Barlow, B; Barlow, A				Barlow, Brooke; Barlow, Ashley			Management of Obesity in Patients With Diabetes	US PHARMACIST			English	Article							WEIGHT-LOSS; GLYCEMIC CONTROL; TYPE-2; METFORMIN; PREVENTION; OVERWEIGHT; REDUCTION; EXENATIDE; EFFICACY	Obesity is one of the leading causes of type 2 diabetes, and it has continued to rise in incidence and prevalence in recent years. Many diabetes-related factors, such as diabetes medications and alterations in glucose metabolism, contribute to an increased risk of obesity. A core element to selecting glucose-lowering therapies, according to current diabetes guidelines, is the medication's impact on weight. Classes of medications such as metformin, glucagon-like peptide-1 agonists, and sodium-glucose cotransporter 2 inhibitors aid in weight loss and improve overall cardiovascular health. Pharmacists should review treatment plans and counsel patients about incorporating diet and lifestyle changes for optimal outcomes.	[Barlow, Brooke] UF Hlth Shands Hosp, Gainesville, FL USA; [Barlow, Ashley] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA		Barlow, B (通讯作者)，UF Hlth Shands Hosp, Gainesville, FL USA.						Amer Diabet Assoc, 2021, DIABETES CARE, V44, pS100, DOI 10.2337/dc21-S008; Amer Diabet Assoc, 2021, DIABETES CARE, V44, pS111, DOI 10.2337/dc21-S009; [Anonymous], 2020, SAX LIR PACK INS; Aroda VR, 2016, J CLIN ENDOCR METAB, V101, P1754, DOI 10.1210/jc.2015-3754; Bolinder J, 2014, DIABETES OBES METAB, V16, P159, DOI 10.1111/dom.12189; Cai XL, 2018, OBESITY, V26, P70, DOI 10.1002/oby.22066; CDC, OV OB OB IS COMM SER; CDC, DIAB RISK FACT DIAB; Davies M, 2021, LANCET, V397, P971, DOI 10.1016/S0140-6736(21)00213-0; Davies MJ, 2015, JAMA-J AM MED ASSOC, V314, P687, DOI 10.1001/jama.2015.9676; De Block CEM, 2012, EXPERT REV ENDOCRINO, V7, P611, DOI [10.1586/eem.12.51, 10.1586/EEM.12.51]; Dormandy JA, 2005, LANCET, V366, P1279, DOI 10.1016/S0140-6736(05)67528-9; Heine RJ, 2005, ANN INTERN MED, V143, P559, DOI 10.7326/0003-4819-143-8-200510180-00006; Kahan Scott, 2017, Diabetes Spectr, V30, P250, DOI 10.2337/ds17-0044; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Lee A, 1998, OBES RES, V6, P47, DOI 10.1002/j.1550-8528.1998.tb00314.x; Lingvay I, 2020, BMJ OPEN DIAB RES CA, V8, DOI 10.1136/bmjdrc-2020-001706; Malin SK, 2014, CURR OPIN ENDOCRINOL, V21, P323, DOI 10.1097/MED.0000000000000095; McAdam-Marx C, 2014, DIABETES RES CLIN PR, V103, P402, DOI 10.1016/j.diabres.2013.12.038; Pereira MJ, 2019, DRUGS, V79, P219, DOI 10.1007/s40265-019-1057-0; Provilus A, 2011, THERAPY, V8, P113; Rabizadeh S, 2019, INT J ENDOCRINOL MET, V17, DOI 10.5812/ijem.84353; Shah M, 2014, REV ENDOCR METAB DIS, V15, P181, DOI 10.1007/s11154-014-9289-5; STUMVOLL M, 1995, NEW ENGL J MED, V333, P550, DOI 10.1056/NEJM199508313330903; Van Gaal L, 2015, DIABETES CARE, V38, P1161, DOI 10.2337/dc14-1630; Wing RR, 2011, DIABETES CARE, V34, P1481, DOI 10.2337/dc10-2415; Yanovski JA, 2011, DIABETES, V60, P477, DOI 10.2337/db10-1185	27	0	0	3	3	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	NOV	2021	46	11					31	42					12	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	XB5IC	WOS:000721361900007					2022-04-28	
J	Luu, L; Adamzadeh, B; Neumiller, JJ				Luu, Lynn; Adamzadeh, Bahar; Neumiller, Joshua J.			Update on the Management of Diabetic Kidney Disease	US PHARMACIST			English	Article								Diabetic kidney disease (DKD) is a complication that occurs in approximately 40% of patients with type 2 diabetes. DKD is associated with significant morbidity and mortality and, additionally, complicates glycemic management. While interventions to prevent and/or slow the progression of DKD have historically been limited, agents from the sodium-glucose cotransporter-2 inhibitor, glucagon-like peptide-1 receptor agonist, and nonsteroidal mineralocorticoid receptor antagonist classes of medication offer new hope for DKD patients. Pharmacists can play a critical role as members of the care team to promote the safe and appropriate use of these kidney-protective agents in appropriate individuals to improve patient outcomes.	[Luu, Lynn; Adamzadeh, Bahar; Neumiller, Joshua J.] Washington State Univ, Coll Pharm & Pharmaceut Sci, Dept Pharmacotherapy, Spokane, WA 99202 USA		Luu, L (通讯作者)，Washington State Univ, Coll Pharm & Pharmaceut Sci, Dept Pharmacotherapy, Spokane, WA 99202 USA.							0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	NOV	2021	46	11					57	66					10	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	XB5IC	WOS:000721361900011					2022-04-28	
J	Allen, LV				Allen, Loyd V., Jr.			Ketamine Hydrochloride 10%, Gabapentin 10%, and Ketoprofen 10% in Lipoderm	US PHARMACIST			English	Editorial Material									[Allen, Loyd V., Jr.] Univ Oklahoma, Coll Pharm, Oklahoma City, OK 73114 USA		Allen, LV (通讯作者)，Univ Oklahoma, Coll Pharm, Oklahoma City, OK 73114 USA.						Allen Loyd V Jr, 2019, Int J Pharm Compd, V23, P299; Allen Loyd V Jr, 2019, Int J Pharm Compd, V23, P211; ALLEN LV, 1998, IJPC, V2, P308; [Anonymous], 2021, US PHARM NAT FORM; Durham Melissa J, 2018, Int J Pharm Compd, V22, P172; Professional Compounding Centers of America, LIP; Quinn ME, 2021, HDB PHARM EXCIPIENTS, V9th, P867; Sweetman SC, 2002, MARTINDALE COMPLETE, P1262; Sweetman SC, 2009, MARTINDALE COMPLETE, P482	9	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	MAR	2021	46	3					60	61					2	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	QU8YG	WOS:000627563800014					2022-04-28	
J	Davidson, R				Davidson, Robert			Metformin Reduces Death Risk in COVID-19 Patients With Diabetes	US PHARMACIST			English	Editorial Material												rdavidson@uspharmacist.com						0	0	0	0	1	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	FEB	2021	46	2					3	3					1	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	QU8YE	WOS:000627563600001					2022-04-28	
J	[Anonymous]				[Anonymous]			Diverticular Disease	US PHARMACIST			English	Editorial Material								Diverticular disease is a widespread gastrointestinal condition where small pouches form in the lining of the digestive tract. Each one of these pockets or sacs is called a diverticulum. It is present in 70% of people aged 80 years or older, with similar rates for men and women. For some, these sacs can be present in the intestine and not cause any noticeable symptoms. For others, however, the symptoms can be severe, and further dangerous complications can arise. Diverticulosis is the presence of diverticula without associated complications and is the most common finding during a routine colonoscopy. However, when these pouches become inflamed, it is called diverticulitis.										0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	DEC	2021	46	12					15	16					2	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	XY4CD	WOS:000736921600006					2022-04-28	
J	Allen, LV				Allen, Loyd V., Jr.			Progesterone Compounded Vaginal Inserts, USP The beyond-use date for this official preparation is supported by valid stability-indicating analytical methods	US PHARMACIST			English	Editorial Material									[Allen, Loyd V., Jr.] Univ Oklahoma, Coll Pharm, Oklahoma City, OK 73190 USA		Allen, LV (通讯作者)，Univ Oklahoma, Coll Pharm, Oklahoma City, OK 73190 USA.						Allen Loyd V Jr, 2019, Int J Pharm Compd, V23, P299; Allen Loyd V Jr, 2019, Int J Pharm Compd, V23, P211; [Anonymous], 2021, US PHARM NAT FORM; McEvoy GK, 2016, AHFS DRUG INFORM 201, P3327; Moreton RC, 2021, HDB PHARM EXCIPIENTS, V9th, P1059	5	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	SEP	2021	46	9					60	61					2	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	UT3BM	WOS:000697994900014					2022-04-28	
J	[Anonymous]				[Anonymous]			New Approach to Metastatic Melanoma Discovered	US PHARMACIST			English	News Item																		0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	AUG	2021	46	8					34	35					2	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	UB4JE	WOS:000685813400010					2022-04-28	
J	Ambizas, EM				Ambizas, Emily M.			Stuffy, Sneezy, and Congested: Allergic Rhinitis and Self-Care Management	US PHARMACIST			English	Editorial Material									[Ambizas, Emily M.] St Johns Univ, Coll Pharm & Hlth Sci, Jamaica, NY 11439 USA; [Ambizas, Emily M.] Walgreens Pharm, Whitestone, NY 11357 USA		Ambizas, EM (通讯作者)，St Johns Univ, Coll Pharm & Hlth Sci, Jamaica, NY 11439 USA.; Ambizas, EM (通讯作者)，Walgreens Pharm, Whitestone, NY 11357 USA.							0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	MAY	2021	46	5					41	44					4	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	SE9UV	WOS:000652413000019					2022-04-28	
J	[Anonymous]				[Anonymous]			COVID-19 Pandemic Linked With Unhealthy Eating Behaviors	US PHARMACIST			English	News Item																		0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	MAY	2021	46	5					4	4					1	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	SE9UV	WOS:000652413000002					2022-04-28	
J	[Anonymous]				[Anonymous]			Children Who Lost a Parent to Pandemic Need Swift Support	US PHARMACIST			English	News Item																		0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	MAY	2021	46	5					5	6					2	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	SE9UV	WOS:000652413000003					2022-04-28	
J	[Anonymous]				[Anonymous]			Diabetic Peripheral Neuropathy	US PHARMACIST			English	Editorial Material																		0	0	0	0	1	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	MAR	2021	46	3					15	+					2	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	QU8YG	WOS:000627563800007					2022-04-28	
J	Patel, HB; Witte, AP				Patel, Hansita B.; Witte, Amy P.			Update on Basal Insulin Therapy for Type 2 Diabetes Mellitus	US PHARMACIST			English	Article							GLARGINE 100 UNITS/ML; TO-TARGET TRIAL; GLUCOSE CONTROL; DOSE-RESPONSE; OPEN-LABEL; DEGLUDEC; PEOPLE; ANALOGS; HYPOGLYCEMIA; MANAGEMENT	Although it is possible for patients with type 2 diabetes mellitus to achieve glycemic control with lifestyle changes and oral medications, many patients require insulin therapy to achieve adequate glycemic control. Long-acting basal insulins are the cornerstone of all insulin regimens. More novel basal insulins created to exhibit superior pharmacokinetic profiles are now being developed; recently, two novel long-acting basal insulins with superior pharmacokinetic profiles have emerged on the market. Insulin icodec, a once-weekly, ultralong-acting basal insulin analogue is currently in development for the treatment of diabetes. Additionally, biosimilar products are becoming more common and offer more costsaving options for patients. Pharmacists must be knowledgeable about how novel basal insulins differ from traditional insulin analogues.	[Patel, Hansita B.; Witte, Amy P.] Univ Incarnate Word, Feik Sch Pharm, Dept Pharm Practice, San Antonio, TX 78212 USA		Patel, HB (通讯作者)，Univ Incarnate Word, Feik Sch Pharm, Dept Pharm Practice, San Antonio, TX 78212 USA.						Amer Diabet Assoc, 2021, DIABETES CARE, V44, pS111, DOI 10.2337/dc21-S009; [Anonymous], 2020, LEV INS DET PACK INS; [Anonymous], 2021, LANT INS GLARG PACK; [Anonymous], BIOS INT PROD; Ashwell SG, 2006, DIABETIC MED, V23, P879, DOI 10.1111/j.1464-5491.2006.01913.x; Bajaj HS, 2021, DIABETES CARE, V44, P1586, DOI 10.2337/dc20-2877; Becker RHA, 2015, DIABETES CARE, V38, P637, DOI 10.2337/dc14-0006; Blevins TC, 2019, DIABETES OBES METAB, V21, P129, DOI 10.1111/dom.13495; Bolli GB, 2015, DIABETES OBES METAB, V17, P386, DOI 10.1111/dom.12438; CDC, PREV DIAGN DIAB; FDA, FDA FTC ANN NEW EFF; Garber AJ, 2012, LANCET, V379, P1498, DOI 10.1016/S0140-6736(12)60205-0; Garcia-Perez LE, 2013, DIABETES THER, V4, P175, DOI 10.1007/s13300-013-0034-y; Grant PJ, 1996, DIABETES CARE, V19, P64, DOI 10.2337/diacare.19.1.64; Heise T, 2012, DIABETES OBES METAB, V14, P944, DOI 10.1111/j.1463-1326.2012.01638.x; Holman RR, 2008, NEW ENGL J MED, V359, P1577, DOI 10.1056/NEJMoa0806470; Insulin degludec, LEX DRUGS; Insulin detemir, LEX DRUGS; Insulin glargine, LEX DRUGS; Insulin NPH, LEX DRUGS; Kjeldsen TB, 2021, J MED CHEM, V64, P8942, DOI 10.1021/acs.jmedchem.1c00257; Klein O, 2007, DIABETES OBES METAB, V9, P290, DOI 10.1111/j.1463-1326.2006.00685.x; Kuhlmann M.K., 2014, BIOSIMILARS, V4, P45; Lingvay I, 2021, DIABETES CARE, V44, P1595, DOI 10.2337/dc20-2878; Meneghini L, 2013, DIABETES CARE, V36, P858, DOI 10.2337/dc12-1668; Monami M, 2008, DIABETES RES CLIN PR, V81, P184, DOI 10.1016/j.diabres.2008.04.007; Nishimura E, 2021, BMJ OPEN DIAB RES CA, V9, DOI 10.1136/bmjdrc-2021-002301; Novolin N, 2019, ISOPHANE INSULIN HUM; Owens DR, 2014, DIABETES-METAB RES, V30, P104, DOI 10.1002/dmrr.2469; Petznick A, 2011, AM FAM PHYSICIAN, V84, P183; Plank J, 2005, DIABETES CARE, V28, P1107, DOI 10.2337/diacare.28.5.1107; Riddle MC, 2014, DIABETES CARE, V37, P2755, DOI 10.2337/dc14-0991; Rosenstock J, 2020, NEW ENGL J MED, V383, P2107, DOI 10.1056/NEJMoa2022474; Scarpello JH, 2001, BR J DIABETES VASC D, P28; Stratton IM, 2000, BMJ-BRIT MED J, V321, P405, DOI 10.1136/bmj.321.7258.405; Wang ZH, 2010, DIABETES CARE, V33, P1555, DOI 10.2337/dc09-2011; Yki-Jarvinen H, 2014, DIABETES CARE, V37, P3235, DOI 10.2337/dc14-0990; Zinman B, 2012, DIABETES CARE, V35, P2464, DOI 10.2337/dc12-1205	38	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	NOV	2021	46	11					44	50					7	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	XB5IC	WOS:000721361900008					2022-04-28	
J	Wong, S; Tran, MD; Tsu, L				Wong, Sandy; Tran, Michael D.; Tsu, Laura			Hyperglycemia and Insulin Management in Critically Ill Patients	US PHARMACIST			English	Article							PRACTICE GUIDELINE; THERAPY; RESISTANCE	Hyperglycemia is a leading cause of increased morbidity and mortality in critically ill diabetic and nondiabetic patients in the ICU. Stricter control should be implemented in this setting in order to reduce mortality as well as other complications caused by hyperglycemia. Because hypoglycemia is associated with an increased risk of adverse effects, the optimal intensity of glucose control has been extensively investigated. Hyperglycemia is better controlled through continuous glucose infusions than with intermittent injections or IV infusions because it is easier to titrate the concentration of insulin to achieve a target glucose range. Pharmacists in acute-care and ambulatory-care settings are able to adjust insulin therapy and educate patients about hypoglycemia or hyperglycemia in order to optimize patient outcomes.	[Wong, Sandy] Providence St Joseph Hosp, Orange, CA 92868 USA; [Tran, Michael D.] CVS Pharm, Los Angeles, CA USA; [Tsu, Laura] Chapman Univ, Sch Pharm, Pharm Practice, Irvine, CA USA		Wong, S (通讯作者)，Providence St Joseph Hosp, Orange, CA 92868 USA.						[Anonymous], 2017, DIABETES CARE, V40, pS1, DOI 10.2337/dc17-S001; [Anonymous], 2019, FIASP INSULIN ASPART; [Anonymous], 2021, LANTUS INSULIN GLARG; [Anonymous], 2021, LYUMJEV INSULIN LISP; [Anonymous], 2020, ADMELOG INSULIN LISP; [Anonymous], 2020, SEMGLEE INSULIN GLAR; [Anonymous], 2020, MYXREDLIN INSULIN HU; [Anonymous], 2021, NOVOLOG INSULIN ASPA; [Anonymous], 2019, TRESIBA INSULIN DEGL; [Anonymous], 2019, HUMALOG INSULIN LISP; [Anonymous], 2020, TOUJEO INSULIN GLARG; [Anonymous], 2020, LEVEMIR INSULIN DETE; [Anonymous], 2021, BASAGLAR INSULIN GLA; [Anonymous], 2020, APIDRA INSULIN GLULI; Brunkhorst FM, 2008, NEW ENGL J MED, V358, P125, DOI 10.1056/NEJMoa070716; Eakins James, 2009, J Diabetes Sci Technol, V3, P1373; Finfer S, 2009, NEW ENGL J MED, V360, P1283, DOI 10.1056/NEJMoa0810625; Friedberg SJ, 2006, METABOLISM, V55, P614, DOI 10.1016/j.metabol.2005.12.004; Heinemann L, 2000, DIABETES CARE, V23, P644, DOI 10.2337/diacare.23.5.644; Heise T, 2017, CLIN PHARMACOKINET, V56, P551, DOI 10.1007/s40262-017-0514-8; Hsu Chien-Wei, 2012, World J Crit Care Med, V1, P31, DOI 10.5492/wjccm.v1.i1.31; Humulin N., 2019, ISOPHANE INSULIN HUM; Humulin R., 2019, INSULIN HUMAN PACKAG; Kapitza C, 2020, DIABETES TECHNOL THE, V22, P278, DOI 10.1089/dia.2019.0351; Lazar HL, 2009, ANN THORAC SURG, V87, P663, DOI 10.1016/j.athoracsur.2008.11.011; Morigny P, 2016, BIOCHIMIE, V125, P259, DOI 10.1016/j.biochi.2015.10.024; Novolin N., 2019, ISOPHANE INSULIN HUM; Novolin R., 2019, INSULIN HUMAN PACKAG; Pasala S, 2013, OCHSNER J, V13, P407; Pieber TR, 2019, DIABETES OBES METAB, V21, P2068, DOI 10.1111/dom.13767; Plank J, 2005, DIABETES CARE, V28, P1107, DOI 10.2337/diacare.28.5.1107; Qaseem A, 2011, ANN INTERN MED, V154, P260, DOI 10.7326/0003-4819-154-4-201102150-00007; Rhodes A, 2017, CRIT CARE MED, V45, P486, DOI 10.1097/CCM.0000000000002255; Surgical Care Improvement Project, CARD SURG PAT CONTR; Thau L., 2021, STATPEARLS; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Vanhorebeek I, 2006, SEMIN THORAC CARDIOV, V18, P309, DOI 10.1053/j.semtcvs.2006.05.001; Wieser V, 2013, ARCH IMMUNOL THER EX, V61, P119, DOI 10.1007/s00005-012-0210-1; Yao RQ, 2020, INT J BIOL SCI, V16, P1658, DOI 10.7150/ijbs.43447	39	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	NOV	2021	46	11					HS7	HS12					6	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	XB5IC	WOS:000721361900003					2022-04-28	
J	Sarbacker, GB				Sarbacker, G. Blair			Aducanumab for the Treatment of Alzheimer's Disease	US PHARMACIST			English	Article								Aducanumab is a monoclonal antibody directed against the beta-amyloid plaques thought to be involved in the development of Alzheimer's disease. This agent was granted accelerated approval by the FDA despite an almost unanimous vote against approval by the FDA's expert independent advisory committee; the committee's opinion was based on uncertainty regarding the strength of evidence of efficacy in phase III clinical trials. Phase IV studies of aducanumab will be conducted to verify the suspected clinical benefit, and the data will be used to determine whether traditional drug approval will be granted. There are no contraindications to aducanumab use, but amyloid-related imaging abnormalities can occur. Other medications for treating dementia include the acetylcholinesterase inhibitors donepezil, galantamine, and rivastigmine and the N-methyl-D-aspartate receptor antagonist memantine. It is important for the pharmacist to be up-to-date on the management of dementia in order to help patients and caregivers make treatment decisions and monitor for adverse events associated with treatment.	[Sarbacker, G. Blair] Presbyterian Coll, Sch Pharm, Pharm Practice, Clinton, SC 29325 USA		Sarbacker, GB (通讯作者)，Presbyterian Coll, Sch Pharm, Pharm Practice, Clinton, SC 29325 USA.						Alexander GC, 2021, JAMA-J AM MED ASSOC, V325, P1717, DOI 10.1001/jama.2021.3854; [Anonymous], 2021, ALZHEIMERS DEMENT, V17, P327, DOI 10.1002/alz.12328; [Anonymous], 2021, AD AD PACK INS; [Anonymous], 2020, EXELON PATCH RIVASTI; [Anonymous], 2018, NAM MEM PACK INS; [Anonymous], 2016, EX RIV PACK INS; [Anonymous], 2012, AR DON PACK INS; [Anonymous], 2015, RAZ GAL PACK INS; ClinicalTrials.gov, 221AD302 PHAS 3 STUD; ClinicalTrials.gov, 221AD301 PHAS 3 STUD; Dunn B, ACCELERATED APPROVAL; FDA, FIN SUMM MIN PER CEN; FDA, FDA GRANTS ACC APPR; FDA, ACC APPR PROGR; Galantamine, LEX ONL; Knopman DS, 2021, ALZHEIMERS DEMENT, V17, P696, DOI 10.1002/alz.12213; Livingston G, 2020, LANCET, V396, P413, DOI 10.1016/S0140-6736(20)30367-6; Memantine, LEXI ONL; Namenda XR, 2019, MEMANTINE; PLUM F, 1986, GERONTOLOGY, V32, P67, DOI 10.1159/000212832; Rivastigmine, LEX ONL; Xu Jiaquan, 2020, NCHS Data Brief, P1	22	0	0	3	3	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	OCT	2021	46	10					51	57					7	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	WI6KL	WOS:000708466800013					2022-04-28	
J	Dao, A; Caliendo, T				Dao, Ashley; Caliendo, Tina			Addressing Barriers to Emergency-Contraceptive Access	US PHARMACIST			English	Article								In the United States, almost 50% of pregnancies are unintended, and the rate is 75% among teens aged 15 to 19 years. Emergency contraceptives (ECs), including levonorgestrel (Plan B One-Step and generic brands), ulipristal acetate, and the copper intrauterine device, are crucial for preventing unintended pregnancies. The approval of levonorgestrel for OTC use increased patient access to ECs, but many patients still face barriers. Obstacles such as state regulations, antitheft boxes, and misinformation prevent patients from obtaining ECs in a timely manner. Because of their accessibility, pharmacists play a key role in counseling patients on ECs; consequently, it is imperative for pharmacists to address these barriers to access.	[Dao, Ashley; Caliendo, Tina] St Johns Univ, Coll Pharm & Hlth Sci, Queens, NY 11439 USA		Dao, A (通讯作者)，St Johns Univ, Coll Pharm & Hlth Sci, Queens, NY 11439 USA.						American College of Obstetricians and Gynecologists, IND AB; [Anonymous], 2021, MMWR Morb Mortal Wkly Rep, V70, P145, DOI 10.15585/mmwr.mm7004a7; [Anonymous], 2010, ELLA ULIPRISTAL ACET; [Anonymous], 2019, PARAGARD INTRAUTERIN; [Anonymous], 2009, PLAN B 1 STEP LEVONO; CDC, UNINTENDED PREGNANCY; Cleland K, 2016, WOMEN HEALTH ISS, V26, P622, DOI 10.1016/j.whi.2016.08.003; FDA, FDA APPR PLAN B 1 ST; Guttmacher Institute, EMERGENCY CONTRACEPT; Guttmacher Institute, IND AB US; Hickey MT, 2015, SEX REPROD HEALTHC, V6, P28, DOI 10.1016/j.srhc.2014.09.008; Nash E., DANGER AHEAD EARLY I; National Conference of State Legislatures, PHARM CONSC CLAUS LA; Rafie S, 2017, INTEGR PHARM RES PRA, V6, P99, DOI 10.2147/IPRP.S99541; Stone RH, 2020, PHARMACY-BASEL, V8, DOI 10.3390/pharmacy8020105; Yen S, 2015, J PEDIATR ADOL GYNEC, V28, P337, DOI 10.1016/j.jpag.2014.09.018	16	0	0	1	1	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	SEP	2021	46	9					8	12					5	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	UT3BM	WOS:000697994900002					2022-04-28	
J	Pal, S				Pal, Somnath			Misuse of Prescription Psychotropic Drugs	US PHARMACIST			English	Editorial Material									[Pal, Somnath] St Johns Univ, Coll Pharm & Hlth Sci, Pharm Adm, Jamaica, NY 11439 USA		Pal, S (通讯作者)，St Johns Univ, Coll Pharm & Hlth Sci, Pharm Adm, Jamaica, NY 11439 USA.							0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	MAY	2021	46	5					14	14					1	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	SE9UV	WOS:000652413000010					2022-04-28	
J	Ryu, R				Ryu, Rachel			Update on the Safety and Efficacy of Oral Anticoagulation in CKD and ESRD	US PHARMACIST			English	Article								Atrial fibrillation (AF) is a supraventricular tachyarrhythmia that can cause stroke/systemic embolism (SE), and therefore, anticoagulation may be indicated. Patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD) may have greater risk for AF, stroke/SE, and bleeding, so the net benefit of anticoagulation is controversial. Evaluation of published data on oral anticoagulation in patients with CKD/ESRD shows that overall, warfarin has been associated with an increased risk for stroke and death, compared with no anticoagulation. Compared with warfarin users, apixaban users were shown to have significantly lower risk for stroke/ SE, death, and major bleeding, but no difference was seen for efficacy outcomes when compared with no anticoagulation. The overall benefit-risk ratio must be carefully analyzed in this high-risk patient population, and the decision to anticoagulate must be conducted in a patient-specific manner.	[Ryu, Rachel] Western Univ Hlth Sci, Coll Pharm, Pharm Practice & Adm, Pomona, CA 91766 USA		Ryu, R (通讯作者)，Western Univ Hlth Sci, Coll Pharm, Pharm Practice & Adm, Pomona, CA 91766 USA.			Ryu, Rachel/0000-0002-9593-8928				0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	MAR	2021	46	3					36	40					5	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	QU8YG	WOS:000627563800011					2022-04-28	
J	Pal, S				Pal, Somnath			Stroke Prevalence and Risk Factors	US PHARMACIST			English	Editorial Material									[Pal, Somnath] St Johns Univ, Pharm Adm, Coll Pharm & Hlth Sci, Jamaica, NY 11439 USA		Pal, S (通讯作者)，St Johns Univ, Pharm Adm, Coll Pharm & Hlth Sci, Jamaica, NY 11439 USA.							0	1	1	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	JAN	2021	46	1					14	14					1	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	PY9CO	WOS:000612338200004					2022-04-28	
J	Williams, V				Williams, Valerie			Neurocutaneous Disorders: Tuberous Sclerosis Complex and Sturge-Weber Syndrome	US PHARMACIST			English	Article								Neurocutaneous disorders are a diverse group of congenital disorders that encompass abnormalities of neuroectodermal and, sometimes, mesodermal development and often involve the skin, eye, and central nervous system.Tuberous sclerosis complex (TSC) and Sturge-Weber syndrome (SWS) are prototypical neurocutaneous disorders. Neurocutaneous disorders are often inherited conditions and typically present in early childhood or adolescence. There is an increased risk of neoplastic formation in many of the syndromes. Neurocutaneous syndromes are characterized by distinctive cutaneous stigmata and neurologic symptomology. Treatments are usually palliative rather than curative. Pharmacists can assist patients with medication therapy management for some symptoms of TSC and SWS.										0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	JAN	2021	46	1					22	26					5	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	PY9CO	WOS:000612338200006					2022-04-28	
J	Caliendo, T; Hiles, O				Caliendo, Tina; Hiles, Olga			Probiotic Use in Gastrointestinal Disorders	US PHARMACIST			English	Article								Probiotics are live microorganisms that are available without a prescription for use as dietary supplements. In the United States, millions of adults have taken some form of probiotic to treat or prevent a variety of conditions, most commonly gastrointestinal (GI) disorders. Based on the widespread use of these products specifically for improvement of GI health, in 2020 the American Gastroenterological Association published clinical practice guidelines with evidence-based recommendations for probiotics in the treatment and/or prevention of prioritized disorders. Pharmacists should incorporate these recommendations into patient care and educational activities as appropriate, and they should understand the variations in available probiotic formulations and combinations as well as the need for more research to determine the safety and potential health benefits of different probiotic strains.	[Caliendo, Tina; Hiles, Olga] St Johns Univ, Coll Pharm & Hlth Sci, Queens, NY 11439 USA		Caliendo, T (通讯作者)，St Johns Univ, Coll Pharm & Hlth Sci, Queens, NY 11439 USA.							0	0	0	2	2	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	DEC	2021	46	12					18	20					3	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	XY4CD	WOS:000736921600007					2022-04-28	
J	[Anonymous]				[Anonymous]			Pediatric Antibiotic Prescriptions Plummet During Pandemic	US PHARMACIST			English	Editorial Material																		0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	AUG	2021	46	8					1	1					1	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	UB4JE	WOS:000685813400001					2022-04-28	
J	[Anonymous]				[Anonymous]			COVID-19 NEWS DIGEST	US PHARMACIST			English	Editorial Material																		0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	JUN	2021	46	6					44	46					3	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	SR7UE	WOS:000661251200014					2022-04-28	
J	[Anonymous]				[Anonymous]			Adult Vaccination Recommendations Updated by Public Health Officials	US PHARMACIST			English	Editorial Material																		0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	APR	2021	46	4					36	39					4	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	SE9UN	WOS:000652412200014					2022-04-28	
J	[Anonymous]				[Anonymous]			PATIENTEDUCATION. Why Is the Prostate Important?	US PHARMACIST			English	Editorial Material																		0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	SEP	2021	46	9					38	38					1	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	UT3BM	WOS:000697994900010					2022-04-28	
J	Dellarocca, MA				Dellarocca, Mena Alrais			The Pharmacist's Role in Pediatric Poison Control	US PHARMACIST			English	Article							AMERICAN-ASSOCIATION; EXPOSURE	Poisoning is a significant public-health issue for children and adolescents. Most poisoning cases occurring in this patient population are unintentional, and most exposures occur in the home. Because pharmacists are drug experts, the community relies on them to be knowledgeable about ingredients found not only in drugs but also in OTC supplements and household products. For this reason, pharmacists may receive incoming calls or cases concerning pediatric ingestion of possibly harmful products. Pharmacists should accordingly be aware of the many aspects of poison control and its public-health implications and understand how to refer and possibly manage these cases with the help of the appropriate resources.	[Dellarocca, Mena Alrais] Univ Southern Calif, Sch Pharm, Pharm Practice, Los Angeles, CA 90007 USA		Dellarocca, MA (通讯作者)，Univ Southern Calif, Sch Pharm, Pharm Practice, Los Angeles, CA 90007 USA.						Bond GR, 2012, J PEDIATR-US, V160, P265, DOI 10.1016/j.jpeds.2011.07.042; CDC, POIS PREV; Gummin DD, 2020, CLIN TOXICOL, V58, P1360, DOI 10.1080/15563650.2020.1834219; Gummin DD, 2019, CLIN TOXICOL, V57, P1220, DOI 10.1080/15563650.2019.1677022; HealthyChildren.org, POIS PREV TREATM TIP; KidsHealth, HOUS SAF PREV POIS; LITOVITZ T, 1992, PEDIATRICS, V89, P999; Lovegrove MC, 2015, PEDIATRICS, V136, pE821, DOI 10.1542/peds.2015-2092; Neville K, 2015, PEDIATRICS, V135, P784, DOI 10.1542/peds.2015-0072; Pandve Harshal T, 2014, J Family Med Prim Care, V3, P309; Safe Kids Worldwide, POIS PREV TIPS; Spiller HA, 2019, J PEDIATR-US, V210, P201, DOI 10.1016/j.jpeds.2019.02.045; Wolkin AF, 2012, ANN EMERG MED, V59, P56, DOI 10.1016/j.annemergmed.2011.08.004; Wynn PM, 2016, INT J INJ CONTROL SA, V23, P3, DOI 10.1080/17457300.2015.1032978; Yip L, 2020, MMWR-MORBID MORTAL W, V69, P1070, DOI 10.15585/mmwr.mm6932e1	15	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	AUG	2021	46	8					HS10	HS16					7	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	UB4JE	WOS:000685813400005					2022-04-28	
J	LaPreze, J; Robinson, A				LaPreze, Jennifer; Robinson, Alexis			The Impact of COVID-19 on Mental Health in Patients	US PHARMACIST			English	Editorial Material								Mental health concerns have risen amid the coronavirus disease 2019 (COVID-19) pandemic. Depression and anxiety symptoms are exacerbated due to fear, uncertainty, and social isolation. Full mental health assessments of patients affected by COVID-19 should be completed to help guide treatment of depression and anxiety. Pharmacists can ensure that appropriate treatment is initiated and continued with appropriate monitoring. Treatment is individualized based on comorbidities, interactions, and patient needs. Telehealth solutions are utilized in the inpatient and outpatient settings to provide mental health services. Ultimately, additional research is needed regarding the long-term impact of the COVID-19 pandemic on mental health.	[LaPreze, Jennifer] Atrium Hlth, Ft Mill, SC 29715 USA; [Robinson, Alexis] Atrium Hlth, Ambulatory Setting, Charlotte, NC USA		LaPreze, J (通讯作者)，Atrium Hlth, Ft Mill, SC 29715 USA.							0	0	0	0	3	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	MAY	2021	46	5					HS7	HS12					6	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	SE9UV	WOS:000652413000009					2022-04-28	
J	Clark, KJ; Braga, SFF; Dalton, EE				Clark, Kelly J.; Braga, Sarah F. Fowler; Dalton, Erin E.			PMS and PMDD: Overview and Current Treatment Approaches	US PHARMACIST			English	Article								Premenstrual disorders are common among premenopausal women and can have a major impact on their daily lives. Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) can cause physical symptoms and (c) gettyimages.com / JobsonHealthcare psychological symptoms similar to those of depression, with PMDD being the most severe form of PMS. Treatment approaches range from lifestyle changes and self-care to behavioral therapies and prescription medications. Many patients express a preference for OTC supplements as a more natural approach to treating their symptoms. Selective serotonin reuptake inhibitors are the gold standard for pharmacologic treatment of PMS and PMDD. Pharmacist knowledge of these various therapies is invaluable for informing patients' treatment selection, medication adherence, and therapeutic progress.	[Clark, Kelly J.; Braga, Sarah F. Fowler; Dalton, Erin E.] South Univ, Sch Pharm, Dept Pharm Practice, Columbia, SC 29203 USA		Clark, KJ (通讯作者)，South Univ, Sch Pharm, Dept Pharm Practice, Columbia, SC 29203 USA.							0	0	0	4	6	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	SEP	2021	46	9					21	25					5	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	UT3BM	WOS:000697994900007					2022-04-28	
J	Burmeister, MA; Fincher, TK; Todd, AM; Virga, KG; Maddox, MM				Burmeister, Melissa A.; Fincher, Timothy K.; Todd, Anthony M.; Virga, Kristopher G.; Maddox, Mary M.			An Overview of Male Osteoporosis	US PHARMACIST			English	Article							FRACTURE RISK; BONE; MEN; TESTOSTERONE; PATHOGENESIS; PREDICTION; MANAGEMENT; ANDROGENS; SKELETAL; BMD	Osteoporosis is characterized by aberrant bone remodeling that results in reduced bone mineral density, excessive bone loss, and increased fracture risk. Although osteoporosis most commonly affects postmenopausal women, it also occurs in older men. Some of the risk factors associated with male osteoporosis are age 70 years or older, reduced testosterone, sedentary lifestyle, poor nutrition, and medications that impair healthy bone turnover. Osteoporosis is undertreated in men, and screening is not routine. Given that men experience decreased quality of life and have an increased mortality risk following a traumatic fracture event, it is imperative for pharmacists to be aware of risk factors, causes, and pharmacologic and nonpharmacologic management of male osteoporosis in order to counsel this patient segment.	[Burmeister, Melissa A.; Fincher, Timothy K.; Virga, Kristopher G.; Maddox, Mary M.] William Carey Univ, Sch Pharm, Dept Pharmaceut Sci, Biloxi, MS 39532 USA; [Todd, Anthony M.; Maddox, Mary M.] William Carey Univ, Sch Pharm, Dept Pharm Practice, Biloxi, MS USA		Burmeister, MA (通讯作者)，William Carey Univ, Sch Pharm, Dept Pharmaceut Sci, Biloxi, MS 39532 USA.						Adler RA, 2018, BEST PRACT RES CL EN, V32, P759, DOI 10.1016/j.beem.2018.05.007; Adler RA, 2014, BONE RES, V2, DOI 10.1038/boneres.2014.1; Adler RA, 2011, THER ADV MUSCULOSKEL, V3, P191, DOI 10.1177/1759720X11411600; Adler RA, 2011, MATURITAS, V68, P143, DOI 10.1016/j.maturitas.2010.11.003; Almeida M, 2017, PHYSIOL REV, V97, P135, DOI 10.1152/physrev.00033.2015; Alswat Khaled A, 2017, J Clin Med Res, V9, P382, DOI 10.14740/jocmr2970w; [Anonymous], 2019, FOS AL PACK INS; [Anonymous], 2020, EV ROM AQQG PACK INS; [Anonymous], 2019, ACT RIS PACK INS; [Anonymous], 2020, BON IB PACK INS; [Anonymous], 2020, FORT TER PACK INS; [Anonymous], 2021, PROL DEN PACK INS; [Anonymous], 2018, ZOM ZOL AC PACK INS; Aw D, 2016, POSTGRAD MED J, V92, P267, DOI 10.1136/postgradmedj-2015-133454; Briot K, 2015, RMD OPEN, V1, DOI 10.1136/rmdopen-2014-000014; Clinical resource #361008, 2020, PHARM LETT       OCT; Cosman F, 2014, OSTEOPOROSIS INT, V25, P2359, DOI 10.1007/s00198-014-2794-2; Dimai HP, 2017, BONE, V104, P39, DOI 10.1016/j.bone.2016.12.016; Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032; Ebeling PR, 2008, NEW ENGL J MED, V358, P1474, DOI 10.1056/NEJMcp0707217; Endo Y, 2005, J ORTHOP TRAUMA, V19, P29, DOI 10.1097/00005131-200501000-00006; Faria, 2014, ENDOCRINOLOGY DIABET, P293; FEHER JJ, 1992, AM J PHYSIOL, V262, pC517, DOI 10.1152/ajpcell.1992.262.2.C517; Fitzpatrick LA, 2002, MAYO CLIN PROC, V77, P453, DOI 10.4065/77.5.453; Foger-Samwald U, 2020, EXCLI J, V19, P1017, DOI 10.17179/excli2020-2591; Gadam RK, 2013, ENDOCR PRACT, V19, P780, DOI 10.4158/EP12416.OR; Glass DA, 2006, CURR TOP DEV BIOL, V73, P43, DOI 10.1016/S0070-2153(05)73002-7; Gross RA, 2004, NEUROLOGY, V62, pE24, DOI 10.1212/01.WNL.0000129704.29460.FA; Guise TA, 2006, ONCOLOGIST, V11, P1121, DOI 10.1634/theoncologist.11-10-1121; Hodsman AB, 2005, ENDOCR REV, V26, P688, DOI 10.1210/er.2004-0006; Jeremiah MP, 2015, AM FAM PHYSICIAN, V92, P261; Kastelan D, 2006, MED HYPOTHESES, V67, P1052, DOI 10.1016/j.mehy.2006.04.040; Komrakova M, 2020, CALCIFIED TISSUE INT, V107, P593, DOI 10.1007/s00223-020-00751-x; Leslie WD, 2012, J CLIN ENDOCR METAB, V97, P4329, DOI 10.1210/jc.2012-2863; Lewiecki EM, 2018, J CLIN ENDOCR METAB, V103, P3183, DOI 10.1210/jc.2017-02163; Maalouf NM, 2005, J CLIN ENDOCR METAB, V90, P2456, DOI 10.1210/jc.2004-1978; McClung M, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2167; McDonough AK, 2008, NAT CLIN PRACT ENDOC, V4, P507, DOI 10.1038/ncpendmet0920; Michael H, 2005, J BONE MINER RES, V20, P2224, DOI 10.1359/JBMR.050803; Noirrit-Esclassan E, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22041568; Orwoll E, 2000, NEW ENGL J MED, V343, P604, DOI 10.1056/NEJM200008313430902; Pietrzyk B, 2017, ADV CLIN EXP MED, V26, P1283, DOI 10.17219/acem/68739; Ralston SH, 2007, P NUTR SOC, V66, P158, DOI 10.1017/S002966510700540X; Rao SS, 2010, AM FAM PHYSICIAN, V82, P503; RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605; Sansone Randy A, 2012, Innov Clin Neurosci, V9, P42; Sapre S, 2021, J MIDLIFE HLTH, V5, P3; Shetty Sahana, 2016, Indian J Endocrinol Metab, V20, P846; Shigehara K, 2021, J CLIN MED, V10, DOI 10.3390/jcm10030530; Signorelli SS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20215275; SPENCER H, 1985, J AM COLL NUTR, V4, P121; Stewart TL, 2000, J ENDOCRINOL, V166, P235, DOI 10.1677/joe.0.1660235; Sunyecz John A, 2008, Ther Clin Risk Manag, V4, P827; Thong BKS, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16091571; Tuchendler D, 2014, THYROID RES, V7, DOI 10.1186/s13044-014-0012-0; Vanderschueren D, 2004, ENDOCR REV, V25, P389, DOI 10.1210/er.2003-0003; Veronese N, 2021, ORTHOGERIATRICS MANA	57	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	JUN	2021	46	6					18	24					7	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	SR7UE	WOS:000661251200008					2022-04-28	
J	Mospan, C				Mospan, Cortney			Osteoarthritis 2019 Guideline Updates and Best Practices	US PHARMACIST			English	Editorial Material									[Mospan, Cortney] Wingate Univ, Levine Coll Hlth Sci, Pharm, Wingate, NC 28174 USA		Mospan, C (通讯作者)，Wingate Univ, Levine Coll Hlth Sci, Pharm, Wingate, NC 28174 USA.							0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	APR	2021	46	4					49	56					8	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	SE9UN	WOS:000652412200017					2022-04-28	
J	Terrie, YC				Terrie, Yvette C.			Challenges in Managing and Preventing Rheumatoid Arthritis Pain	US PHARMACIST			English	Article								Rheumatoid arthritis (RA) is a prevalent chronic, progressive, inflammatory autoimmune disease that affects not only the joints but also other organs, including the eyes, heart, and lungs. It is characterized by painful, tender, and swollen joints that can significantly affect a patient's quality of life and productivity due to pain, stiffness, and sleep disturbances. Pain is often reported as the most debilitating symptom associated with RA. Pharmacologic therapies used in the treatment and management of RA include nonbiologic and biologic disease-modifying antirheumatic drugs and adjunctive agents such as immunosuppressants, corticosteroids, nonsteroidal anti-inflammatory drugs, and other analgesics. Pharmacists can educate patients and make clinical recommendations when warranted to improve clinical outcomes.	[Terrie, Yvette C.] Freelance Med Writer, Haymarket, VA 20169 USA		Terrie, YC (通讯作者)，Freelance Med Writer, Haymarket, VA 20169 USA.							0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	MAR	2021	46	3					42	47					6	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	QU8YG	WOS:000627563800012					2022-04-28	
J	Chim, C; Sharma, P				Chim, Christine; Sharma, Pallak			Pharmacists Prescribing Hormonal Contraceptives: A Status Update	US PHARMACIST			English	Article								Since Oregon became the first state allowing pharmacists to prescribe hormonal contraceptives, many other states across the country have followed suit. States vary in terms of what pharmacists are allowed to do when furnishing hormonal contraceptives based on the designated prescriptive authority. Training requirements typically entail a state board-approved program or continuing education program. General steps for a pharmacist to prescribe hormonal contraceptives include screening, counseling, documentation, and monitoring. Some states have restrictions in their protocols. Community pharmacists remain integral providers who can prescribe hormonal contraceptives within their scope of practice.	[Chim, Christine; Sharma, Pallak] St Johns Univ, Coll Pharm & Hlth Sci, Queens, NY 11439 USA		Chim, C (通讯作者)，St Johns Univ, Coll Pharm & Hlth Sci, Queens, NY 11439 USA.						[Anonymous], 2018, TENNESSEE CODE CHAPT; California State Legislature, 493 CAL STAT LEG; Hawaii State Legislature, 2017, SB 513 PHARM PRESCR; Idaho Legislature, 2019, HOUS BILL 182 PHARM; Joslin CM, 2020, R STREET POLICY STUD; Joslin CM, 2018, R STREET POLICY STUD; Kellogg S, 2021, SENATE COMMITTEE PAS; Landau, 2019, BIRTH CONTROL PHARM; Nevada Legislature, SB 190 2021 LEG 81 S; Oregon Legislature, HB 2879 2015 LEG REG; Orris A., 2021, IMPLEMENTING PHARM C; Rodriguez MI, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.5252; Tepper NK, 2020, MMWR-MORBID MORTAL W, V69, P405, DOI 10.15585/mmwr.mm6914a3; Vermont Legislature, 2020, ACT NO 157 H663 HLTH	14	0	0	1	1	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	SEP	2021	46	9					45	49					5	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	UT3BM	WOS:000697994900012					2022-04-28	
J	Pal, S				Pal, Somnath			Trends in Selected Parameters of Men's Health	US PHARMACIST			English	Editorial Material									[Pal, Somnath] St Johns Univ, Coll Pharm & Hlth Sci, Pharm Adm, Jamaica, NY 11439 USA		Pal, S (通讯作者)，St Johns Univ, Coll Pharm & Hlth Sci, Pharm Adm, Jamaica, NY 11439 USA.							0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	JUN	2021	46	6					14	14					1	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	SR7UE	WOS:000661251200006					2022-04-28	
J	Sarbacker, GB; Sarbacker, LC				Sarbacker, G. Blair; Sarbacker, Lloyd C.			Revisiting Heart Failure: Guidelines and Beyond	US PHARMACIST			English	Article							PHARMACIST	Heart-failure prevalence continues to rise. Despite new treatments, 5-year mortality remains around 50%. Men are more likely to have heart failure with reduced ejection fraction, which has a plethora of treatment options available to decrease morbidity and mortality. New agents to target heart failure have been discovered since the last update to the guidelines in 2017. Health system pharmacists play a significant role in heart failure management, helping to decrease hospital readmission rates via appropriate drug selection and patient counseling.	[Sarbacker, G. Blair] Presbyterian Coll, Sch Pharm, Pharm Practice, Clinton, SC 29325 USA; [Sarbacker, Lloyd C.] Bon Secours St Francis, Greenville, SC USA		Sarbacker, GB (通讯作者)，Presbyterian Coll, Sch Pharm, Pharm Practice, Clinton, SC 29325 USA.			Sarbacker, G. Blair/0000-0003-3081-6935			Anderson SL, 2018, ADV THER, V35, P311, DOI 10.1007/s12325-018-0671-7; Armstrong PW, 2020, NEW ENGL J MED, V382, P1883, DOI 10.1056/NEJMoa1915928; Chang PP, 2018, CIRCULATION, V138, P12, DOI 10.1161/CIRCULATIONAHA.117.027551; CHEN J, 2018, INTEG PHARM RES PRAC, V7, DOI DOI 10.3390/IJGI7060213; Christensen M, 2013, COCHRANE DB SYST REV, V2; Eggink RN, 2010, PHARM WORLD SCI, V32, P759, DOI 10.1007/s11096-010-9433-6; Folsom AR, 2015, AM J MED, V128, P970, DOI 10.1016/j.amjmed.2015.03.027; Martinez AS, 2013, AM J HEALTH-SYST PH, V70, P1070, DOI 10.2146/ajhp120267; McMurray JJV, 2019, NEW ENGL J MED, V381, P1995, DOI 10.1056/NEJMoa1911303; McMurray JJV, 2014, NEW ENGL J MED, V371, P993, DOI 10.1056/NEJMoa1409077; Murray MD, 2007, ANN INTERN MED, V146, P714, DOI 10.7326/0003-4819-146-10-200705150-00005; Neal B, 2017, NEW ENGL J MED, V377, P644, DOI 10.1056/NEJMoa1611925; Noschese Laurie A, 2017, Fed Pract, V34, pS10; Pallangyo P, 2020, BMC RES NOTES, V13, DOI 10.1186/s13104-020-04959-w; Peri-Okonny PA, 2019, JACC-HEART FAIL, V7, P350, DOI 10.1016/j.jchf.2018.11.011; Perkovic V, 2019, NEW ENGL J MED, V380, P2295, DOI 10.1056/NEJMoa1811744; Ruppar TM, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.115.002606; Ryan R, 2011, COCHRANE DB SYST REV, V5; SAMSON P, 2012, 1 REPORT MANAGED CAR, V9; Seid MA, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211768; Steinberg BA, 2012, CIRCULATION, V126, P65, DOI 10.1161/CIRCULATIONAHA.111.080770; Swedberg K, 2010, LANCET, V376, P875, DOI 10.1016/S0140-6736(10)61198-1; Virani SS, 2021, CIRCULATION, V143, pe254, DOI 10.1161/CIR.0000000000000950; Warden BA, 2014, AM J HEALTH-SYST PH, V71, P134, DOI 10.2146/ajhp130103; Wiviott SD, 2019, NEW ENGL J MED, V380, P347, DOI 10.1056/NEJMoa1812389; Yancy CW, 2017, J AM COLL CARDIOL, V70, P776, DOI 10.1016/j.jacc.2017.04.025; YANCY CW, 2013, J AM COLL CARDIOL, V62, pE14, DOI DOI 10.1016/J.JACC.2013.05.019; Zinman B, 2016, NEW ENGL J MED, V374, P1094, DOI 10.1056/NEJMc1600827	28	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	JUN	2021	46	6					HS2	HS10					9	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	SR7UE	WOS:000661251200004					2022-04-28	
J	Yousuf, A; Jacob, EC				Yousuf, Adwah; Jacob, Elsen C.			Uncovering the Impact of Storage on Generic Medications	US PHARMACIST			English	Article							SOCIOECONOMIC-STATUS	Storage conditions are vitally important to the overall integrity and quality of medications, and the United States Pharmacopeial Convention, the FDA, and drug manufacturers provide guidelines for proper storage. However, this factor is often overlooked, ultimately impacting the quality of the drug products patients use. The increase in the use of medication mail-order and delivery services magnifies the importance of strict adherence to recommended storage criteria from the point of manufacture to distribution of the medication to the patient. Pharmacists can play an integral role in educating patients and finding ways to overcome barriers preventing their adherence to storage protocols; additionally, pharmacists are best suited to monitoring and advising on the many factors that could impact the quality of the drug products their patients use.	[Yousuf, Adwah] St Johns Univ, Coll Pharm & Hlth Sci, Queens, NY 11439 USA; [Jacob, Elsen C.] St Johns Univ, Dept Clin Hlth Profess, Coll Pharm & Hlth Sci, Queens, NY USA		Yousuf, A (通讯作者)，St Johns Univ, Coll Pharm & Hlth Sci, Queens, NY 11439 USA.						ALKHAWAJAH AM, 1992, PUBLIC HEALTH, V106, P231, DOI 10.1016/S0033-3506(05)80541-4; Allegra JR, 1999, ACAD EMERG MED, V6, P1098, DOI 10.1111/j.1553-2712.1999.tb00110.x; [Anonymous], BUSINESS WIRE; [Anonymous], 2011, NITR NITR SUBL TABL; Braune K, 2019, DIABETES TECHNOL THE, V21, P238, DOI 10.1089/dia.2019.0046; Charter Home Health, WHY PROP MED STOR ES; Constance J, 2020, INT J PUBLIC HEALTH, V65, P1773, DOI 10.1007/s00038-020-01513-0; Curtis LM, 2012, J ASTHMA, V49, P178, DOI 10.3109/02770903.2011.648297; FDA, DSCSA PIL PROJ PROGR; Gintzler International, WHAT IS PED WHY IS I; Graedon J, WAS YOUR MED STORED; Hopkins J, MAIL ORDER DRUG DELI; Huntley GD, 2017, ACAD MED, V92, P221, DOI 10.1097/ACM.0000000000001514; Lyle A, OPINION MAIL ORDER P; Mansur JM, 2016, DRUG AGING, V33, P213, DOI 10.1007/s40266-016-0358-1; Mullins CD, 2005, AM J HEALTH-SYST PH, V62, P1873, DOI 10.2146/ajhp050064; Pilz J, CAN EXTREME WEATHER; Smith A., EXTREME TEMPERATURES; Sumners C, DRUG STABILITY STORA; Swichtenberg B, DRUG PEDIGREE STANDA; U.S. Pharmacopeia, 1079 GOOD STOR SHIPP; U.S. Pharmacopeia, USP; U.S. Pharmacopeia -National Formulary, GEN CHAPT 659 PACK S; Vlieland ND, 2016, RHEUMATOLOGY, V55, P704, DOI 10.1093/rheumatology/kev394; Yin HS, 2012, ACAD PEDIATR, V12, P117, DOI 10.1016/j.acap.2012.01.001	25	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	JUN	2021	46	6					30	38					9	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	SR7UE	WOS:000661251200010					2022-04-28	
J	Allen, LV				Allen, Loyd V., Jr.			Atomoxetine 4 mg/mL Oral Solution/Suspension This preparation may be used to treat attention-deficit/hyperactivity disorder	US PHARMACIST			English	Editorial Material									[Allen, Loyd V., Jr.] Univ Oklahoma, Coll Pharm, Oklahoma City, OK 73106 USA		Allen, LV (通讯作者)，Univ Oklahoma, Coll Pharm, Oklahoma City, OK 73106 USA.						Allen Loyd V Jr, 2019, Int J Pharm Compd, V23, P299; Allen Loyd V Jr, 2019, Int J Pharm Compd, V23, P211; [Anonymous], 2018, ORA SWEET PRODUCT IN; [Anonymous], 2018, ORA SWEET SF PRODUCT; [Anonymous], 2018, ORA PLUS PRODUCT INF; Brayfield A, 2014, MARTINDALE COMPLETE, P2214; Electronic Medicines Compendium, STRATTERA 4 MGML ORA; PubChem, ATOMOXETINE; U.S. Pharmacopeia/National Formulary, 2021, US PHARM NAT FORM CU	9	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	MAY	2021	46	5					60	61					2	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	SE9UV	WOS:000652413000022					2022-04-28	
J	Floris, L				Floris, Lauren			The Role of Oral Antibiotics in Bacterial Bloodstream Infections	US PHARMACIST			English	Article								IV antibiotics are generally thought to be the mainstay of treatment for bloodstream infections due to their high bioavailability and fast peak plasma levels. However, the ideal route of administration of any medication is one that achieves serum concentrations sufficient to produce the desired result without any unwanted effects. Associated costs and risks with IV agents make them less than ideal in many infectious diseases, including bacteremia. Oral therapy offers several benefits with similar outcomes, and the decision to treat a patient with oral antibiotics should be based on current evidence as well as patient, pathogen, and drug characteristics.	[Floris, Lauren] Atrium Navicent Hlth Med Ctr, Macon, GA 31201 USA		Floris, L (通讯作者)，Atrium Navicent Hlth Med Ctr, Macon, GA 31201 USA.							0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	APR	2021	46	4					17	20					4	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	SE9UN	WOS:000652412200010					2022-04-28	
J	Chung, C				Chung, Clement			Pharmacologic Management of Cancer-Related Pain	US PHARMACIST			English	Article								Cancer-induced pain reflects a multiplicity of underlying mechanisms. It may arise from nociceptive damage, neuropathic damage, or both, and neuropathic pain may also be related to treatment. Initial and ongoing assessment of pain should be an integral part of supportive oncology. A variety of options are available for pain management, depending on the type and source of the pain. Opioids are the mainstay of management of moderate-to-severe cancer-induced pain. Interventional management of pain, which comprises a number of invasive analgesic therapies, may be used in selected patients. Buprenorphine, a biased opioid agonist, produces analgesia with fewer adverse effects. The use of pharmacogenomic testing for opioids remains controversial in cancer patients.	[Chung, Clement] Houston Methodist West Hosp, Houston, TX 77094 USA		Chung, C (通讯作者)，Houston Methodist West Hosp, Houston, TX 77094 USA.							0	0	0	0	1	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	MAR	2021	46	3					HS1	+					8	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	QU8YG	WOS:000627563800004					2022-04-28	
J	Kathuria, A; Roosan, MR; Sharma, A				Kathuria, Avani; Roosan, Moom R.; Sharma, Ajay			CYP2C9 Polymorphism and Use of Oral Nonsteroidal Anti-Inflammatory Drugs	US PHARMACIST			English	Article								Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used for management of inflammation and pain, but they can cause gastrointestinal, cardiovascular, and renal adverse effects. Genetic variations in CYP450 enzymes affect their metabolic activity, thus impacting the hepatic clearance, elimination half-life, and risk of adverse effects of drugs metabolized by that CYP. Celecoxib, ibuprofen, flurbiprofen, meloxicam, and piroxicam are significantly metabolized by CYP2C9. The Clinical Pharmacogenetic Implementation Consortium has published evidence-based recommendations on CYP2C9 polymorphism-based safe usage of NSAIDs. As pharmacogenetics becomes more common, pharmacists will play a critical role in optimizing drug regimens based on pharmacogenetic test results.	[Kathuria, Avani] CVS Hlth, Orange, CA 92868 USA; [Roosan, Moom R.] Chapman Univ, Sch Pharm, Irvine, CA USA; [Sharma, Ajay] Chapman Univ, Sch Pharm, Pharmacol, Irvine, CA USA		Kathuria, A (通讯作者)，CVS Hlth, Orange, CA 92868 USA.							0	1	1	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	MAR	2021	46	3					23	+					7	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	QU8YG	WOS:000627563800009					2022-04-28	
J	Ledan, SH				Ledan, Seema H.			Managing Cardiovascular Risk Post Transplant	US PHARMACIST			English	Article								Cardiovascular (CV) disease is a major cause of graft loss and the leading cause of death in renal-transplant recipients. Nearly 40% of patients have a CV-related event within 36 months after transplantation, with congestive heart failure being the major known cause of CV mortality and hospital readmission. The incidence of myocardial infarction is high as well among transplant recipients. Management should focus on identifying and optimizing modifiable risk factors and maintaining allograft function to reduce CV events.	[Ledan, Seema H.] Kaiser Permanente Midatlantic States, Clin Pharm Serv, Silver Spring, MD 20904 USA		Ledan, SH (通讯作者)，Kaiser Permanente Midatlantic States, Clin Pharm Serv, Silver Spring, MD 20904 USA.							0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	FEB	2021	46	2					HS12	HS17					5	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	QU8YE	WOS:000627563600004					2022-04-28	
J	Jacob, EC				Jacob, Elsen C.			Understanding the Neurologic Manifestations of COVID-19	US PHARMACIST			English	Article								Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus that causes coronavirus disease 2019 (COVID-19), has impacted many people worldwide. SARS-CoV-2 primarily affects the respiratory system and has the potential to result in serious illness and death. However, it is now recognized that COVID-19 infection can manifest beyond the respiratory tract. In fact, the neurologic, cardiovascular, renal, hematologic, dermatologic, and gastrointestinal systems may be affected. Neurologic sequelae are wide-ranging and may include loss of taste, loss of smell, acute cerebrovascular disease, seizures, encephalopathy, encephalitis, and Guillain-Barre syndrome. In order to adequately care for patients, it is important for pharmacists to have a good understanding of these neurologic complications.	[Jacob, Elsen C.] St Johns Univ, Coll Pharm & Hlth Sci, Dept Clin Hlth Profess, Queens, NY 11439 USA		Jacob, EC (通讯作者)，St Johns Univ, Coll Pharm & Hlth Sci, Dept Clin Hlth Profess, Queens, NY 11439 USA.						Agyeman AA, 2020, MAYO CLIN PROC, V95, P1621, DOI 10.1016/j.mayocp.2020.05.030; American Academy of Otolaryngology-Head and Neck Surgery, COVID 19 AN REP TOOL; Baig AM, 2020, ACS CHEM NEUROSCI, V11, P995, DOI 10.1021/acschemneuro.0c00122; Berlin DA, 2020, NEW ENGL J MED, V383, P2451, DOI 10.1056/NEJMcp2009575; Byambasuren O., 2020, OFF J ASS MED MICROB, V5, P223, DOI DOI 10.3138/JAMMI-2020-0030; Carrillo-Larco Rodrigo M, 2020, Wellcome Open Res, V5, P107, DOI 10.12688/wellcomeopenres.15987.1; CDC, HUM COR TYP; CDC, WHAT IS ME CFS; CDC, COVID 19 PROT YOURS; CDC, COVID 19 COR DIS SYM; Centers for Disease Control and Prevention (CDC), TREATM ME CFS; Cardona GC, 2020, J NEUROL SCI, V412, DOI 10.1016/j.jns.2020.116824; Davido B, 2020, CLIN MICROBIOL INFEC, V26, P1448, DOI 10.1016/j.cmi.2020.07.028; Dell'Era V, 2020, HEAD NECK-J SCI SPEC, V42, P1591, DOI 10.1002/hed.26288; Diez-Porras L, 2020, NEUROMUSCULAR DISORD, V30, P859, DOI 10.1016/j.nmd.2020.08.354; Ellul MA, 2020, LANCET NEUROL, V19, P767, DOI 10.1016/S1474-4422(20)30221-0; FDA, FDA TAK ADD ACT FIGH; Gandhi RT, 2020, NEW ENGL J MED, V383, P1757, DOI 10.1056/NEJMcp2009249; Garrigues E, 2020, J INFECTION, V81, pE4, DOI 10.1016/j.jinf.2020.08.029; Goff Debra A, 2020, J Am Coll Clin Pharm, DOI 10.1002/jac5.1329; Iadecola C, 2020, CELL, V183, P16, DOI 10.1016/j.cell.2020.08.028; Khan S, 2020, ELIFE, V9, DOI 10.7554/eLife.59136; Khatoon F, 2020, J NEUROVIROL, V26, P619, DOI 10.1007/s13365-020-00895-4; Lavezzo E, 2020, NATURE, V584, P425, DOI 10.1038/s41586-020-2488-1; Lechien JR, 2020, EUR ARCH OTO-RHINO-L, V277, P2251, DOI 10.1007/s00405-020-05965-1; Li YC, 2020, J MED VIROL, V92, P552, DOI 10.1002/jmv.25728; Mainland JD, 2020, CHEM SENSES, V45, P493, DOI 10.1093/chemse/bjaa038; Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127; Montalvan V, 2020, CLIN NEUROL NEUROSUR, V194, DOI 10.1016/j.clineuro.2020.105921; Nepal G, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03121-z; Nordvig AS, 2020, NEUROL CLIN PRACT; Pierron D, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18963-y; Qureshi AI, 2020, INT J STROKE, V15, P540, DOI 10.1177/1747493020923234; Rubin R, 2020, JAMA-J AM MED ASSOC, V324, P1381, DOI 10.1001/jama.2020.17709; Scheidl E, 2020, J PERIPHER NERV SYST, V25, P204, DOI 10.1111/jns.12382; Shang J, 2020, P NATL ACAD SCI USA, V117, P11727, DOI 10.1073/pnas.2003138117; Tenforde MW, 2020, MMWR-MORBID MORTAL W, V69, P993, DOI 10.15585/mmwr.mm6930e1externalicon; Tolebeyan AS, 2020, HEADACHE, V60, P2131, DOI 10.1111/head.13980; Toptan T, 2020, HEADACHE, V60, P1788, DOI 10.1111/head.13940; Uncini A, 2020, J NEUROL NEUROSUR PS, V91, P1105, DOI 10.1136/jnnp-2020-324491; Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045; Wei WE, 2020, MMWR-MORBID MORTAL W, V69, P411, DOI 10.15585/mmwr.mm6914e1; Wenting A, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.00860; Whitcroft KL, 2020, JAMA-J AM MED ASSOC, V323, P2512, DOI 10.1001/jama.2020.8391; Whittaker A, 2020, ACTA NEUROL SCAND, V142, P14, DOI 10.1111/ane.13266; WHO, GLOB SCI COMM UN TRA; WHO, PNEUM UNKN CAUS CHIN; Wiersinga WJ, 2020, JAMA-J AM MED ASSOC, V324, P782, DOI 10.1001/jama.2020.12839; Willison HJ, 2016, LANCET, V388, P717, DOI 10.1016/S0140-6736(16)00339-1; World Health Organization, WHO DIR GEN OP REM M; Xydakis MS, 2020, LANCET INFECT DIS, V20, P1015, DOI 10.1016/S1473-3099(20)30293-0; Zhang RY, 2020, P NATL ACAD SCI USA, V117, P14857, DOI 10.1073/pnas.2009637117; Zhou ZQ, 2020, J NEUROL, V267, P2179, DOI 10.1007/s00415-020-09929-7; Zimmer C, 2018, NY TIMES; Zubair AS, 2020, JAMA NEUROL, V77, P1018, DOI 10.1001/jamaneurol.2020.2065	55	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	JAN	2021	46	1					33	41					9	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	PY9CO	WOS:000612338200008					2022-04-28	
J	Liu, AN; Behrend, BA; Ambizas, EM				Liu, Amy N.; Behrend, Benjamin A.; Ambizas, Emily M.			CONSULTYOURPHARMACIST	US PHARMACIST			English	Article									[Liu, Amy N.; Behrend, Benjamin A.] St Johns Univ, Coll Pharm & Hlth Sci, Queens, NY USA; [Ambizas, Emily M.] St Johns Univ, Coll Pharm & Hlth Sci, Experiential Pharm Educ, Queens, NY USA; [Ambizas, Emily M.] Walgreens Pharm, Whitestone, NY USA		Liu, AN (通讯作者)，St Johns Univ, Coll Pharm & Hlth Sci, Queens, NY USA.							0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	NOV	2021	46	11					51	55					5	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	XB5IC	WOS:000721361900009					2022-04-28	
J	Allen, LV				Allen, Loyd V. Jrd			Imipramine Hydrochloride 5 mg/mL Oral Liquid	US PHARMACIST			English	Editorial Material									[Allen, Loyd V. Jrd] Univ Oklahoma, Coll Pharm, Oklahoma City, OK 73106 USA		Allen, LV (通讯作者)，Univ Oklahoma, Coll Pharm, Oklahoma City, OK 73106 USA.						Allen Loyd V Jr, 2019, Int J Pharm Compd, V23, P299; Allen Loyd V Jr, 2019, Int J Pharm Compd, V23, P211; Fagron, SYRSPEND SF FAM PROD; Fagron, PROD INN SYRSPEND SF; Polonini HC, 2016, PHARMAZIE, V71, P185, DOI 10.1691/ph.2016.5177; RxList, TOFR	6	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	AUG	2021	46	8					58	59					2	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	UB4JE	WOS:000685813400017					2022-04-28	
J	Clark, KJ; Braga, SFF; Dalton, EE				Clark, Kelly J.; Braga, Sarah F. Fowler; Dalton, Erin E.			Keys to Sunburn Treatment and Prevention	US PHARMACIST			English	Article								Many people experience sunburn in their lifetime. Symptoms range from redness and pain to blistered skin, headache, fever, and nausea in severe cases. Repeated overexposure to ultraviolet (UV) rays increases the risk of skin cancer, the most common form of cancer in the United States. Preventative measures include hats, sunglasses, clothing, and sunscreen. However, sunburn and the resultant skin damage still occur. Most cases of sunburn are self-limiting, and steps can be taken to mitigate the symptoms. Pharmacists play a pivotal role in educating patients regarding the risks associated with UV exposure, sunburn preventative techniques, and pharmacologic and nonpharmacologic treatment options.	[Clark, Kelly J.; Braga, Sarah F. Fowler] South Univ, Sch Pharm, Dept Pharm Practice, Columbia, SC 29203 USA; [Dalton, Erin E.] South Univ, Sch Pharm, Dept Pharm Practice, Savannah, GA USA		Clark, KJ (通讯作者)，South Univ, Sch Pharm, Dept Pharm Practice, Columbia, SC 29203 USA.						Ambizas EM, 2016, US PHARM, V41, P26; American Academy of Dermatology Association, TREAT SUN BURN; American Academy of Dermatology Association, SUNSCR FAQS; American Academy of Dermatology Association, APPL SUNSCR; American Cancer Society, SKIN CANC PREV EARLY; Anonymous, 2007, Morbidity and Mortality Weekly Report, V56, P524; Balk S.J., 2011, PEDIATRICS, V127, pE791, DOI DOI 10.1542/peds.2010-3502; Beutler AI, 2009, AM FAM PHYSICIAN, V80, P1472; CDC, NIOSH FAST FACTS PRO; Crosby KM, 2018, HDB NONPRESCRIPTION, V19th, P743; FDA, SUNSCR HELP PROT YOU; Federal Register, FED REG; Guerra KC, NCBI BOOKSHELF WEB S; Hartman Anne M., 2012, Morbidity and Mortality Weekly Report, V61, P317; Matta MK, 2019, JAMA-J AM MED ASSOC, V321, P2082, DOI 10.1001/jama.2019.5586; Mayo Clinic, SUNB SYMPT CAUS; Mayo Clinic, BURNS 1 AID; Monseau AJ, 2015, PRIMARY CARE, V42, P591, DOI 10.1016/j.pop.2015.07.003; Narayanan DL, 2010, INT J DERMATOL, V49, P978, DOI 10.1111/j.1365-4632.2010.04474.x; National Cancer Institute, CANC TRENDS PROGR RE; Skin Cancer Foundation, SUNB YOUR SKIN; Stern RS, 2010, ARCH DERMATOL, V146, P279, DOI 10.1001/archdermatol.2010.4; United States Department of Health and Human Services, SKIN CANC QUICK FACT; Young AR, SUNBURN SYMPTOMS CAU	24	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	AUG	2021	46	8					39	42					4	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	UB4JE	WOS:000685813400015					2022-04-28	
J	Kasbekar, R; Ambizas, EM				Kasbekar, Ruchira; Ambizas, Emily M.			Chronic Kidney Disease	US PHARMACIST			English	Article									[Kasbekar, Ruchira] Clover Pharm, Trenton, NJ 08619 USA; [Ambizas, Emily M.] St Johns Univ, Coll Pharm & Hlth Sci, Queens, NJ USA; [Ambizas, Emily M.] Walgreens Pharm, Whitestone, NY USA		Kasbekar, R (通讯作者)，Clover Pharm, Trenton, NJ 08619 USA.							0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	MAR	2021	46	3					6	10					5	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	QU8YG	WOS:000627563800002					2022-04-28	
J	Mefford, BM; Donaldson, JC				Mefford, Breanne M.; Donaldson, J. Chris			Analgesia and Sedation Strategies in COVID-19 Patients	US PHARMACIST			English	Article								The novel severe acute respiratory syndrome coronavirus 2, first discovered in December 2019, has presented with many challenges, impacting individuals globally with many requiring ICU admission and the need for invasive mechanical ventilation secondary to severe acute respiratory distress syndrome. To facilitate appropriate ventilator management, pain and sedation strategies as well as neuromuscular blocking agents are often utilized.	[Mefford, Breanne M.; Donaldson, J. Chris] Univ Kentucky, Dept Pharm, Med Ctr, Lexington, KY 40506 USA		Mefford, BM (通讯作者)，Univ Kentucky, Dept Pharm, Med Ctr, Lexington, KY 40506 USA.							0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	MAR	2021	46	3					HS11	+					5	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	QU8YG	WOS:000627563800005					2022-04-28	
J	[Anonymous]				[Anonymous]			What Is Chronic Kidney Disease?	US PHARMACIST			English	Editorial Material																		0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	MAR	2021	46	3					12	12					1	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	QU8YG	WOS:000627563800003					2022-04-28	
J	Sekhery, B; Ambizas, EM				Sekhery, Bisma; Ambizas, Emily M.			Glaucoma: The Pharmacist Has a Better Vision	US PHARMACIST			English	Editorial Material									[Sekhery, Bisma; Ambizas, Emily M.] St Johns Univ, Coll Pharm & Hlth Sci, Queens, NY 11439 USA; [Ambizas, Emily M.] Walgreens Pharm, Whitestone, NY USA		Sekhery, B (通讯作者)，St Johns Univ, Coll Pharm & Hlth Sci, Queens, NY 11439 USA.							0	0	0	0	1	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	JAN	2021	46	1					28	31					4	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	PY9CO	WOS:000612338200007					2022-04-28	
J	Davidson, R				Davidson, Robert			Diabetes Drug Promising as COVID-19 Lung Inflammation Treatment	US PHARMACIST			English	Editorial Material												rdavidson@uspharmacist.com						0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	JUL	2021	46	7					1	1					1	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	TP3SU	WOS:000677515000001					2022-04-28	
J	Pal, S				Pal, Somnath			Primary Diagnosis of COPD in the Ambulatory-Care Settingy	US PHARMACIST			English	Editorial Material									[Pal, Somnath] St Johns Univ, Coll Pharm & Hlth Sci, Pharm Adm, Jamaica, NY 11439 USA		Pal, S (通讯作者)，St Johns Univ, Coll Pharm & Hlth Sci, Pharm Adm, Jamaica, NY 11439 USA.							0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	JUL	2021	46	7					14	14					1	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	TP3SU	WOS:000677515000005					2022-04-28	
J	Terrie, YC				Terrie, Yvette C.			A Review of the Treatment and Management of Idiopathic Pulmonary Fibrosis	US PHARMACIST			English	Article								Idiopathic pulmonary fibrosis (IPF) is an irreversible, chronic, and progressive pulmonary disorder characterized by thickening and scarring of the lung tissue. The disease course of IPF can be unpredictable, but it is associated with a poor prognosis with an average life expectancy of 2 to 4 years after diagnosis. Common symptoms include shortness of breath and a persistent dry, hacking cough. Although the cause of IPF is unknown, risk factors for the development of IPF include smoking, certain genetic mutations, and possibly gastroesophageal reflux disease. There is no cure. Management of IPF is multifaceted and may include the use of the antifibrotic agents nintedanib and pirfenidone, smoking cessation, and supportive care, including oxygen therapy, pulmonary rehabilitation, and in some cases, lung transplantation. Pharmacists can educate patients about treatments for IPF and make clinical recommendations when warranted that are tailored to patient- specific needs.										0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	JUL	2021	46	7											5	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	TP3SU	WOS:000677515000004					2022-04-28	
J	Smith, UD; Smith, L; Jackson, M; Honeywell, MS; Caldwell, C; Brooks, TCA				Smith, Ukamaka Dike; Smith, Lillian; Jackson, Marissa; Honeywell, Marlon S.; Caldwell, Courtney; Brooks, Travis C. A.			Afinion HbA1c Dx Test	US PHARMACIST			English	Editorial Material									[Smith, Ukamaka Dike] Florida A&M Univ, Coll Pharm & Pharmaceut Sci, Pharm Practice, Tallahassee, FL 32307 USA; [Smith, Lillian] LECOM Sch Pharm Bradenton, Pharm Practice, Bradenton, FL USA; [Jackson, Marissa; Honeywell, Marlon S.; Caldwell, Courtney; Brooks, Travis C. A.] Florida A&M Univ, Coll Pharm & Pharmaceut Sci, Tallahassee, FL 32307 USA		Smith, UD (通讯作者)，Florida A&M Univ, Coll Pharm & Pharmaceut Sci, Pharm Practice, Tallahassee, FL 32307 USA.						Abbott, MIN HBALC DX; Amer Diabet Assoc, 2020, DIABETES CARE, V43, pS14, DOI 10.2337/dc20-S002; Amer Diabet Assoc, 2020, DIABETES CARE, V43, pS66, DOI 10.2337/dc20-S006; [Anonymous], 2020, MIN HBAL C DX PACK I; Arnold William D, 2020, J Diabetes Sci Technol, V14, P883, DOI 10.1177/1932296819831292; Benjamin EM, 2002, CLIN DIABETES, V20, P45, DOI [10.2337/diaclin.20.1.45, DOI 10.2337/DIACLIN.20.1.45]; Centers for Disease Control and Prevention (CDC), 2020, NATL DIAB STAT REP 2; Foerster V., 2016, CADTH ISSUES EMERGIN, P156; Funtanilla Vienica D, 2019, P T, V44, P550; Garber AJ, 2020, ENDOCR PRACT, V26, P107, DOI 10.4158/CS-2019-0472; National Institute of Diabetes and Digestive and Kidney Diseases, WHAT IS DIAB; Radin MS, 2014, J GEN INTERN MED, V29, P388, DOI 10.1007/s11606-013-2595-x; Sacks DB, 2012, DIABETES CARE, V35, P2674, DOI 10.2337/dc12-1348	13	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	MAY	2021	46	5					9	12					4	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	SE9UV	WOS:000652413000007					2022-04-28	
J	Creese, M; Farag, R; Gill, D; Haile, C; Hudson, D; Mcdonald, A; Vassar, B; Wills, J; Smith, UD; Journee, B; Honeywell, MS				Creese, Mekaliah; Farag, Rebekah; Gill, D'Andra; Haile, Christian; Hudson, Danielle; Mcdonald, Ashani; Vassar, Brandon; Wills, Josef; Smith, Ukamaka Dike; Journee, Briana; Honeywell, Marlon S.			A Review of the SalivaDirect Test for COVID-19	US PHARMACIST			English	Editorial Material									[Creese, Mekaliah; Farag, Rebekah; Gill, D'Andra; Haile, Christian; Hudson, Danielle; Mcdonald, Ashani; Vassar, Brandon; Wills, Josef; Smith, Ukamaka Dike; Journee, Briana] Florida A&M Univ, Inst Publ Hlth, Coll Pharm & Pharmaceut Sci, Pharm Practice, Tallahassee, FL 32307 USA; [Honeywell, Marlon S.] Florida A&M Univ, Inst Publ Hlth, Coll Pharm & Pharmaceut Sci, Tallahassee, FL 32307 USA		Creese, M (通讯作者)，Florida A&M Univ, Inst Publ Hlth, Coll Pharm & Pharmaceut Sci, Pharm Practice, Tallahassee, FL 32307 USA.						[Anonymous], 2020, FDA APPR 1 TREATM CO; ASM.org, 2020, WHAT IS COVID 19 SAL; Azzi L, 2020, J INFECTION, V81, pE45, DOI 10.1016/j.jinf.2020.04.005; Bajwah S, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00815-2020; CDC, 2020, YOU AR IMM PROT YOUR; CDC, 2020, SYMPT COR; CDC, COVID DAT TRACK; Centers for Disease Control and Prevention (CDC), OLD AD COVID 19; Centers for Disease Control and Prevention (CDC), PROT YOURS OTH; Czumbel LM, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00465; Fang FC, 2020, CLIN INFECT DIS, V71, P2996, DOI 10.1093/cid/ciaa742; Fda, 2020, COR COVID 19 UPD FDA; Food and Drug Administration (FDA), FREQ ASK QUEST EM US; Infectious Diseases Society of America, 2020, INF DIS SOC AM GUID; Iwasaki S, 2020, J INFECTION, V81, pE145, DOI 10.1016/j.jinf.2020.05.071; Moore JT, 2020, MMWR-MORBID MORTAL W, V69, P1122, DOI 10.15585/mmwr.mm6933e1; National Institutes of Health (NIH), 2020, COVID 19 TREATM GUID; NIH, COVID 19 TREATM GUID; Santosh TS, 2020, CUREUS, V12, DOI 10.7759/cureus.7708; Tiwari Manjul, 2011, J Nat Sci Biol Med, V2, P53, DOI 10.4103/0976-9668.82322; US Department of Health and Human Services, 2020, US GOV ENG PFIZ PROD; Vogels CB, 2020, SALIVADIRECT SIMPLE, DOI [10.1101/2020.08.03.20167791v1.full.pdf, DOI 10.1101/2020.08.03.20167791V1.FULL.PDF]; Wang H, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00334; World Health Organization, 2020, TRANSM SARS COV 2 IM; Yale School of Public Health, SALIVADIRECT; Yuki K, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108427; Zhang CZ, 2016, INT J ORAL SCI, V8, P133, DOI 10.1038/ijos.2016.38	27	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	FEB	2021	46	2					39	42					4	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	QU8YE	WOS:000627563600012					2022-04-28	
J	Whitehead, T; Goldwire, MA				Whitehead, Tyler; Goldwire, Micheline A.			Influenza in the Age of COVID-19	US PHARMACIST			English	Article								Very little data are available on how the coronavirus disease 2019 (COVID-19) pandemic will affect influenza, and although new information is emerging daily, much remains to be learned. Infection-control measures undertaken as a result of the COVID-19 pandemic have significantly impacted the annual influenza season, with a substantial drop in positive influenza cases compared with previous years. Despite the lack of influenza circulation, data suggest that coinfection with influenza and severe acute respiratory syndrome coronavirus 2 worsens disease severity and worsens prognosis. Although the spread of influenza decreased, misinformation has widely increased. Pharmacists have proven to be essential in the community, offering support not only in vaccine administration and point-of-care testing but also in combating misinformation through education.	[Whitehead, Tyler] Regis Univ, Sch Pharm, Denver, CO 80221 USA; [Goldwire, Micheline A.] Regis Univ, Sch Pharm, Drug Informat Serv, Denver, CO USA		Whitehead, T (通讯作者)，Regis Univ, Sch Pharm, Denver, CO 80221 USA.						American Society of Health -System Pharmacists, PROV STAT; [Anonymous], 2019, TAM OS PACK INS; Bai L, 2021, CELL RES, V31, P395, DOI 10.1038/s41422-021-00473-1; CDC, HIST 1918 FLU PAND; CDC, GET KNOW YOUR PHARM; CDC, INFL VACC ADM PHARM; CDC, 2020 2021 FLU SEAS S; CDC, COVID 19 ACIP VACC R; CDC, TEST GUID CLIN SARS; CDC, SYMPT COVID 19; CDC, DIFF COVID 19 VACC; CDC, WAIV TESTS; CDC, DIS BURD FLU; CDC, HIST REF SEAS INFL V; CDC, FLU SYMPT COMPL; CDC, FED RET PHARM PROGR; CDC, INFL HOSP SURV NETW; Centers for Disease Control and Prevention (CDC), SEL ADV EV REP COVID; Division of Clinical Laboratory Improvement and Quality Centers for Medicare & Medicaid Services, LAB TYP ACT; Dou D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01581; Erku DA, 2021, RES SOC ADMIN PHARM, V17, P1954, DOI 10.1016/j.sapharm.2020.04.032; Flerlage T, 2021, NAT REV MICROBIOL, V19, P425, DOI 10.1038/s41579-021-00542-7; Hogue MD, 2006, J AM PHARM ASSOC, V46, P168, DOI 10.1331/154434506776180621; Huang Y, 2020, ACTA PHARMACOL SIN, V41, P1141, DOI 10.1038/s41401-020-0485-4; IQVIA, US NAT PHARM MARK SU; Klepser NS, 2021, RES SOC ADMIN PHARM, V17, P1574, DOI 10.1016/j.sapharm.2020.12.003; Piroth L, 2021, LANCET RESP MED, V9, P251, DOI 10.1016/S2213-2600(20)30527-0; Potter CW, 2001, J APPL MICROBIOL, V91, P572, DOI 10.1046/j.1365-2672.2001.01492.x; Scudellari M, 2021, NATURE, V595, P640, DOI 10.1038/d41586-021-02039-y; Solomon DA, 2020, JAMA-J AM MED ASSOC, V324, P1342, DOI 10.1001/jama.2020.14661; The National Institutes of Health, COVID 19 TREATM GUID; The White House, PRESS BRIEF WHIT HOU; WHO, WHO COR COVID 19 DAS; World Health Organization, WHO DIR GEN OP REM M; Yue HH, 2020, J MED VIROL, V92, P2870, DOI 10.1002/jmv.26163; Zhang ANJX, 2021, CLIN INFECT DIS, V72, pE978, DOI 10.1093/cid/ciaa1747	36	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	DEC	2021	46	12					31	39					9	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	XY4CD	WOS:000736921600009					2022-04-28	
J	LaPreze, J; Robinson, A				LaPreze, Jennifer; Robinson, Alexis			Detecting and Managing Drug-Induced Diabetes	US PHARMACIST			English	Article								Certain medications and medication classes have adverse effects that can induce other medical conditions. Two adverse events of importance are hyperglycemia and diabetes. Among medications that can induce hyperglycemia and diabetes are alpelisib, antipsychotics, and antiretrovirals; thus, proper management strategies are necessary when they are prescribed. Uncontrolled hyperglycemia can increase the risk of microvascular and macrovascular complications; therefore, early detection and management are crucial for avoidance of these issues. In some cases, the hyperglycemia or diabetes can resolve with medication cessation, or alternative therapy may lower the risk of associated hyperglycemia. Ultimately, shared decision-making between patients and providers is necessary for improved health outcomes.										0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	NOV	2021	46	11					18	30					13	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	XB5IC	WOS:000721361900006					2022-04-28	
J	[Anonymous]				[Anonymous]			Studying Skin-Related Side Effects of Cancer Immune Therapies	US PHARMACIST			English	News Item																		0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	AUG	2021	46	8					37	38					2	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	UB4JE	WOS:000685813400013					2022-04-28	
J	Demler, TL				Demler, Tammie Lee			FDA Update: Improving Access to Biosimilar Drug Products	US PHARMACIST			English	Article								The need to enhance the transparency of the pharmaceutical supply chain and ensure availability of generic and biosimilar drug products has become more evident during the pandemic. It is important to recognize the regulatory challenges involved in ensuring the quality and integrity of biosimilar formulations. The biosimilar market continues to grow significantly, with notable new drug approvals for 2020. An FDA spokesperson answered U.S. Pharmacist's questions regarding the latest biosimilar regulations. Even as the FDA moves to improve access to biosimilar drug products, strategies some manufacturers use to navigate around the patent and regulatory systems to prolong the market exclusivity for brand-name products are also impacting accessibility.	[Demler, Tammie Lee] SUNY Buffalo, Sch Med, Dept Psychiat, Buffalo, NY 14260 USA; [Demler, Tammie Lee] SUNY Buffalo, Pharm Residency Programs, Sch Pharm & Pharmaceut Sci, Buffalo, NY 14260 USA		Demler, TL (通讯作者)，SUNY Buffalo, Sch Med, Dept Psychiat, Buffalo, NY 14260 USA.; Demler, TL (通讯作者)，SUNY Buffalo, Pharm Residency Programs, Sch Pharm & Pharmaceut Sci, Buffalo, NY 14260 USA.							0	0	0	1	2	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	JUN	2021	46	6					39	42					4	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	SR7UE	WOS:000661251200011					2022-04-28	
J	[Anonymous]				[Anonymous]			Novel Immunotherapy Approach to Fight Melanoma	US PHARMACIST			English	News Item																		0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	MAY	2021	46	5					38	39					2	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	SE9UV	WOS:000652413000016					2022-04-28	
J	Terrie, YC				Terrie, Yvette C.			The Role of the Pharmacist in Overcoming Vaccine Hesitancy	US PHARMACIST			English	Article							UNITED-STATES; PREVENTABLE DISEASES; RECOMMENDATIONS; IMMUNIZATION	Although vaccines are considered to be one of the most cost-effective means of preventing illness and death from certain diseases, some individuals are still reluctant to obtain vaccines recommended by the Advisory Committee on Immunization Practices. As frontline healthcare providers, pharmacists can act as patient educators and vaccine administrators and address vaccine hesitancy. By implementing effective comunication strategies, pharmacists can inform patients about the safety and efficacy of available vaccines, address their concerns and fears, and dispel common myths and misconceptions, allowing patients to make informed decisions.									American Pharmacists Association, VACC HES; Andre FE, VACCINATION GREATLY; Arede M, 2019, FRONT PUBLIC HEALTH, V6, DOI 10.3389/fpubh.2018.00381; Bach AT, 2015, INTEGR PHARM RES PRA, V4, P67, DOI 10.2147/IPRP.S63822; CDC, VACC DIS; CDC, AD VACC INF HEALTHC; Ecarnot F, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-8044-y; Esposito S, 2014, EUR J INTERN MED, V25, P203, DOI 10.1016/j.ejim.2013.12.004; Geoghegan S, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00372; Immunization Action Coalition, STRAT IMPR AD VACC C; Koppaka Ram, 2011, Morbidity and Mortality Weekly Report, V60, P814; Latner DR, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004791; Lisenby KM, 2021, J PHARM PRACT, V34, P127, DOI 10.1177/0897190019895437; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; National Foundation for Infectious Diseases, TOP 10 REAS GET VACC; Oldfield BJ, 2016, SOUTH MED J, V109, P38, DOI 10.14423/SMJ.0000000000000399; Phadke VK, 2016, JAMA-J AM MED ASSOC, V315, P1149, DOI 10.1001/jama.2016.1353; Poland GA, 2013, VACCINE, V31, P4689, DOI 10.1016/j.vaccine.2013.03.031; Poudel A, 2019, VACCINE, V37, P5939, DOI 10.1016/j.vaccine.2019.08.060; Remy V, 2015, J MARKET ACCESS HLTH, V3; Shen SX, 2019, CAN FAM PHYSICIAN, V65, P175; Tanzi MG, 2017, PHARM TODAY, V23, P43; Thomson A, 2016, VACCINE, V34, P1018, DOI 10.1016/j.vaccine.2015.11.065; Ventola C Lee, 2016, P T, V41, P426; Violette R, 2019, CAN PHARM J, V152, P391, DOI 10.1177/1715163519878745; Williams WW, 2016, MMWR SURVEILL SUMM, V65, P1, DOI 10.15585/mmwr.ss6501a1; World Health Organization, 2019, 10 THEATS GLOB HLTH	27	2	2	2	3	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	APR	2021	46	4					28	31					4	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	SE9UN	WOS:000652412200012					2022-04-28	
J	Barlow, A; Barlow, B; Hanna, K				Barlow, Ashley; Barlow, Brooke; Hanna, Kirollos			Managing Ovarian Cancer in the Era of New Therapies	US PHARMACIST			English	Article							PHASE-III TRIAL; PEGYLATED LIPOSOMAL DOXORUBICIN; GYNECOLOGIC-ONCOLOGY-GROUP; INTRAPERITONEAL CISPLATIN; PLUS PACLITAXEL; DOUBLE-BLIND; CARBOPLATIN; MAINTENANCE; CARCINOMA; BEVACIZUMAB	Epithelial ovarian cancer (OC), a common gynecologic malignancy, continues to be a leading cause of death in women, with just under 50% of patients surviving 5 years after diagnosis. Survival is often tied to the tumor stage; however, many women are diagnosed with advanced disease because of the asymptomatic nature of earlier stages. To date, surgery and systemic chemotherapy with platinum-based agents remain the standards of care. Recently, poly (adenosine diphosphate-ribose) polymerase inhibitors have demonstrated a significant benefit for patients diagnosed with OC. Accordingly, it is critical for the pharmacist to be familiar with the OC treatment armamentarium in order to ensure an optimal outcome for the patient.	[Barlow, Ashley] MD Anderson Canc Ctr, Houston, TX 77030 USA; [Barlow, Brooke] Univ Kentucky HealthCare, Lexington, KY USA; [Hanna, Kirollos] M Hlth Fairview, Maple Grove, MN USA; [Hanna, Kirollos] Mayo Clin, Coll Med, Maple Grove, MN USA		Barlow, A (通讯作者)，MD Anderson Canc Ctr, Houston, TX 77030 USA.						[Anonymous], 2020, RUBR RUC; [Anonymous], 2020, ZEJ NIR; [Anonymous], 2020, LYNP OL; [Anonymous], 2018, LYNP OL; Armstrong DK, 2006, NEW ENGL J MED, V354, P34, DOI 10.1056/NEJMoa052985; Berek JS, 2018, ANN ONCOL, V29, P1784, DOI 10.1093/annonc/mdy181; Boulanger J, 2014, CURR ONCOL, V21, pE630, DOI 10.3747/co.21.1966; Burger RA, 2013, GYNECOL ONCOL, V131, P21, DOI 10.1016/j.ygyno.2013.07.100; Coleman RL, 2017, LANCET, V390, P1949, DOI 10.1016/S0140-6736(17)32440-6; del Campo JM, 2019, J CLIN ONCOL, V37, P2968, DOI 10.1200/JCO.18.02238; Domchek SM, 2016, GYNECOL ONCOL, V140, P199, DOI 10.1016/j.ygyno.2015.12.020; Fleming G, 2013, PRINCIPLES PRACTICE, P757; Franzese E, 2019, CANCER TREAT REV, V73, P1, DOI 10.1016/j.ctrv.2018.12.002; Gibson JM, 2013, ONCOLOGIST, V18, P1022, DOI 10.1634/theoncologist.2013-0126; Gonzalez-Martin A, 2019, NEW ENGL J MED, V381, P2391, DOI 10.1056/NEJMoa1910962; Howlader N., 2017, SEER CANC STAT REV; Jelovac D, 2011, CA-CANCER J CLIN, V61, P183, DOI 10.3322/caac.20113; Markman M, 2001, J CLIN ONCOL, V19, P1001, DOI 10.1200/JCO.2001.19.4.1001; Matsuo K, 2010, EXPERT OPIN INV DRUG, V19, P1339, DOI 10.1517/13543784.2010.515585; Mazumdar M, 2000, J NATL CANCER I, V92, P1434, DOI 10.1093/jnci/92.17.1434; Mirza MR, 2019, LANCET ONCOL, V20, P1409, DOI 10.1016/S1470-2045(19)30515-7; Moore K, 2018, NEW ENGL J MED, V379, P2495, DOI 10.1056/NEJMoa1810858; Moore KN, 2019, LANCET ONCOL, V20, P636, DOI 10.1016/S1470-2045(19)30029-4; National Comprehensive Cancer Network, 2020, NCCN CLIN PRACTICE G; Ozols RF, 2003, J CLIN ONCOL, V21, P3194, DOI 10.1200/JCO.2003.02.153; Pignata S, 2011, J CLIN ONCOL, V29, P3628, DOI 10.1200/JCO.2010.33.8566; Prat J, 2012, ANN ONCOL, V23, P111, DOI 10.1093/annonc/mds300; Pujade-Lauraine E, 2017, LANCET ONCOL, V18, P1274, DOI 10.1016/S1470-2045(17)30469-2; Ray-Coquard I, 2019, NEW ENGL J MED, V381, P2416, DOI 10.1056/NEJMoa1911361; Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332; Swisher EM, 2017, LANCET ONCOL, V18, P75, DOI [10.1016/s1470-2045(16)30559-9, 10.1016/S1470-2045(16)30559-9]; Takase N, 2015, INT J CLIN ONCOL, V20, P566, DOI 10.1007/s10147-014-0731-1; Vasey PA, 2004, JNCI-J NATL CANCER I, V96, P1682, DOI 10.1093/jnci/djh323; Winter-Roach BA, 2009, COCHRANE DATABASE SY	34	0	0	0	1	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	JAN	2021	46	1					6	12					7	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	PY9CO	WOS:000612338200002					2022-04-28	
J	[Anonymous]				[Anonymous]			Viral Infection That Attacks the Liver	US PHARMACIST			English	Editorial Material								Hepatitis C is caused by a virus that infects the liver. Unlike most viruses, it is spread only through contact with infected blood. Most people infected with the hepatitis C virus (HCV) do not have symptoms for many years, so they are unaware of their condition. Several drugs for treating hepatitis C are very effective, and new treatments cause fewer side effects than older drug regimens. Hepatitis C affects more than 3 million people in the United States and causes thousands of deaths each year from liver-related diseases. This infection increases a person's risk of developing cirrhosis and liver cancer.										0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	OCT	2021	46	10					15	16					2	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	WI6KL	WOS:000708466800006					2022-04-28	
J	Chung, C				Chung, Clement			Focus on Anemia in Managing Lower-Risk Myelodysplastic Syndromes	US PHARMACIST			English	Article							QUALITY-OF-LIFE; DARBEPOETIN ALPHA; SCORING SYSTEM; MUTATIONS; MDS; TRANSFUSION; LENALIDOMIDE; LUSPATERCEPT; PHASE-2	Myelodysplastic syndromes (MDS) are a heterogeneous group of malignant blood disorders that affect the bone marrow, ultimately resulting in bone-marrow failure, acute leukemia, and death. Treatment selection for MDS is influenced by the severity of symptoms, cytopenias, cytogenetics, prognostic category, medical fitness, and patient preferences. Although erythropoiesis-stimulating agents (ESAs) help improve anemia and reduce the transfusion burden, limited treatment options exist when patients experience treatment failure with ESAs. Recent regulatory approval of luspatercept, which targets an erythropoietic cell signaling pathway, represents a major therapeutic advance in the management of anemia in MDS patients who are refractory to ESAs.	[Chung, Clement] Houston Methodist West Hosp, Houston, TX 77094 USA		Chung, C (通讯作者)，Houston Methodist West Hosp, Houston, TX 77094 USA.						Bataller A, 2019, LEUKEMIA, V33, P1076, DOI 10.1038/s41375-019-0420-1; Bejar R, 2011, NEW ENGL J MED, V364, P2496, DOI 10.1056/NEJMoa1013343; Blank U, 2015, BLOOD, V125, P3542, DOI 10.1182/blood-2014-12-618090; Carraway HE, 2020, HEMATOL-AM SOC HEMAT, P426, DOI 10.1182/hematology.2020000127; Estey EH, OVERVIEW TREATMENT M; Fenaux P, 2020, NEW ENGL J MED, V382, P140, DOI 10.1056/NEJMoa1908892; Franke GN, 2021, CL LYMPH MYELOM LEUK, V21, P1, DOI 10.1016/j.clml.2020.10.008; Gangat N, 2016, AM J HEMATOL, V91, P76, DOI 10.1002/ajh.24253; Ganguly BB, 2016, MUTAT RES-REV MUTAT, V769, P47, DOI 10.1016/j.mrrev.2016.04.009; Germing U, 2012, LEUKEMIA RES, V36, P1463, DOI 10.1016/j.leukres.2012.08.005; Giagounidis AAN, 2006, CLIN CANCER RES, V12, P5, DOI 10.1158/1078-0432.CCR-05-1437; Greenberg P, 1997, BLOOD, V89, P2079, DOI 10.1182/blood.V89.6.2079; Greenberg PL, 2012, BLOOD, V120, P2454, DOI 10.1182/blood-2012-03-420489; Greenberg PL, 2009, BLOOD, V114, P2393, DOI 10.1182/blood-2009-03-211797; Hellstrom-Lindberg E, 2003, BRIT J HAEMATOL, V120, P1037, DOI 10.1046/j.1365-2141.2003.04153.x; Jadersten M, 2011, J CLIN ONCOL, V29, P1971, DOI 10.1200/JCO.2010.31.8576; Jiang Y, 2009, BLOOD, V113, P1315, DOI 10.1182/blood-2008-06-163246; Kelaidi C, 2013, ANN HEMATOL, V92, P621, DOI 10.1007/s00277-013-1686-4; Kordasti SY, 2009, BRIT J HAEMATOL, V145, P64, DOI 10.1111/j.1365-2141.2009.07593.x; List A, 2006, NEW ENGL J MED, V355, P1456, DOI 10.1056/NEJMoa061292; Malcovati L, 2013, BLOOD, V122, P2943, DOI 10.1182/blood-2013-03-492884; Malcovati L, 2011, BLOOD, V118, P6239, DOI 10.1182/blood-2011-09-377275; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; National Cancer Institute, MYEL SYNDR TREATM PD; National Comprehensive Cancer Network, NCCN CLIN PRACTICE G; Park S, 2016, BRIT J HAEMATOL, V174, P730, DOI 10.1111/bjh.14116; Park S, 2010, LEUKEMIA RES, V34, P1430, DOI 10.1016/j.leukres.2010.05.030; Platzbecker U, 2017, LANCET ONCOL, V18, P1338, DOI 10.1016/S1470-2045(17)30615-0; Platzbecker U, 2012, LEUKEMIA RES, V36, P525, DOI 10.1016/j.leukres.2012.01.006; Raza A, 2008, BLOOD, V111, P86, DOI 10.1182/blood-2007-01-068833; Saft L, 2014, BLOOD, V124; Santini V, 2016, HEMATOL-AM SOC HEMAT, P462, DOI 10.1182/asheducation-2016.1.462; SANZ GF, 1989, BLOOD, V74, P395; Stauder R, 2018, BLOOD, V131, P505, DOI 10.1182/blood-2017-07-746446; Steensma DP, 2012, LEUKEMIA RES, V36, P1441, DOI 10.1016/j.leukres.2012.08.007; Tefferi A, 2009, NEW ENGL J MED, V361, P1872, DOI 10.1056/NEJMra0902908; Tehranchi R, 2005, BLOOD, V106, P247, DOI 10.1182/blood-2004-12-4649; Villegas A, 2011, CURR MED RES OPIN, V27, P951, DOI 10.1185/03007995.2011.561834; Zhao BB, 2019, CANCER MED-US, V8, P1169, DOI 10.1002/cam4.1969	39	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	SEP	2021	46	9					39	44					6	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	UT3BM	WOS:000697994900011					2022-04-28	
J	Saljoughian, M				Saljoughian, Manouchehr			Medical Immunization: Children and Adolescents	US PHARMACIST			English	Editorial Material									[Saljoughian, Manouchehr] Alta Bates Summit Med Ctr, Dept Pharm, Berkeley, CA 94705 USA		Saljoughian, M (通讯作者)，Alta Bates Summit Med Ctr, Dept Pharm, Berkeley, CA 94705 USA.							0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	JUN	2021	46	6					10	12					3	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	SR7UE	WOS:000661251200003					2022-04-28	
J	Bookwalter, CM				Bookwalter, Christina M.			Challenges in Community Pharmacy During COVID-19: The Perfect Storm for Personnel Burnout	US PHARMACIST			English	Article								The new, unique challenges directly associated with the COVID-19 pandemic are exacerbating an already stressful work environment in community pharmacy. Initially, with the country on lock-down, prescription volume increased overnight as patients went into panic mode. With social distancing, use of pharmacy drive-through lanes expanded dramatically. Pharmacies were later recognized as an ideal access point to provide COVID-19 testing along with COVID-19 vaccination services. These challenges and increased responsibilities in community pharmacy have created ideal conditions to leave burned-out pharmacy personnel in the aftermath. Pharmacy professional organizations have responded with resources to address and prevent burnout.	[Bookwalter, Christina M.] Womack Army Med Ctr, Ft Bragg, NC 28310 USA		Bookwalter, CM (通讯作者)，Womack Army Med Ctr, Ft Bragg, NC 28310 USA.						Abu Farha R, 2017, SAUDI PHARM J, V25, P1231, DOI 10.1016/j.jsps.2017.09.008; American Pharmacists Association, WELL BEING COVID 19; American Society of Health-System Pharmacists, 2021, WELLB YOU; CDC, 2020, GUID PHARM PHARM TEC; CDC, COVID DAT TRACK; FDA, PFIZ BIONTEC COVID 1; Lindley M. C., 2020, EARLY SEASON INFLUEN; Mental Health America, 2021, MENT HLTH HEALTHC WO; Patel SK, 2021, J AM PHARM ASSOC, V61, P145, DOI 10.1016/j.japh.2020.09.022; PBA Health, EL WILL COVID 19 CHA; U.S. Department of Health and Human Services, 2021, TRUMP ADM PART CVS W; United States Department of Health and Human Services, HHS STAT AUTH LIC PH; West CP, 2018, J INTERN MED, V283, P516, DOI 10.1111/joim.12752; WHO, BURN OUT OCC PHEN	14	2	2	2	2	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	MAY	2021	46	5					28	31					4	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	SE9UV	WOS:000652413000014					2022-04-28	
J	Allen, LV				Allen, Loyd V., Jr.			Baclofen 2%, Clonidine HCl 0.2%, Gabapentin 10%, and Ketamine HCl 5% in Lipoderm This preparation may be used to treat restless legs syndrome and certain other neuropathic disorders	US PHARMACIST			English	Editorial Material									[Allen, Loyd V., Jr.] Univ Oklahoma, Coll Pharm, Oklahoma City, OK 73104 USA		Allen, LV (通讯作者)，Univ Oklahoma, Coll Pharm, Oklahoma City, OK 73104 USA.						Allen Loyd V Jr, 2019, Int J Pharm Compd, V23, P299; Allen Loyd V Jr, 2019, Int J Pharm Compd, V23, P211; [Anonymous], 2020, US PHARM NAT FORM; Ash M, 1995, HDB PHARM ADDITIVES, P484; McEvoy GK, 2016, AHFS DRUG INFORM 201, P1489; Professional Compounding Centers of America, LIPODERM 30 3338; Sweetman SC, 2009, MARTINDALE COMPLETE, P523	7	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	JAN	2021	46	1					44	45					2	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	PY9CO	WOS:000612338200009					2022-04-28	
J	Flanagan, M; Spangler, M				Flanagan, Mariel; Spangler, Mikayla			Overview and Treatment of IBS With Predominant Constipation in Women	US PHARMACIST			English	Article								Irritable bowel syndrome with predominant constipation (IBS- C) is a chronic disorder that primarily affects women. In 2020, the first clinical guideline by the American College of Gastroenterology for the treatment of IBS was published. A variety of nonpharmacologic recommendations for IBS-C include gut-directed psychotherapy, psyllium fiber, peppermint oil, and a diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols. Women with IBS-C have four FDA-approved prescriptiontreatment options including lubiprostone, linaclotide, plecanatide, and tegaserod. Selection of medication therapy may be guided by cost/insurance coverage, adverse-effect profile, and desired frequency of dosing.	[Flanagan, Mariel] Creighton Univ, Sch Pharm & Hlth Profess, Omaha, NE 68178 USA; [Spangler, Mikayla] Creighton Univ, Sch Pharm & Hlth Profess, Pharm Practice, Omaha, NE 68178 USA		Flanagan, M (通讯作者)，Creighton Univ, Sch Pharm & Hlth Profess, Omaha, NE 68178 USA.							0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	SEP	2021	46	9					26	33					8	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	UT3BM	WOS:000697994900008					2022-04-28	
J	Berger, SC				Berger, Steven C.			An Introduction to Aspiration Pneumonia	US PHARMACIST			English	Article							COMMUNITY-ACQUIRED PNEUMONIA; VENTILATOR-ASSOCIATED PNEUMONIA; INFECTIOUS-DISEASES SOCIETY; KLEBSIELLA-PNEUMONIAE; RESISTANT BACTERIA; LUNG ABSCESS; PENICILLIN-G; MANAGEMENT; GUIDELINES; IMPACT	The appropriate selection of empiric antimicrobials for the management of aspiration pneumonia can be challenging for providers. Studies detailing the likely bacterial etiology of aspiration pneumonia span more than 40 years and are sufficiently contradictory to cause significant confusion regarding optimal drug therapy. Recommendations from recently published guidelines provide some elucidation, but available literature and the evidence on which these recommendations are based suggest that more research is needed. In the meantime, the clinical pharmacist has an opportunity to impact the use of overly broad antimicrobials while improving therapy for patients who are diagnosed with aspiration pneumonia.	[Berger, Steven C.] St Joseph East Hosp, Lexington, KY 40509 USA		Berger, SC (通讯作者)，St Joseph East Hosp, Lexington, KY 40509 USA.						BARTLETT JG, 1975, CHEST, V68, P560, DOI 10.1378/chest.68.4.560; BARTLETT JG, 1974, AM J MED, V56, P202, DOI 10.1016/0002-9343(74)90598-1; BARTLETT JG, 1975, JAMA-J AM MED ASSOC, V234, P935, DOI 10.1001/jama.234.9.935; Campbell SG, 2003, CHEST, V123, P1142, DOI 10.1378/chest.123.4.1142; CDC, AT PNEUM AT PNEUM; Dean NC, 2015, ANN EMERG MED, V66, P511, DOI 10.1016/j.annemergmed.2015.02.003; Dragan V, 2018, CLIN INFECT DIS, V67, P513, DOI 10.1093/cid/ciy120; El-Solh AA, 2004, CHEST, V126, P1575, DOI 10.1378/chest.126.5.1575; Ewig S, 2002, CHEST, V121, P1486, DOI 10.1378/chest.121.5.1486; Furuya EY, 2006, NAT REV MICROBIOL, V4, P36, DOI 10.1038/nrmicro1325; Gleeson K, 1997, CHEST, V111, P1266, DOI 10.1378/chest.111.5.1266; GONZALEZC CL, 1975, ARCH INTERN MED, V135, P711, DOI 10.1001/archinte.1975.00330050085014; Hannawi Y, 2013, CEREBROVASC DIS, V35, P430, DOI 10.1159/000350199; Happel KI, 2006, ALCOHOL CLIN EXP RES, V30, P1200, DOI 10.1111/j.1530-0277.2006.00144.x; Kadowaki M, 2005, CHEST, V127, P1276, DOI 10.1378/chest.127.4.1276; Kalil AC, 2016, CLIN INFECT DIS, V63, pE61, DOI 10.1093/cid/ciw353; LEVY M, 1988, CHEST, V93, P43, DOI 10.1378/chest.93.1.43; Mandell LA, 2012, HARRISONS PRINCIPLES, V18th; Mandell LA, 2019, NEW ENGL J MED, V380, P651, DOI 10.1056/NEJMra1714562; Marik PE, 2001, NEW ENGL J MED, V344, P665, DOI 10.1056/NEJM200103013440908; Marik PE, 1999, CHEST, V115, P178, DOI 10.1378/chest.115.1.178; Metlay JP, 2019, AM J RESP CRIT CARE, V200, pE45, DOI 10.1164/rccm.201908-1581ST; MIER L, 1993, INTENS CARE MED, V19, P279, DOI 10.1007/BF01690548; Neill S, 2019, CURR OPIN INFECT DIS, V32, P152, DOI 10.1097/QCO.0000000000000524; Rebuck JA, 2001, CRIT CARE MED, V29, P2239, DOI 10.1097/00003246-200112000-00001; Shen KR, 2017, J THORAC CARDIOV SUR, V153, pE129, DOI 10.1016/j.jtcvs.2017.01.030; van Duin D, 2016, INFECT DIS CLIN N AM, V30, P377, DOI 10.1016/j.idc.2016.02.004; Wang JL, 2005, CLIN INFECT DIS, V40, P915, DOI 10.1086/428574; Webb BJ, 2015, RESP MED, V109, P1, DOI 10.1016/j.rmed.2014.10.017; Wiese AD, 2018, ANN INTERN MED, V168, P396, DOI 10.7326/M17-1907; Wipf JE, 1999, ARCH INTERN MED, V159, P1082, DOI 10.1001/archinte.159.10.1082	31	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	JUL	2021	46	7											6	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	TP3SU	WOS:000677515000003					2022-04-28	
J	Demler, TL				Demler, Tammie Lee			Addressing Mental and Physical Health in Vulnerable Patients During the COVID-19 Pandemic	US PHARMACIST			English	Editorial Material									[Demler, Tammie Lee] SUNY Buffalo, Sch Med, Dept Psychiat, Buffalo, NY 14260 USA; [Demler, Tammie Lee] SUNY Buffalo, Sch Pharm & Pharmaceut Sci, Psychiat Pharm Residency Programs, Buffalo, NY 14260 USA		Demler, TL (通讯作者)，SUNY Buffalo, Sch Med, Dept Psychiat, Buffalo, NY 14260 USA.; Demler, TL (通讯作者)，SUNY Buffalo, Sch Pharm & Pharmaceut Sci, Psychiat Pharm Residency Programs, Buffalo, NY 14260 USA.							0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	MAY	2021	46	5					47	56					10	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	SE9UV	WOS:000652413000021					2022-04-28	
J	[Anonymous]				[Anonymous]			How Remote Workers Can Best Manage Work-Home Conflict	US PHARMACIST			English	News Item																		0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	MAY	2021	46	5					6	8					3	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	SE9UV	WOS:000652413000005					2022-04-28	
J	Hornecker, JR; Papke, J				Hornecker, Jaime R.; Papke, Jessica			Review and Update on Pneumococcal Vaccine Recommendations	US PHARMACIST			English	Review							POLYSACCHARIDE VACCINE	Infections caused by Streptococcus pneumoniae represent a significant public-health concern. Invasive pneumococcal disease, including pneumonia, meningitis, and bacteremia, are more common in high-risk populations, including young children, older adults, and the immunocompromised. PPSV23 (Pneumovax 23) and PCV13 (Prevnar 13) are two vaccines included as part of routine immunization schedules and are recommended for use in those with high-risk comorbidities. Pharmacists play an important role in improving immunization rates and reducing missed opportunities for pneumococcal vaccinations.	[Hornecker, Jaime R.; Papke, Jessica] Univ Wyoming, Sch Pharm, Casper, WY 82601 USA		Hornecker, JR (通讯作者)，Univ Wyoming, Sch Pharm, Casper, WY 82601 USA.						[Anonymous], 1997, MMWR Recomm Rep, V46, P1; [Anonymous], 2014, PREVN 13 PNEUM 13 VA; CDC, GLOB PNEUM DIS VACC; CDC, TIM SPAC IMM; CDC, PNEUMORECS VAXADVISO; Centers for Disease Control and Prevention (CDC) U.S. Department of Health & Human Services, WHAT EV SHOULD KNOW; Demirdal T, 2021, EXPERT REV ANTI-INFE, V19, P927, DOI 10.1080/14787210.2021.1858799; MacIntyre CR, 2010, HUM VACCINES, V6, P894, DOI 10.4161/hv.6.11.12852; Marechal C, 2018, VACCINE, V36, P4278, DOI 10.1016/j.vaccine.2018.05.110; Matanock A, 2019, MMWR-MORBID MORTAL W, V68, P1069, DOI 10.15585/mmwr.mm6846a5; Olasupo O, 2020, J INFECT PUBLIC HEAL, V13, P101, DOI 10.1016/j.jiph.2019.06.010; United States Department of Health and Human Servces OffiDisease Prevention and Health Promotion, HLTH PEOPL 2030; Whit eh, 2013, PNEUM 23 PNEUM VACC; Wolfe S., 2015, EPIDEMIOLOGY PREVENT, V13th ed	14	0	0	2	4	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	APR	2021	46	4					32	35					4	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	SE9UN	WOS:000652412200013					2022-04-28	
J	Pal, S				Pal, Somnath			Prescription Opioid Use During Pregnancy	US PHARMACIST			English	Editorial Material									[Pal, Somnath] St Johns Univ, Coll Pharm & Hlth Sci, Pharm Adm, Jamaica, NY 11439 USA		Pal, S (通讯作者)，St Johns Univ, Coll Pharm & Hlth Sci, Pharm Adm, Jamaica, NY 11439 USA.							0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	MAR	2021	46	3					14	14					1	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	QU8YG	WOS:000627563800006					2022-04-28	
J	Como, M; Carter, C; Honeywell, M				Como, Madison; Carter, Chenita; Honeywell, Marlon			binx health io CT/NG Assay	US PHARMACIST			English	Editorial Material									[Como, Madison; Carter, Chenita; Honeywell, Marlon] Florida A&M Univ, Pharm Practice, Tallahassee, FL 32307 USA		Como, M (通讯作者)，Florida A&M Univ, Pharm Practice, Tallahassee, FL 32307 USA.						Binx Health press release, BINX HLTH REC FDA CL; CDC, DET STD FACTS GON; CDC, 2020, SEXUALLY TRANSMITTED; CDC, DET STD FACTS CHLAM; Hill SA, 2016, MICROB CELL, V3, P371, DOI 10.15698/mic2016.09.524; Papp JR, 2014, MMWR RECOMM REP, V63, P1; St Cyr S, 2020, MMWR-MORBID MORTAL W, V69, P1911, DOI 10.15585/mmwr.mm6950a6; Van der Pol B, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.4819; Widdice LE, 2018, SEX TRANSM DIS, V45, P723, DOI 10.1097/OLQ.0000000000000865; World Health Organization, POINT OF CAR DIAGN T	10	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	DEC	2021	46	12					8	12					5	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	XY4CD	WOS:000736921600002					2022-04-28	
J	Pal, S				Pal, Somnath			Incidence, Survival, and Mortality Rates for Colorectal Cancer	US PHARMACIST			English	Editorial Material									[Pal, Somnath] St Johns Univ, Coll Pharm & Hlth Sci, Pharm Adm, Jamaica, NY 11439 USA		Pal, S (通讯作者)，St Johns Univ, Coll Pharm & Hlth Sci, Pharm Adm, Jamaica, NY 11439 USA.							0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	DEC	2021	46	12					14	14					1	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	XY4CD	WOS:000736921600005					2022-04-28	
J	Williams, V				Williams, Valerie			Diabetes-Related Gastrointestinal Emergencies: Gallstones and Acute Pancreatitis	US PHARMACIST			English	Article								Gastrointestinal (GI) diseases affect the alimentary tract, liver, biliary system, and pancreas. GI diseases are often encountered in the ICU setting, either as the major cause that prompted admission to the ICU or as a comorbid complication of another primary disease process. GI complications of diabetes have become increasingly prevalent as the rate of diabetes has risen. The most common and immediately life-threatening diabetes-related GI complications seen in emergency departments are gallstones and acute pancreatitis. Pharmacists in acute-care settings need to be aware of the prevalence, etiology, diagnosis, pathogenesis, and management of these two common complications of diabetes.										0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	DEC	2021	46	12					HS2	HS9					8	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	XY4CD	WOS:000736921600003					2022-04-28	
J	DeRuiter, J; Holston, PL				DeRuiter, Jack; Holston, Pamela L.			New Drug Review 2021	US PHARMACIST			English	Editorial Material									[DeRuiter, Jack] Auburn Univ, Harrison Sch Pharm, Dept Drug Discovery & Dev, Auburn, AL 36849 USA; [Holston, Pamela L.] Keystone Peer Review Org, Harrisburg, PA USA		DeRuiter, J (通讯作者)，Auburn Univ, Harrison Sch Pharm, Dept Drug Discovery & Dev, Auburn, AL 36849 USA.						[Anonymous], 2021, QELBREE VIL EXT REL; [Anonymous], 2021, EVK EV DGNB INJ PACK; [Anonymous], 2021, CAB CAB EXT REL INJ; [Anonymous], 2021, NEXTST DROSP EST TAB; Bennink FC, 2008, CLIMACTERIC, V11, P69, DOI 10.1080/13697130802056321; Raal FJ, 2020, NEW ENGL J MED, V383, P711, DOI 10.1056/NEJMoa2004215; Swindells S, 2020, NEW ENGL J MED, V382, P1112, DOI 10.1056/NEJMoa1904398	7	1	1	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	OCT	2021	46	10					28	40					13	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	WI6KL	WOS:000708466800010					2022-04-28	
J	Pal, S				Pal, Somnath			Nutrient Intake From Food and Dietary Supplements Among Women	US PHARMACIST			English	Editorial Material									[Pal, Somnath] St Johns Univ, Coll Pharm & Hlth Sci, Pharm Adm, Jamaica, NY 11439 USA		Pal, S (通讯作者)，St Johns Univ, Coll Pharm & Hlth Sci, Pharm Adm, Jamaica, NY 11439 USA.							0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	SEP	2021	46	9					14	14					1	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	UT3BM	WOS:000697994900005					2022-04-28	
J	Barlow, A				Barlow, Ashley			Treatment of Metastatic Bone Disease in Prostate Cancer	US PHARMACIST			English	Article							ZOLEDRONIC ACID; OSTEONECROSIS; SURVIVAL; JAW; PREVENTION; MANAGEMENT; RADIUM-223; MEN	More than 90% of patients with metastatic prostate cancer (PCa) are diagnosed with bone metastases. The presence of metastatic bone disease contributes to decreased quality of life resulting from pain and pathologic fractures, as well as increased treatment cost and overall mortality. A multimodal approach with analgesics, radiation, bone-modifying therapy, surgery, and chemotherapy are used to manage bone metastases from PCa. These treatments can be used independently or concurrently based on patient symptoms, complications of disease, plan for other systemic chemotherapy, and goals of care. Pharmacists are key components of the healthcare team that guide patients' management by providing counseling on side effects, treatment monitoring, and cost of therapy for the agents used for metastatic PCa.	[Barlow, Ashley] MD Anderson Canc Ctr, Houston, TX 77030 USA		Barlow, A (通讯作者)，MD Anderson Canc Ctr, Houston, TX 77030 USA.						[Anonymous], 2021, XGEVA DENOSUMAB; [Anonymous], 2020, ZOL AC INJ PACK INS; [Anonymous], 2021, PROL DEN PACK INS; [Anonymous], 2019, XOFIGO RADIUM RA 223; [Anonymous], 2021, RECL ZOL AC PACK INS; Autio KA, 2012, CURR TREAT OPTION ON, V13, P174, DOI 10.1007/s11864-012-0190-8; Bamias A, 2005, J CLIN ONCOL, V23, P8580, DOI 10.1200/JCO.2005.02.8670; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Cathomas R, 2014, UROL INT, V92, P377, DOI 10.1159/000358258; D'Oronzo S, 2019, J BONE ONCOL, V15, DOI 10.1016/j.jbo.2018.10.004; Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140-6736(10)62344-6; Himelstein AL, 2017, JAMA-J AM MED ASSOC, V317, P48, DOI 10.1001/jama.2016.19425; Jehn CF, 2016, ANTICANCER RES, V36, P2631; Miller K, 2011, J UROLOGY, V185, pE262, DOI 10.1016/j.juro.2011.02.1550; Mohamad NV, 2016, CLIN INTERV AGING, V11, P1317, DOI 10.2147/CIA.S115472; National Comprehensive Cancer Network, PROSTATE CANC VERSIO; Parker C, 2013, NEW ENGL J MED, V369, P213, DOI 10.1056/NEJMoa1213755; Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831; Rosella D, 2016, J INT SOC PREV COMMU, V6, P97, DOI 10.4103/2231-0762.178742; Ross RW, 2002, J UROLOGY, V167, P1952, DOI 10.1016/S0022-5347(05)65060-4; Ruggiero S, 2006, J ONCOL PRACT, V2, P7, DOI 10.1200/JOP.2.1.7; Saad F, 2004, J NATL CANCER I, V96, P879, DOI 10.1093/jnci/djh141; Sartor O, 2015, EUR J CANCER, V51, pS484, DOI 10.1016/S0959-8049(16)31349-1; Smith MR, 2012, LANCET, V379, P39, DOI 10.1016/S0140-6736(11)61226-9	24	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	JUN	2021	46	6					47	56					10	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	SR7UE	WOS:000661251200012					2022-04-28	
J	Laskey, CS				Laskey, Corey S.			Antidepressant Use in the Breastfeeding Patient	US PHARMACIST			English	Article							MILK; INFANT; BUPROPION; MOTHER; WOMEN	It is well known that the peripartum period carries an increased risk of psychiatric disorders in the mother, and treatment is often necessary; however, given concerns about medication exposure in infants, uncertainty exists on how to safely manage treatment in breastfeeding patients with psychiatric illnesses. Additionally, the impact of the drug on milk production should be considered. However, pharmacologic treatment is not always incompatible with breastfeeding. As patients and providers may seek information on the use of antidepressants and other psychotropics while breastfeeding, pharmacists must consult current resources to keep abreast of risks, benefits, and treatment guidelines. By optimizing care for breastfeeding patients, pharmacists can help prevent adverse outcomes in both mother and baby.	[Laskey, Corey S.] Western New England Univ, Coll Pharm & Hlth Sci, Psychiat, Springfield, MA 01119 USA		Laskey, CS (通讯作者)，Western New England Univ, Coll Pharm & Hlth Sci, Psychiat, Springfield, MA 01119 USA.						Anderson PO, 2016, CLIN PHARMACOL THER, V100, P42, DOI 10.1002/cpt.377; [Anonymous], 2021, DRUGS LACT DAT LACTM; Berens PD, 2019, WOMENS HLTH LIFESPAN, V2nd; Berle JO, 2011, CURR WOMENS HEALTH R, V7, P28, DOI 10.2174/157340411794474784; Briggs GG, 2017, DRUGS PREGNANCY LACT; Chaudron LH, 2004, J CLIN PSYCHIAT, V65, P881; Damsa C, 2004, J CLIN PSYCHIAT, V65, P1064; Franssen EJE, 2006, THER DRUG MONIT, V28, P2, DOI 10.1097/01.ftd.0000187972.02624.2e; Grzeskowiak LE, 2018, BRIT J CLIN PHARMACO, V84, P1373, DOI 10.1111/bcp.13575; InfantRisk Center, INFANTRISK CTR; Ito S, 2016, CLIN PHARMACOL THER, V100, P8, DOI 10.1002/cpt.383; Johannsen BMW, 2016, AM J PSYCHIAT, V173, P635, DOI 10.1176/appi.ajp.2015.14121510; MacQueen GM, 2016, CAN J PSYCHIAT, V61, P588, DOI 10.1177/0706743716659276; Meltzer-Brody S, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2018.22; Muller MJ, 2013, BREASTFEED MED, V8, P327, DOI 10.1089/bfm.2012.0084; Neuman G, 2014, ANN PHARMACOTHER, V48, P928, DOI 10.1177/1060028014529548; Potts AL, 2007, J PERINATOL, V27, P120, DOI 10.1038/sj.jp.7211640; Sachs HC, 2013, PEDIATRICS, V132, pE796, DOI 10.1542/peds.2013-1985; Schoretsanitis G, 2019, ARCH WOMEN MENT HLTH, V22, P383, DOI 10.1007/s00737-018-0905-3; Sriraman NK, 2015, BREASTFEED MED, V10, P290, DOI 10.1089/bfm.2015.29002; Uguz F, 2019, BREASTFEED MED, V14, P131, DOI 10.1089/bfm.2018.0197; Uguz F, 2021, AM J THER, V28, pE118, DOI 10.1097/MJT.0000000000000909; Weissman AM, 2004, AM J PSYCHIAT, V161, P1066, DOI 10.1176/appi.ajp.161.6.1066	23	0	0	0	1	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	MAY	2021	46	5					17	22					6	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	SE9UV	WOS:000652413000012					2022-04-28	
J	Pal, S				Pal, Somnath			Recent Trends in Approvals of Novel Drugs	US PHARMACIST			English	Editorial Material									[Pal, Somnath] St Johns Univ, Coll Pharm & Hlth Sci, Pharm Adm, Jamaica, NY 11439 USA		Pal, S (通讯作者)，St Johns Univ, Coll Pharm & Hlth Sci, Pharm Adm, Jamaica, NY 11439 USA.							0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	OCT	2021	46	10					14	14					1	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	WI6KL	WOS:000708466800005					2022-04-28	
J	Pruett, W; Perman, BE; Morrow, LE; Malesker, MA				Pruett, William; Perman, Bryton E.; Morrow, Lee E.; Malesker, Mark A.			Oral Inhaled Medications-Beyond Bronchodilators	US PHARMACIST			English	Article								Historically, the inhaled route of medication administration has been associated with the delivery of bronchodilators and/or corticosteroids to treat pulmonary conditions such as chronic obstructive pulmonary disease and asthma. However, this modality of drug delivery is increasingly being explored for use in other disease states, as drug inhalation is associated with several benefits including decreased systemic side effects, higher bioavailability, and more rapid absorption into the body. Certain inhaled medications that are used on- and off-label are encountered less frequently in daily medical practice than conventional bronchodilators. The most common on-label indications for inhaled medications include pulmonary arterial hypertension and pulmonary infections. The most reported off-label uses of inhaled medications include pulmonary infections, acute respiratory distress syndrome, pulmonary hemorrhage, and post-lung transplant.	[Pruett, William] Creighton Univ, Sch Med, Pulm & Crit Care Med, Omaha, NE 68178 USA; [Perman, Bryton E.] Creighton Univ, Sch Med, Internal Med, Omaha, NE USA; [Morrow, Lee E.; Malesker, Mark A.] Creighton Univ, Sch Med, Med, Omaha, NE USA; [Morrow, Lee E.; Malesker, Mark A.] Creighton Univ, Sch Pharm & Hlth Profess, Pharm Practice, Omaha, NE 68178 USA		Pruett, W (通讯作者)，Creighton Univ, Sch Med, Pulm & Crit Care Med, Omaha, NE 68178 USA.			Morrow, Lee/0000-0001-9001-3419				0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	JUL	2021	46	7					4	12					9	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	TP3SU	WOS:000677515000002					2022-04-28	
J	[Anonymous]				[Anonymous]			COVID-19 Severely Impacts Mental Health of Young People	US PHARMACIST			English	News Item																		0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	MAY	2021	46	5					6	6					1	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	SE9UV	WOS:000652413000004					2022-04-28	
J	[Anonymous]				[Anonymous]			B-Cell Factor Possible Key to Hemophilia Immune Tolerance	US PHARMACIST			English	News Item																		0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	MAY	2021	46	5					39	40					2	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	SE9UV	WOS:000652413000017					2022-04-28	
J	Davidson, R				Davidson, Robert			Opioid-Use Policies Causing Unintended Consequences	US PHARMACIST			English	Editorial Material												rdavidson@uspharmacist.com						0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	MAR	2021	46	3					3	3					1	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	QU8YG	WOS:000627563800001					2022-04-28	
J	Pal, S				Pal, Somnath			Diabetes-Related Complications in Adults	US PHARMACIST			English	Editorial Material									[Pal, Somnath] St Johns Univ, Coll Pharm & Hlth Sci, Jamaica, NY 11439 USA		Pal, S (通讯作者)，St Johns Univ, Coll Pharm & Hlth Sci, Jamaica, NY 11439 USA.							0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	NOV	2021	46	11					14	14					1	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	XB5IC	WOS:000721361900004					2022-04-28	
J	Mishiyeva, O; Ngai, L; Rattu, MA				Mishiyeva, Oksana; Ngai, Lena; Rattu, Mohammad A.			Factors Affecting Adherence to Oral Liquid Medications	US PHARMACIST			English	Article									[Mishiyeva, Oksana] Long Isl Univ, Arnold & Marie Schwartz Coll Pharm & Hlth Sci, Brooklyn, NY 11201 USA; [Ngai, Lena] Mt Sinai Hosp, Pediat, New York, NY 10029 USA; [Rattu, Mohammad A.] Mt Sinai Hosp, Oncol, New York, NY 10029 USA		Mishiyeva, O (通讯作者)，Long Isl Univ, Arnold & Marie Schwartz Coll Pharm & Hlth Sci, Brooklyn, NY 11201 USA.							0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	OCT	2021	46	10					10	12					3	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	WI6KL	WOS:000708466800002					2022-04-28	
J	Callen, ED; Pray, WS				Callen, Erin D.; Pray, W. Steven			Ramsay Hunt Syndrome and the Pharmacist	US PHARMACIST			English	Article							PALSY	Ramsay Hunt syndrome (RHS) begins with an attack of herpes zoster (i.e., shingles) inside the ear canal. RHS primarily affects the facial nerve, but it can also affect cranial nerves that communicate with the facial nerve. Damage to cranial nerves causes otic pain, otic rash, hemifacial paralysis, and several other complications. Prompt administration of antiviral therapy can improve the prognosis, lessening the risk of permanent sequelae, such as facial distortion. Being aware of RHS enables the pharmacist to recognize its possible presence. The pharmacist can then explain the nature of the condition to the patient and stress the vital need for immediate physician care. The pharmacist can also assist the patient with relieving pain and other troublesome symptoms that often accompany RHS.	[Callen, Erin D.; Pray, W. Steven] Southwestern Oklahoma State Univ, Coll Pharm, Weatherford, OK 73096 USA		Callen, ED (通讯作者)，Southwestern Oklahoma State Univ, Coll Pharm, Weatherford, OK 73096 USA.						Callen ED, 2019, US PHARM, V44, P26; CDC, VACC; Coulson S, 2011, OTOL NEUROTOL, V32, P1025, DOI 10.1097/MAO.0b013e3182255727; Donati D, 2012, J NEUROL SCI, V318, P160, DOI 10.1016/j.jns.2012.04.011; Finnerup NB, 2015, LANCET NEUROL, V14, P162, DOI 10.1016/S1474-4422(14)70251-0; Freedman M, 2020, ANN INTERN MED, V172, P337, DOI 10.7326/M20-0046; Johnson RW, 2014, NEW ENGL J MED, V371, P1526, DOI 10.1056/NEJMcp1403062; Kanerva M, 2020, EUR ARCH OTO-RHINO-L, V277, P1235, DOI 10.1007/s00405-020-05817-y; Liesegang TJ, 2008, OPHTHALMOLOGY, V115, pS3, DOI 10.1016/j.ophtha.2007.10.009; Marin Mona, 2007, Morbidity and Mortality Weekly Report, V56, P1; Murakami S, 1997, ANN NEUROL, V41, P353, DOI 10.1002/ana.410410310; Salinas TJ., DRY MOUTH TREATMENT; Shaikh S, 2002, AM FAM PHYSICIAN, V66, P1723; Sweeney CJ, 2001, J NEUROL NEUROSUR PS, V71, P149, DOI 10.1136/jnnp.71.2.149; Tricco AC, 2018, BMJ-BRIT MED J, V363, DOI 10.1136/bmj.k4029; Wagner G, 2012, J DTSCH DERMATOL GES, V10, P238, DOI 10.1111/j.1610-0387.2012.07894.x; Watson PN, POSTHERPETIC NEURALG; Williams David S, 2010, J Insur Med, V42, P41; Zainine R, 2012, EUR ANN OTORHINOLARY, V129, pE22, DOI 10.1016/j.anorl.2011.08.003	19	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	MAR	2021	46	3					31	35					5	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	QU8YG	WOS:000627563800010					2022-04-28	
J	DeSimone, EM; Davidian, MH; Lineman, J; Penzotti, CS				DeSimone, Edward M., II; Davidian, Michael H.; Lineman, Jennifer; Penzotti, Constance S.			Treatment Approaches for Fibromyalgia	US PHARMACIST			English	Article								Fibromyalgia, a condition affecting the central nervous system, causes widespread pain as well as other symptoms-such as sleep disruptions, fatigue, and difficulty concentrating-that adversely affect the patient's quality of life. There is no specific diagnostic test for fibromyalgia, but a variety of tools are used to evaluate the patient's symptoms in order to confirm the diagnosis. Although several classes of medications, such as antidepressants, are useful for treating fibromyalgia pain and other associated symptoms, nonpharmacologic treatments such as exercise, mindfulness techniques, acupuncture, and others have been shown to be equally effective-if not more effective-options.	[DeSimone, Edward M., II] Creighton Univ, Sch Pharm & Hlth Profess, Pharm Sci, Omaha, NE 68178 USA; [Davidian, Michael H.] Creighton Univ, Sch Med, Med, Omaha, NE 68178 USA; [Lineman, Jennifer] Creighton Univ, Sch Pharm & Hlth Profess, Pharm Practice, Omaha, NE 68178 USA; [Penzotti, Constance S.] Creighton Univ, Sch Pharm & Hlth Profess, Omaha, NE USA		DeSimone, EM (通讯作者)，Creighton Univ, Sch Pharm & Hlth Profess, Pharm Sci, Omaha, NE 68178 USA.						Fattah YHA, 2020, INT J RHEUM DIS, V23, P1474, DOI 10.1111/1756-185X.13953; [Anonymous], 2008, Prim Care Companion J Clin Psychiatry, V10, P133; [Anonymous], 2020, CLIN PHARM; Barakat A, 2019, CNS DRUGS, V33, P481, DOI 10.1007/s40263-019-00623-5; Bodere C, 2020, SAGE OPEN MED, V8, DOI 10.1177/2050312120943072; Clauw DJ, 2014, JAMA-J AM MED ASSOC, V311, P1547, DOI 10.1001/jama.2014.3266; Ellerbrock I, 2021, EUR J PAIN, V25, P398, DOI 10.1002/ejp.1680; Hauser W, 2009, JAMA-J AM MED ASSOC, V301, P198, DOI 10.1001/jama.2008.944; Hao Jason Jishun, 2014, Glob Adv Health Med, V3, P6, DOI 10.7453/gahmj.2014.042; IIiades C, FIBROMYALGIA PAINKIL; Karatay S, 2018, PAIN MED, V19, P615, DOI 10.1093/pm/pnx263; Mease P, 2007, J RHEUMATOL, V34, P1415; Ngian GS, 2011, INT J RHEUM DIS, V14, P6, DOI 10.1111/j.1756-185X.2010.01567.x; Sanabria-Mazo JP, 2020, J CLIN MED, V9, DOI 10.3390/jcm9103246; Serrat M, 2020, J CLIN MED, V9, DOI 10.3390/jcm9103348; Thorpe J, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010585.pub2; Wolfe F, 2016, SEMIN ARTHRITIS RHEU, V46, P319, DOI 10.1016/j.semarthrit.2016.08.012; Zhang XC, 2019, J PAIN RES, V12, P527, DOI 10.2147/JPR.S186227	18	0	0	0	2	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	MAR	2021	46	3					17	22					6	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	QU8YG	WOS:000627563800008					2022-04-28	
J	Allen, LV				Allen, Loyd V., Jr.			Valsartan 4 mg/mL in SyrSpend SF PH4	US PHARMACIST			English	Editorial Material									[Allen, Loyd V., Jr.] Univ Oklahoma, Coll Pharm, Oklahoma City, OK 73104 USA		Allen, LV (通讯作者)，Univ Oklahoma, Coll Pharm, Oklahoma City, OK 73104 USA.						Allen Jr LV, 1999, IJPC, V3, P146; [Anonymous], 2021, US PHARM NAT FORM CU; Polonini HC, 2016, PHARMAZIE, V71, P185, DOI 10.1691/ph.2016.5177	3	0	0	3	3	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	FEB	2021	46	2					56	57					2	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	QU8YE	WOS:000627563600015					2022-04-28	
J	Bookwalter, CM				Bookwalter, Christina M.			Drug Shortages Amid the COVID-19 Pandemic	US PHARMACIST			English	Article								The uncertainty of coronavirus disease 2019 (COVID-19) caused anticipatory purchasing of medications around the world, driving demand to an unprecedented high. Meanwhile, drug factories shut down in order to prevent the spread of COVID-19, the drug-supply chain was disrupted, and drug shortages resulted. In the face of these drug shortages, pharmacy personnel responded by initiating local policy changes, implementing detailed antibiotic stewardship, and enacting quantity limits for in-demand medications. Pharmacists are indispensable during a drug shortage because of their unique skills and ability to bridge shortage gaps with effective action plans that will not imperil patient safety.	[Bookwalter, Christina M.] Womack Army Med Ctr, Ft Bragg, NC 28310 USA		Bookwalter, CM (通讯作者)，Womack Army Med Ctr, Ft Bragg, NC 28310 USA.							0	4	4	3	4	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	FEB	2021	46	2					25	28					4	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	QU8YE	WOS:000627563600009					2022-04-28	
J	Sun, C; Venrick, B; Rao, H; Tsu, L				Sun, Caroline; Venrick, Brianne; Rao, Hindu; Tsu, Laura			Antithrombotic Therapy in Patients With Valvular Heart Disease	US PHARMACIST			English	Article								Valvular heart disease (VHD) is a disorder in which a heart valve is damaged or diseased, resulting in poor cardiac blood flow. Types of VHD include aortic stenosis, aortic regurgitation, mitral stenosis, mitral regurgitation, and tricuspid regurgitation. Most patients with VHD require surgery to repair or replace the valve and subsequent antithrombotic therapy to prevent clotting. Antithrombotic therapy options that are commonly used after valve replacement or repair are vitamin K antagonists, such as warfarin, and antiplatelet agents, such as aspirin. Patient counseling points should include drug-drug or drug-food interactions, frequency of international normalized ratio monitoring with warfarin, and signs and symptoms of bleeding. Pharmacists are in an ideal position to partake in the management and care of patients with VHD.	[Sun, Caroline; Venrick, Brianne] Chapman Univ, Sch Pharm, Irvine, CA 92618 USA; [Rao, Hindu; Tsu, Laura] Chapman Univ, Sch Pharm, Pharm Practice, Irvine, CA USA		Sun, C (通讯作者)，Chapman Univ, Sch Pharm, Irvine, CA 92618 USA.							0	0	0	0	3	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	FEB	2021	46	2					21	24					4	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	QU8YE	WOS:000627563600008					2022-04-28	
J	Allen, LV				Allen, Loyd V., Jr.			Metformin Hydrochloride 100 mg/mL Oral Liquid	US PHARMACIST			English	Editorial Material									[Allen, Loyd V., Jr.] Univ Oklahoma, Coll Pharm, Oklahoma City, OK 73104 USA		Allen, LV (通讯作者)，Univ Oklahoma, Coll Pharm, Oklahoma City, OK 73104 USA.						Allen Loyd V Jr, 2019, Int J Pharm Compd, V23, P299; Allen Loyd V Jr, 2019, Int J Pharm Compd, V23, P211; [Anonymous], 2021, NAT FORM CURR REV; Mishra M., 2020, HDB PHARM EXCIPIENTS, V9th, P500; Niazi SK, 2004, HDB PHARM MANUFACTUR, V3, P149; Oga E, 2020, HDB PHARM EXCIPIENTS, V9th, P898; Quinn ME, 2020, HDB PHARM EXCIPIENTS, V9th, P850	7	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	NOV	2021	46	11					70	71					2	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	XB5IC	WOS:000721361900012					2022-04-28	
J	Delgado, E; Taylor, KA; Tran, P				Delgado, Elina; Taylor, Kiernan A.; Tran, Phyllis			Treatment Updates for Metastatic Breast Cancer	US PHARMACIST			English	Article								About one in eight women will be diagnosed with breast cancer in her lifetime. Of these, 6% will have metastatic disease that carries a 5-year survival rate of about 29%. The year 2020 brought about FDA approval for three new agents targeting varying forms of metastatic breast cancer in the hope that more women will be able to successfully combat this stage of disease. The approval of Trodelvy provides a second-line treatment option for patients with triple-negative metastatic breast cancer. For patients with HER2+ metastatic breast cancer, Tukysa and Margenza are new second- and third-line options available.	[Delgado, Elina; Taylor, Kiernan A.; Tran, Phyllis] William Carey Univ, Sch Pharm, Dept Pharm Practice, Tradit Campus, Biloxi, MS 39532 USA		Delgado, E (通讯作者)，William Carey Univ, Sch Pharm, Dept Pharm Practice, Tradit Campus, Biloxi, MS 39532 USA.							0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	OCT	2021	46	10					42	46					5	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	WI6KL	WOS:000708466800011					2022-04-28	
J	Richards, T; Brown, J				Richards, Tamara; Brown, Jamal			Folate Deficiency and Neural Tube Defects in Pregnancy	US PHARMACIST			English	Article							FOLIC-ACID; NATIONAL-HEALTH; SUPPLEMENT USE; UNITED-STATES; WOMEN; RISK; PREVENTION; PREVALENCE; PHARMACIST; DECLINE	Folic acid is essential for women's health and is especially important during pregnancy. Within the first 28 days of pregnancy, the neural tube, which is responsible for the development of the brain and spine, closes. Inadequate concentrations of folate can prevent closure of the neural tube, which can lead to a neural tube defect. To prevent folate deficiency, it is recommended that all women of childbearing age use a prenatal vitamin with at least 400 mcg of folic acid and eat foods that contain folate to maintain adequate concentrations. In 1998, the United States mandated fortification of grained cereals with folate and, as a result, there was a significant reduction in both folate deficiency and neural tube defects among women and their offspring. Despite this initiative, high-risk populations such as minority, obese, and diabetic women remain at an increased risk for folate deficiency.	[Richards, Tamara; Brown, Jamal] Florida A&M Univ, Coll Pharm, Tampa, FL 33613 USA		Richards, T (通讯作者)，Florida A&M Univ, Coll Pharm, Tampa, FL 33613 USA.						American Academy of Pediatrics and American College of Obstetrics and Gynecologist, 2017, GUID PER CAR, V8th, P139; Anderson SL, 2018, ADV THER, V35, P311, DOI 10.1007/s12325-018-0671-7; [Anonymous], 1996, FED REGISTER, V61, P8781; Berenbrok LA, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.9132; Bibbins-Domingo K, 2017, JAMA-J AM MED ASSOC, V317, P183, DOI 10.1001/jama.2016.19438; Branum AM, 2017, MATERN CHILD HLTH J, V21, P715, DOI 10.1007/s10995-016-2155-1; CDC, FOL AC NEUR TUB DEF; Cheng TL, 2018, AM J PUBLIC HEALTH, V108, P799, DOI 10.2105/AJPH.2018.304355; Cleves MA, 2004, OBSTET GYNECOL, V103, P746, DOI 10.1097/01.AOG.0000117084.02395.a0; Cordero A., 2010, Morbidity and Mortality Weekly Report, V59, P980; Cordero AM, 2015, MMWR-MORBID MORTAL W, V64, P421; Correa A, 2012, AM J OBSTET GYNECOL, V206, DOI 10.1016/j.ajog.2011.12.018; Crider KS, 2018, AM J CLIN NUTR, V107, P1027, DOI 10.1093/ajcn/nqy065; Crider KS, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g4554; Crider KS, 2011, NUTRIENTS, V3, P370, DOI 10.3390/nu3030370; Dean JH, 2020, J PEDIATR-US, V226, P186, DOI 10.1016/j.jpeds.2020.07.002; Finer LB, 2011, CONTRACEPTION, V84, P478, DOI 10.1016/j.contraception.2011.07.013; Ganji V, 2006, J NUTR, V136, P153, DOI 10.1093/jn/136.1.153; Greene NDE, 2014, ANNU REV NEUROSCI, V37, P221, DOI 10.1146/annurev-neuro-062012-170354; Huang HY, 2017, OBES RES CLIN PRACT, V11, P188, DOI 10.1016/j.orcp.2016.04.005; Iqbal MZ, 2019, J PHARM BIOALLIED SC, V11, P299, DOI 10.4103/jpbs.JPBS_138_19; Jun SY, 2020, OBSTET GYNECOL, V135, P623, DOI 10.1097/AOG.0000000000003657; Kitzmiller JL, 2008, DIABETES CARE, V31, P1060, DOI 10.2337/dc08-9020; Koren G, 2021, CLIN EXP OBSTET GYN, V48, P223, DOI 10.31083/j.ceog.2021.02.2304; Loeken MR, 2005, AM J MED GENET C, V135C, P77, DOI 10.1002/ajmg.c.30056; March of Dimes, FEW HALF US WOM TAK; Medicine I.O., 1998, DIET REF INT THIAM R, P196; Murphy Bethany L., 2012, Pharmacy Pract (Granada), V10, P105, DOI 10.4321/s1886-36552012000200007; Murphy Bethany L., 2010, Pharmacy Pract (Granada), V8, P220; Ortega RM, 2009, J NUTR SCI VITAMINOL, V55, P149, DOI 10.3177/jnsv.55.149; Qu YJ, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.119.015652; Rodrigues Claire R., 2012, Pharmacy Practice (Internet), V10, P168, DOI 10.4321/s1886-36552012000300007; Scholl TO, 2000, AM J CLIN NUTR, V71, p1295S, DOI 10.1093/ajcn/71.5.1295s; Stevenson RE, 2000, PEDIATRICS, V106, P677, DOI 10.1542/peds.106.4.677; Tessema J, 2009, J AM DIET ASSOC, V109, P102, DOI 10.1016/j.jada.2008.10.013; Tinker SC, 2015, BIRTH DEFECTS RES A, V103, P517, DOI 10.1002/bdra.23378; Vincent R, 2020, J PHARM PRACT, V33, P598, DOI 10.1177/0897190018824820; WALD N, 1991, LANCET, V338, P131; Wang A, 2021, NUTRIENTS, V13, DOI 10.3390/nu13041325; Williams LJ, 2005, PEDIATRICS, V116, P580, DOI 10.1542/peds.2005-0592; Yerby MS, 2003, EPILEPSIA, V44, P33, DOI 10.1046/j.1528-1157.44.s3.4.x; Zhang L, 2021, J MATERN-FETAL NEO M, V34, P274, DOI 10.1080/14767058.2019.1606192; Zhu BB, 2016, DIABETES CARE, V39, pE36, DOI 10.2337/dc15-2389	43	0	0	3	3	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	SEP	2021	46	9					HS8	HS12					5	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	UT3BM	WOS:000697994900004					2022-04-28	
J	Burmeister, MA; Delgado, E; Fincher, TK; Virga, KG				Burmeister, Melissa A.; Delgado, Elina; Fincher, Timothy K.; Virga, Kristopher G.			Growing Pains: The Type 2 Diabetes Epidemic in Youth	US PHARMACIST			English	Article							GLUCAGON-LIKE PEPTIDE-1; HIGH BIRTH-WEIGHT; INSULIN-RESISTANCE; CHILDREN; METFORMIN; ADOLESCENTS; MELLITUS; MANAGEMENT; IMPACT; HYPERGLYCEMIA	Type 2 diabetes mellitus (T2DM) is a chronic disease characterized by insulin resistance, pancreatic beta-cell failure, hyperglycemia, and serious cardiovascular complications.The incidence of T2DM in children and adolescents is increasing at an alarming rate, especially in certain ethnic and racial minorities. Predisposition to development is impacted by genetic, social, behavioral, and environmental risk factors. In combination with a healthy diet and exercise, metformin, insulin, and liraglutide are current FDA-approved pharmacotherapies. Pharmacist engagement in multiple aspects of diabetes care has undoubtedly improved clinical outcomes in T2DM youth.	[Burmeister, Melissa A.; Fincher, Timothy K.; Virga, Kristopher G.] William Carey Univ, Sch Pharm, Dept Pharmaceut Sci, Biloxi, MS 39532 USA; [Delgado, Elina] William Carey Univ, Sch Pharm, Dept Pharm Practice, Biloxi, MS USA		Burmeister, MA (通讯作者)，William Carey Univ, Sch Pharm, Dept Pharmaceut Sci, Biloxi, MS 39532 USA.						Akhlaghi F, 2017, CLIN PHARMACOKINET, V56, P561, DOI 10.1007/s40262-016-0472-6; Alejandro EU, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21145003; Amer Diabet Assoc, 2014, DIABETES CARE, V37, pS14, DOI 10.2337/dc14-S014; American Association of Diabetes Educators, ROL DIAB ED PED DIAB; Anderson AD, 2014, SEMIN REPROD MED, V32, P202, DOI 10.1055/s-0034-1371092; Andes LJ, 2020, JAMA PEDIATR, V174, DOI 10.1001/jamapediatrics.2019.4498; Arenaza L, 2017, TRIALS, V18, DOI 10.1186/s13063-017-2117-y; Arslanian S, 2018, DIABETES CARE, V41, P2648, DOI 10.2337/dci18-0052; Batista TM, 2021, DIABETOLOGIA, V64, P994, DOI 10.1007/s00125-021-05415-5; Beaumont RN, 2017, CURR DIABETES REP, V17, DOI 10.1007/s11892-017-0852-9; Bobo WV, 2013, JAMA PSYCHIAT, V70, P1067, DOI 10.1001/jamapsychiatry.2013.2053; Brewster S, 2020, POSTGRAD MED J, V96, P473, DOI 10.1136/postgradmedj-2020-137511; Bridges HR, 2014, BIOCHEM J, V462, P475, DOI 10.1042/BJ20140620; ClinicalTrials.gov, YOUTH TYPE 2 DIABETE; Copeland KC, 2011, J CLIN ENDOCR METAB, V96, P159, DOI 10.1210/jc.2010-1642; Crane J, 2016, THER ADV CHRONIC DIS, V7, P92, DOI 10.1177/2040622315620180; Dabelea D, 2021, ANN NY ACAD SCI, V1495, P99, DOI 10.1111/nyas.14573; Diamanti-Kandarakis E, 2012, ENDOCR REV, V33, P981, DOI 10.1210/er.2011-1034; DiMeglio LA, 2018, PEDIATR DIABETES, V19, P105, DOI 10.1111/pedi.12737; Doyle ME, 2007, PHARMACOL THERAPEUT, V113, P546, DOI 10.1016/j.pharmthera.2006.11.007; Ducat L, 2014, JAMA-J AM MED ASSOC, V312, P691, DOI 10.1001/jama.2014.8040; Dulloo AG, 2006, INT J OBESITY, V30, pS23, DOI 10.1038/sj.ijo.0803516; Fowler M.J., 2008, CLIN DIABETES, V26, P77, DOI [DOI 10.2337/DIACLIN.26.2.77, DOI 10.2337/diaclin.29.3.116]; Frisina RD, 2021, HEARING RES, V402, DOI 10.1016/j.heares.2020.108093; Gunderson EP, 2008, CURR DIABETES REP, V8, P279, DOI 10.1007/s11892-008-0050-x; Gungor N, 2005, DIABETES CARE, V28, P638, DOI 10.2337/diacare.28.3.638; Hamman RF, 2014, DIABETES CARE, V37, P3336, DOI 10.2337/dc14-0574; Hattersley AT, 1999, LANCET, V353, P1789, DOI 10.1016/S0140-6736(98)07546-1; Herrada AA, 2021, OBES REV, V22, DOI 10.1111/obr.13200; Hirsch Jan D, 2017, Am J Manag Care, V23, pS231; Hughes JD, 2017, INTEGR PHARM RES PRA, V6, P15, DOI 10.2147/IPRP.S103783; Johnsson IW, 2015, PEDIATR OBES, V10, P77, DOI 10.1111/ijpo.230; Jones KL, 2002, DIABETES CARE, V25, P89, DOI 10.2337/diacare.25.1.89; Kaar JL, 2020, PEDIATR DIABETES, V21, DOI 10.1111/pedi.12976; Kansra AR, 2021, FRONT PEDIATR, V8, DOI 10.3389/fped.2020.581461; Kapadia C, 2012, INT J PEDIATR ENDOCR, DOI 10.1186/1687-9856-2012-31; Kapodistria K, 2018, J CELL MOL MED, V22, P2970, DOI 10.1111/jcmm.13259; Kasuga M, 2006, J CLIN INVEST, V116, P1756, DOI 10.1172/JCI29189; Kawahito S, 2009, WORLD J GASTROENTERO, V15, P4137, DOI 10.3748/wjg.15.4137; Khunti N, 2013, DIABETES PRIM CARE, V15, P131; Livshits A, 2009, WOMENS HEALTH, V5, P701, DOI 10.2217/WHE.09.47; Silva NDLE, 2019, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00057; Maffeis C, 2018, EUR J CLIN NUTR, V72, P1239, DOI 10.1038/s41430-018-0239-2; Maguolo A, 2020, ACTA PAEDIATR, V109, P481, DOI 10.1111/apa.15031; Marshall JC, 2012, FERTIL STERIL, V97, P18, DOI 10.1016/j.fertnstert.2011.11.036; McGavock J, 2015, CURR DIABETES REP, V15, DOI 10.1007/s11892-014-0568-z; Moran A, 1999, DIABETES, V48, P2039, DOI 10.2337/diabetes.48.10.2039; Musi N, 2002, DIABETES, V51, P2074, DOI 10.2337/diabetes.51.7.2074; Nadeau K, 2008, ENDOCR RES, V33, P35, DOI 10.1080/07435800802080138; Onge Erin St, 2015, J Pediatr Pharmacol Ther, V20, P4, DOI 10.5863/1551-6776-20.1.4; Owen MR, 2000, BIOCHEM J, V348, P607, DOI 10.1042/0264-6021:3480607; Palatianou ME, 2014, HORM METAB RES, V46, P911, DOI 10.1055/s-0034-1395561; Pena AS, 2020, MED J AUSTRALIA, V213, P30, DOI 10.5694/mja2.50666; Preiss D, 2017, DIABETES OBES METAB, V19, P356, DOI 10.1111/dom.12826; Pulgaron ER, 2014, CURR DIABETES REP, V14, DOI 10.1007/s11892-014-0508-y; Reinehr T, 2018, CURR DIABETES REP, V18, DOI 10.1007/s11892-018-1110-5; Reinehr T, 2013, WORLD J DIABETES, V4, P270, DOI 10.4239/wjd.v4.i6.270; Ruperez FJ, 2020, NUTRIENTS, V12, DOI 10.3390/nu12113310; Serbis A, 2021, WORLD J DIABETES, V12, P344, DOI 10.4239/wjd.v12.i4.344; Setty SG, 2016, POSTGRAD MED J, V92, P152, DOI 10.1136/postgradmedj-2015-133716; Singhal S, 2021, CHILDREN-BASEL, V8, DOI 10.3390/children8010037; Springer SC, 2013, PEDIATRICS, V131, pE648, DOI 10.1542/peds.2012-3496; Suliga E, 2009, NUTR RES REV, V22, P137, DOI 10.1017/S0954422409990096; Tamborlane WV, 2019, NEW ENGL J MED, V381, P637, DOI 10.1056/NEJMoa1903822; Temneanu O R, 2016, J Med Life, V9, P235; Tomas E, 2002, ANN NY ACAD SCI, V967, P43; Tsenkova V, 2014, PSYCHOSOM MED, V76, P622, DOI 10.1097/PSY.0000000000000106; Tyagi A, 2021, MOL NEUROBIOL, V58, P2672, DOI 10.1007/s12035-021-02283-3; Vajravelu ME, 2018, CURR DIABETES REP, V18, DOI 10.1007/s11892-018-1012-6; White NH, 2013, DIABETES CARE, V36, P1765, DOI 10.2337/dc12-2390; Xu HN, 2018, AM FAM PHYSICIAN, V98, P590; Zeitler P, 2018, PEDIATR DIABETES, V19, P28, DOI 10.1111/pedi.12719	72	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	AUG	2021	46	8					17	27					11	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	UB4JE	WOS:000685813400007					2022-04-28	
J	Ellis, KD; Patel, R; Phillips, A; Sarbacker, GB				Ellis, Katie D.; Patel, Roma; Phillips, Anna; Sarbacker, G. Blair			Pediatric Hypertension	US PHARMACIST			English	Article								Although prevalence of hypertension (HTN) in children and adolescents has decreased, practitioners must remain vigilant in monitoring risk factors such as diabetes and obesity. A timely diagnosis and appropriate treatment can contribute to adult cardiovascular risk reduction. Despite the declining incidence of hypertension, more children and adolescents are classified as having high blood pressure (BP) under new guidelines. The definition of HTN is based on the normal distribution of BP in healthy children. A diagnosis of hypertension can be made in a child or adolescent based on auscultatory BP measurements at three separate visits. Nonpharmacologic treatment should address modifiable risk factors; pharmacologic treatment should be initiated in hypertensive children aged 3 years and older and adolescents who are unresponsive to nonpharmacologic therapies.	[Ellis, Katie D.; Sarbacker, G. Blair] Presbyterian Coll Sch Pharm, Pharm Practice, Clinton, SC 29325 USA; [Patel, Roma; Phillips, Anna] Presbyterian Coll Sch Pharm, Clinton, SC 29325 USA		Ellis, KD (通讯作者)，Presbyterian Coll Sch Pharm, Pharm Practice, Clinton, SC 29325 USA.						Flynn JT, 2017, PEDIATRICS, V140, DOI 10.1542/peds.2017-3035; Jackson SL, 2018, MMWR-MORBID MORTAL W, V67, P758, DOI 10.15585/mmwr.mm6727a2; Krist AH, 2020, JAMA-J AM MED ASSOC, V324, P1878, DOI 10.1001/jama.2020.20122; Macumber I, 2020, PEDIATR NEPHROL, V35, P969, DOI 10.1007/s00467-019-04268-w; Metoprolol, PEDIAT NEONATAL LEXI; Torrance B, 2007, VASC HEALTH RISK MAN, V3, P139; Whelton PK, 2018, J AM COLL CARDIOL, V71, P2275, DOI 10.1016/j.jacc.2018.03.016	7	0	0	1	1	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	AUG	2021	46	8					9	12					4	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	UB4JE	WOS:000685813400003					2022-04-28	
J	Braga, SFF; Clark, KJ				Braga, Sarah F. Fowler; Clark, Kelly J.			Overview of TNF Inhibitors for Treating Inflammatory Bowel Disease	US PHARMACIST			English	Editorial Material							CROHNS-DISEASE; MAINTENANCE THERAPY; CLINICAL-RESPONSE; INFLIXIMAB; ADALIMUMAB; INDUCTION; REMISSION; MANAGEMENT	Inflammatory bowel disease (IBD) is a gastrointestinal disease marked by cycles of active disease and remission. Patients with IBD are characterized as suffering from ulcerative colitis or Crohn's disease. Although noncurative therapies are widely used, patient relapse and treatment failures lend to the difficulty in managing IBD. IBD treatment modalities encompass several drug classes, including anti-tumor necrosis factor (TNF) agents. These medications have become the mainstay in treating IBD. Guidelines discuss using TNF inhibitors alone or in combination with other agents in moderate-to-severe IBD. Patient education of IBD and anti-TNF agents is key to successful patient outcomes.	[Braga, Sarah F. Fowler; Clark, Kelly J.] South Univ Sch Pharm, Dept Pharm Practice, Columbia, SC 29203 USA		Braga, SFF (通讯作者)，South Univ Sch Pharm, Dept Pharm Practice, Columbia, SC 29203 USA.						Alatab S, 2020, LANCET GASTROENTEROL, V5, P17, DOI 10.1016/S2468-1253(19)30333-4; [Anonymous], 2021, REC AD IMM SCHED MED, P2021; [Anonymous], 2002, HUMIRA; [Anonymous], 2009, SIMPONI; [Anonymous], 1998, REMICADE; [Anonymous], 2008, CIMZIA; Colombel JF, 2007, GASTROENTEROLOGY, V132, P52, DOI 10.1053/j.gastro.2006.11.041; Feuerstein JD, 2020, GASTROENTEROLOGY, V158, P1450, DOI 10.1053/j.gastro.2020.01.006; Griffiths OR, 2020, ADV PROTEIN CHEM STR, V119, P157, DOI 10.1016/bs.apcsb.2019.08.009; Hanauer SB, 2006, GASTROENTEROLOGY, V130, P323, DOI 10.1053/j.gastro.2005.11.030; Hanauer SB, 2002, LANCET, V359, P1541, DOI 10.1016/S0140-6736(02)08512-4; Hemstreet BA, 2020, PHARMACOTHERAPY PATB, V11th; Levin AD, 2016, J CROHNS COLITIS, V10, P989, DOI 10.1093/ecco-jcc/jjw053; Lichtenstein GR, 2018, AM J GASTROENTEROL, V113, P481, DOI 10.1038/ajg.2018.27; Magro F, 2010, BIODRUGS, V24, P3, DOI 10.2165/11586290-000000000-00000; National Institute for Health and Care Excellence, 2019, ULC COL MAN; National Institute for Health and Care Excellence, 2015, INFL AD GOL TREAT MO; National Institute for Health and Care Excellence, 2019, CROHNS DIS MAN; Olesen CM, 2016, PHARMACOL THERAPEUT, V159, P110, DOI 10.1016/j.pharmthera.2016.01.001; Papamichael K, 2015, INFLAMM BOWEL DIS, V21, P182, DOI 10.1097/MIB.0000000000000202; Present DH, 1999, NEW ENGL J MED, V340, P1398, DOI 10.1056/NEJM199905063401804; Rawla P, 2018, J INFLAMM RES, V11, P215, DOI 10.2147/JIR.S165330; Reinisch W, 2011, GUT, P60080; Rubin DT, 2019, AM J GASTROENTEROL, V114, P384, DOI 10.14309/ajg.0000000000000152; Rutgeerts P, 2005, NEW ENGL J MED, V353, P2462, DOI 10.1056/NEJMoa050516; Sandborn WJ, 2007, GUT, V56, P1232, DOI 10.1136/gut.2006.106781; Sandborn WJ, 2007, NEW ENGL J MED, V357, P228, DOI 10.1056/NEJMoa067594; Sandborn WJ, 2014, GASTROENTEROLOGY, V146, P85, DOI 10.1053/j.gastro.2013.05.048; Sandborn WJ, 2014, GASTROENTEROLOGY, V146, P96, DOI 10.1053/j.gastro.2013.06.010; Sands BE, 2004, NEW ENGL J MED, V350, P876, DOI 10.1056/NEJMoa030815; Schreiber S, 2007, NEW ENGL J MED, V357, P239, DOI 10.1056/NEJMoa062897; Terdiman JP, 2013, GASTROENTEROLOGY, V145, P1459, DOI 10.1053/j.gastro.2013.10.047; Tofade T, 2018, APPL THERAPEUTICS CL, V11th, P518; Vulliemoz M, 2020, DIGESTION, V101, P16, DOI 10.1159/000506898	34	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	MAY	2021	46	5					34	37					4	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	SE9UV	WOS:000652413000015					2022-04-28	
J	Dellarocca, MA				Dellarocca, Mena Alrais			Vaccines for Severe Acute Respiratory Syndrome Coronavirus 2 Infection	US PHARMACIST			English	Article								At the end of 2019, a novel coronavirus now known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified as the cause of a cluster of pneumonia cases in Wuhan, China. In February 2020, the World Health Organization named the outbreak coronavirus disease 2019 (COVID-19), and it became a global pandemic. By the end of 2020, several vaccines had become available for use in different parts of the world. In the United States, three vaccines have been granted emergency-use authorization (EUA) for the prevention of COVID-19. As frontline workers, pharmacists are critically needed both in educating patients on safety and efficacy of vaccines and in proper administration, counseling, and monitoring.	[Dellarocca, Mena Alrais] Univ Southern Calif, Sch Pharm, Pharm Practice, Los Angeles, CA 90007 USA		Dellarocca, MA (通讯作者)，Univ Southern Calif, Sch Pharm, Pharm Practice, Los Angeles, CA 90007 USA.						ACIP COVID-19 Vaccine Working Group, 2020, PHAS ALL COVID 19 VA; CDC, CLIN CONS US COVID 1; CDC, INT CLIN CONS US COV; CDC, WHAT DO YOU HAV SEV; Dooling K, 2021, MMWR-MORBID MORTAL W, V69, P1657, DOI 10.15585/mmwr.mm695152e2; FDA, VACC REL BIOL PROD A; FDA, EM US AUTH EUA MOD C; FDA, 2021, EM US AUTH EUA PFIZ; FDA, VACC REL BIOL PROD A; FDA, FDA BRIEF DOC JANSS; FDA, EM US AUTH EUA JANSS; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Riley LE, VACCINATING PREGNANT; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; WHO, DRAFT LANDSC TRACK C; Widge AT, 2021, NEW ENGL J MED, V384, P80, DOI 10.1056/NEJMc2032195	16	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	APR	2021	46	4					21	27					7	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	SE9UN	WOS:000652412200011					2022-04-28	
J	Wu, A				Wu, Amy			Review of Hypertension in Pregnancy for Pharmacists	US PHARMACIST			English	Article							MAGNESIUM-SULFATE; PREECLAMPSIA; MANAGEMENT; ASPIRIN; WOMEN	Hypertension affects approximately 7% to 10% of all pregnancies. If left untreated, it can lead to significant maternal morbidity and mortality. Hypertension in pregnancy is defined as having a systolic blood pressure greater than 140 mm Hg and diastolic blood pressure greater than 90 mm Hg; it is classified into four types. Primary risk factors for hypertension in pregnancy include chronic hypertension, increased serum testosterone concentrations, collagen vascular disease, obesity, insulin resistance, gestational diabetes, diabetes mellitus, and thrombophilia. The mechanisms for pathogenesis are not well understood. Treatment depends on the level of blood pressure, the age of gestation, the occurrence of symptoms, and risk factors associated with them. Pharmacists provide counseling regarding drug-drug interactions, side effects, and adverse effects of antihypertensive medications.									Ananth CV, 2019, HYPERTENSION, V74, P1089, DOI 10.1161/HYPERTENSIONAHA.119.12968; [Anonymous], 2020, Obstet Gynecol, V135, P1492, DOI 10.1097/AOG.0000000000003892; [Anonymous], 2020, WHO RECOMMENDATIONS; Atallah A, 2017, DRUGS, V77, P1819, DOI 10.1007/s40265-017-0823-0; Balogun OAA, 2017, CLIN OBSTET GYNECOL, V60, P183, DOI 10.1097/GRF.0000000000000250; Braunthal S, 2019, SAGE OPEN MED, V7, DOI 10.1177/2050312119843700; Croke L, 2019, AM FAM PHYSICIAN, V100, P649; Dayicioglu V, 2003, HYPERTENS PREGNANCY, V22, P257, DOI 10.1081/PRG-120024029; Duley L, 2002, LANCET, V359, P1877, DOI 10.1016/s0140-6736(02)08778-0; Granger JP, 2001, AM J HYPERTENS, V14, p178S, DOI 10.1016/S0895-7061(01)02086-6; Kattah AG, 2013, ADV CHRONIC KIDNEY D, V20, P229, DOI 10.1053/j.ackd.2013.01.014; Kintiraki E, 2015, HORM-INT J ENDOCRINO, V14, P211, DOI 10.14310/horm.2002.1582; Phelan LK, 2004, HYPERTENS PREGNANCY, V23, P135, DOI 10.1081/PRG-120028289; Podymow T, 2008, HYPERTENSION, V51, P960, DOI 10.1161/HYPERTENSIONAHA.106.075895; Preboth M, 2000, AM FAM PHYSICIAN, V62, P1184; SCHIFF E, 1989, NEW ENGL J MED, V321, P351, DOI 10.1056/NEJM198908103210603; von Dadelszen P, 2000, LANCET, V355, P87, DOI 10.1016/S0140-6736(98)08049-0; WEITZ C, 1987, INT J GYNECOL OBSTET, V25, P35, DOI 10.1016/0020-7292(87)90181-0; Wheeler M., 2020, METHYLDOPA TABLETS	19	0	0	0	1	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	FEB	2021	46	2					45	52					8	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	QU8YE	WOS:000627563600014					2022-04-28	
J	Cummins, LE; Garrett, SJ; Kyle, JA				Cummins, Lauren E.; Garrett, Scott J.; Kyle, Jeffrey A.			Comparing Oral Antiviral Agents for Seasonal Influenza	US PHARMACIST			English	Article							OSELTAMIVIR; ADULTS	The annual influenza vaccine is the best way to reduce the risk of seasonal influenza illnesses. However, due to the limitations of the influenza vaccine and influenza-related complications, antiviral medications were developed to overcome these challenges and serve as an additional line of defense. There are four FDA-approved antiviral drugs recommended by the CDC to treat influenza, two of which are available orally: oseltamivir phosphate and baloxavir marboxil. Differences exist in their uses, dosing, and how they work. Appropriate use of these agents in both treatment and prophylaxis should be carefully considered.	[Cummins, Lauren E.; Garrett, Scott J.] Samford Univ, McWhorter Sch Pharm, Birmingham, AL 35229 USA; [Kyle, Jeffrey A.] Samford Univ, McWhorter Sch Pharm, Pharm Practice, Birmingham, AL USA		Cummins, LE (通讯作者)，Samford Univ, McWhorter Sch Pharm, Birmingham, AL 35229 USA.						[Anonymous], 2019, TAMIFLU OSELTAMIVIR; [Anonymous], 2021, XOFLUZA BALOXAVIR MA; CDC, INFL ANT MED SUMM CL; Davies BE, 2010, J ANTIMICROB CHEMOTH, V65, pII5, DOI 10.1093/jac/dkq015; Dobson J, 2015, LANCET, V385, P1729, DOI 10.1016/S0140-6736(14)62449-1; Dutkowski R, 2003, DRUG SAFETY, V26, P787, DOI 10.2165/00002018-200326110-00004; Fukao K, 2019, J ANTIMICROB CHEMOTH, V74, P654, DOI 10.1093/jac/dky462; Gavin P.J., 2004, CLIN APPL IMMUNOL RE, V4, P151, DOI DOI 10.1016/S1529-1049(03)00064-3; Hayden FG, 2018, NEW ENGL J MED, V379, P913, DOI 10.1056/NEJMoa1716197; Ikematsu H, 2020, NEW ENGL J MED, V383, P309, DOI 10.1056/NEJMoa1915341; Ison MG, 2020, LANCET INFECT DIS, V20, P1204, DOI [10.1016/S1473-3099(20)30004-9, 10.1016/51473-3099(20)30004-9]; Kazempoor D., HEALTHCARE PROVIDER; Koshimichi H, 2018, CLIN DRUG INVEST, V38, P1189, DOI 10.1007/s40261-018-0710-9; McLean HQ, 2015, OPEN FORUM INFECT DI, V2, DOI 10.1093/ofid/ofv100; Principi N, 2019, FRONT MED-LAUSANNE, V6, DOI 10.3389/fmed.2019.00109; Rubin R, 2021, JAMA-J AM MED ASSOC, V326, P899, DOI 10.1001/jama.2021.14131; Shie JJ, 2019, J BIOMED SCI, V26, DOI 10.1186/s12929-019-0567-0; Treanor J, 2019, J INFECT DIS, V219, P171, DOI 10.1093/infdis/jiy413; Uyeki TM, 2019, CLIN INFECT DIS, V68, pE1, DOI 10.1093/cid/ciy866; Yin H, 2021, MOLECULES, V26, DOI 10.3390/molecules26040810	20	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	DEC	2021	46	12					22	30					9	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	XY4CD	WOS:000736921600008					2022-04-28	
J	Saljoughian, M				Saljoughian, Manouchehr			Hypervitaminosis: A Global Concern	US PHARMACIST			English	Editorial Material							VITAMIN-A; TOXICITY		[Saljoughian, Manouchehr] Alta Bates Summit Med Ctr, Dept Pharm, Berkeley, CA 94705 USA		Saljoughian, M (通讯作者)，Alta Bates Summit Med Ctr, Dept Pharm, Berkeley, CA 94705 USA.						American Association of Poison Control Centers' National Poison Data System, ANN REPORTS; Bjelakovic G, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007470.pub2; BURTON GW, 1990, ANNU REV NUTR, V10, P357, DOI 10.1146/annurev.nutr.10.1.357; Charen E, 2020, ADV CHRONIC KIDNEY D, V27, P67, DOI 10.1053/j.ackd.2019.08.003; Elango G., 2015, International Journal of Biomedical Research, V6, P151; Elshama SS, 2016, TURK J MED SCI, V46, P524, DOI 10.3906/sag-1411-6; Evans HM, 1925, P NATL ACAD SCI USA, V11, P334, DOI 10.1073/pnas.11.6.334; Rodahl K, 1943, BIOCHEM J, V37, P166, DOI 10.1042/bj0370166; Roop JK., 2018, INT J HEAL SCI RES, V8, P280; SCHAUMBURG H, 1983, NEW ENGL J MED, V309, P445, DOI 10.1056/NEJM198308253090801; Sizer FS, 2008, NUTR CONCEPTS CONTRO, V11th, P221	11	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	OCT	2021	46	10					47	50					4	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	WI6KL	WOS:000708466800012					2022-04-28	
J	[Anonymous]				[Anonymous]			Enzymes Protect Skin by Ignoring Microbes and Viruses	US PHARMACIST			English	News Item																		0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	AUG	2021	46	8					38	38					1	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	UB4JE	WOS:000685813400014					2022-04-28	
J	Allen, LV				Allen, Loyd V., Jr.			Finasteride 0.1% and Minoxidil 6% Topical Gel	US PHARMACIST			English	Editorial Material									[Allen, Loyd V., Jr.] Univ Oklahoma, Coll Pharm, Oklahoma City, OK 73104 USA		Allen, LV (通讯作者)，Univ Oklahoma, Coll Pharm, Oklahoma City, OK 73104 USA.						Allen Loyd V Jr, 2019, Int J Pharm Compd, V23, P299; Allen Loyd V Jr, 2019, Int J Pharm Compd, V23, P211; Fulzele SS, 2021, HDB PHARM EXCIPIENTS, V9th, P515; Quinn ME, 2021, HDB PHARM EXCIPIENTS, V9th, P404; Quinn ME, 2021, HDB PHARM EXCIPIENTS, V9th, P867; U.S. Pharmacopeia, 2021, US PHARM NAT FORM CU	6	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	JUN	2021	46	6					58	59					2	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	SR7UE	WOS:000661251200013					2022-04-28	
J	Alrais, M				Alrais, Mena			Urinary Incontinence in Men	US PHARMACIST			English	Article								Urinary incontinence (UI) is an involuntary leakage of urine, and various types of male UI differ in their etiologies, clinical manifestations, and treatments. While working with patients, pharmacists should be aware that men may be reluctant to bring incontinence to the attention of their clinician. The work-up of transient UI typically involves identifying possible reversible causes and often implicates drug classes that impair urine flow, bladder contractions, or cognition. Adjunctive and nonpharmacologic care may be used initially, but more severe symptoms require medications and/or surgery, depending on the patient's preference and predominating symptomology.	[Alrais, Mena] Univ Southern Calif, Sch Pharm, Pharm Practice, Los Angeles, CA 90007 USA		Alrais, M (通讯作者)，Univ Southern Calif, Sch Pharm, Pharm Practice, Los Angeles, CA 90007 USA.							0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	JUN	2021	46	6					4	9					6	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	SR7UE	WOS:000661251200002					2022-04-28	
J	[Anonymous]				[Anonymous]			What Is Allergic Rhinitis?	US PHARMACIST			English	Editorial Material							EFFICACY; SAFETY	Rhinitis means inflammation of the nasal passages. It is caused by a nasal reaction to an allergen, a substance that can cause an allergic reaction. Common allergens include pollen, trees, weeds, dust, mold, and animal dander. Allergic rhinitis can be considered seasonal, only occurring during a particular time of year, or perennial, where symptoms are experienced all year. Symptoms can vary but may include a runny nose; sneezing; itchy nose, eyes, or throat; and watery eyes. If you have a fever, body aches, or a sore throat, this may mean you may have a cold.									Allan GM, 2014, CAN MED ASSOC J, V186, P190, DOI 10.1503/cmaj.121442; American College of Allergy Asthma & Immunology, ENV TRIGGER AVOIDANC; Bhattacharyya N, 2011, LARYNGOSCOPE, V121, P1830, DOI 10.1002/lary.22034; Bousquet J, 2008, ALLERGY, V63, P1, DOI 10.1111/j.1398-9995.2007.01594.x; Dykewicz MS, 2017, ANN ALLERG ASTHMA IM, V119, P489, DOI 10.1016/j.anai.2017.08.012; Dykewicz MS, 2010, J ALLERGY CLIN IMMUN, V125, pS103, DOI 10.1016/j.jaci.2009.12.989; Egan Maureen, 2015, Asthma Res Pract, V1, P8; Ferguson BJ, 2008, OTOLARYNG CLIN N AM, V41, P411, DOI 10.1016/j.otc.2007.11.006; Greiner AN, 2011, LANCET, V378, P2112, DOI 10.1016/S0140-6736(11)60130-X; Hadley James A, 2012, J Fam Pract, V61, pS11; Hatton RC, 2007, ANN PHARMACOTHER, V41, P381, DOI 10.1345/aph.1H679; Head K, 2018, Cochrane Database Syst Rev, V6; Herman H, 2007, AM J RHINOL, V21, P70, DOI 10.2500/ajr.2007.21.2896; Malone M, INT ALLER MEDICATION; Meltzer Eli O, 2012, Allergy Asthma Proc, V33 Suppl 1, pS113, DOI 10.2500/aap.2012.33.3603; Meltzer Eli O, 2012, J Fam Pract, V61, pS5; Meltzer EO, 2011, ANN ALLERG ASTHMA IM, V106, pS12, DOI 10.1016/j.anai.2010.10.014; Melvin TAN, 2011, OTOLARYNG CLIN N AM, V44, P727, DOI 10.1016/j.otc.2011.03.010; Mir E, 2012, ASIA PAC ALLERGY, V2, P93, DOI 10.5415/apallergy.2012.2.2.93; Mortuaire G, 2013, EUR ANN OTORHINOLARY, V130, P137, DOI 10.1016/j.anorl.2012.09.005; Radcliff S, 2015, J AM GERIATR SOC, V63, P2227, DOI 10.1111/jgs.13702; Seidman MD, 2015, OTOLARYNG HEAD NECK, V152, pS1, DOI 10.1177/0194599814561600; Simons FER, 2008, WORLD ALLERGY ORGAN, V1, P145, DOI 10.1097/WOX.0b013e318186fb3a; Skoner DR, 2001, J ALLERGY CLIN IMMUN, V108, pS2, DOI 10.1067/mai.2001.115569; Sur DKC, 2015, AM FAM PHYSICIAN, V92, P985; Wallace DV, 2008, J ALLERGY CLIN IMMUN, V122, pS1, DOI 10.1016/j.jaci.2008.06.003	26	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	MAY	2021	46	5					45	46					2	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	SE9UV	WOS:000652413000020					2022-04-28	
J	Dellarocca, MA				Dellarocca, Mena Alrais			Evidence-Based Management of Nonspecific Low Back Pain in Adults	US PHARMACIST			English	Article								To improve the knowledge base concerning the evaluation and treatment of nonspecific low back pain in adult patients, the Low Back Pain Work Group of the North American Spine Society's Evidence-Based Guideline Development Committee and the U.S. Department of Veterans Affairs and the U.S. Department of Defense both recently developed evidence-based clinical practice guidelines (CPG), which serve as an additional resource of updated evidence to the 2017 American College of Physicians CPG. These CPG have been created to aid practitioners in the evaluation and treatment of adult patients with nonspecific low back pain. Patients who have back pain often come into the pharmacy; therefore, community pharmacists should be aware of recent updated evidence in order to effectively counsel on both nonpharmacologic and pharmacologic care.	[Dellarocca, Mena Alrais] Univ Southern Calif, Sch Pharm, Los Angeles, CA 90007 USA		Dellarocca, MA (通讯作者)，Univ Southern Calif, Sch Pharm, Los Angeles, CA 90007 USA.							0	0	0	0	1	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	MAR	2021	46	3					48	57					10	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	QU8YG	WOS:000627563800013					2022-04-28	
J	Backes, JM; Hilleman, DE				Backes, James M.; Hilleman, Daniel E.			Lipid-Lowering Therapies: A Review of Current and Future Options	US PHARMACIST			English	Article							DISEASE	Lipid-lowering therapy is used to reduce the risk of atherosclerotic cardiovascular disease (ASCVD), with statins being the drugs of choice. Despite the use of statins, the risk of additional cardiovascular events persists. Based on lipid levels and estimates of ASCVD risk, statins are used in combination with other lipid-lowering therapies, such as ezetimibe, proprotein convertase subtilisin/kexin type 9 inhibitors, and eicosapentaenoic acid-only omega-3 fatty acids. Overall, combinations of fenofibrate or niacin with a statin have failed to reduce ASCVD risk. Potentially effective drugs with novel lipid-lowering mechanisms are currently being investigated in clinical trials for use in patients with ASCVD or familial hypercholesterolemia.	[Backes, James M.] Univ Kansas, Med Ctr, KU Sch Pharm, Clin & Med Ctr Affairs, Lawrence, KS 66045 USA; [Backes, James M.] Univ Kansas, Med Ctr, KU Sch Pharm, Atherosclerosis & LDL Apheresis Ctr, Lawrence, KS 66045 USA; [Hilleman, Daniel E.] Creighton Univ, Sch Pharm & Hlth, Pharm Practice, Omaha, NE 68178 USA		Backes, JM (通讯作者)，Univ Kansas, Med Ctr, KU Sch Pharm, Clin & Med Ctr Affairs, Lawrence, KS 66045 USA.; Backes, JM (通讯作者)，Univ Kansas, Med Ctr, KU Sch Pharm, Atherosclerosis & LDL Apheresis Ctr, Lawrence, KS 66045 USA.						Baigent C, 2010, LANCET, V376, P1670, DOI 10.1016/S0140-6736(10)61350-5; Benjamin EJ, 2019, CIRCULATION, V139, pE56, DOI 10.1161/CIR.0000000000000659; Bhatt DL, 2019, NEW ENGL J MED, V380, P11, DOI 10.1056/NEJMoa1812792; Catapano AL, 2020, CURR ATHEROSCLER REP, V22, DOI 10.1007/s11883-020-00847-7; DAWBER T. R., 1957, AMER JOUR PUBL HEALTH, V47, P4, DOI 10.2105/AJPH.47.4_Pt_2.4; DAWBER TR, 1959, AM J PUBLIC HEALTH N, V49, P1349, DOI 10.2105/AJPH.49.10.1349; Dyrbus K, 2020, J CLIN LIPIDOL, V14, P16, DOI 10.1016/j.jacl.2019.11.001; Fonarow GC, 2019, JAMA CARDIOL, V4, P691, DOI 10.1001/jamacardio.2019.1647; Ginsberg HN, 2010, NEW ENGL J MED, V362, P1563, DOI 10.1056/NEJMoa1001282; Grundy SM, 2019, J AM COLL CARDIOL, V73, pE285, DOI 10.1016/j.jacc.2018.11.003; Hilleman DE, 2020, ADV THER, V37, P656, DOI 10.1007/s12325-019-01211-1; Jackevicius CA, 2002, JAMA-J AM MED ASSOC, V288, P462, DOI 10.1001/jama.288.4.462; Jia XM, 2020, CURR ATHEROSCLER REP, V22, DOI 10.1007/s11883-020-00856-6; Kastelein JJP, 2008, NEW ENGL J MED, V358, P1431, DOI 10.1056/NEJMoa0800742; Ling H, 2012, POSTGRAD MED, V124, P43, DOI 10.3810/pgm.2012.11.2612; Newman CB, 2015, JAMA-J AM MED ASSOC, V313, P1011, DOI 10.1001/jama.2015.1335; Nurmohamed NS, 2020, EXPERT REV CARDIOVAS, V18, P355, DOI 10.1080/14779072.2020.1768848; Ouchi Y, 2019, CIRCULATION, V140, P992, DOI 10.1161/CIRCULATIONAHA.118.039415; Sabatine MS, 2017, NEW ENGL J MED, V376, P1713, DOI [10.1056/NEJMoa1615664, 10.4997/JRCPE.2017.212]; Saeed A, 2018, CARDIOL CLIN, V36, P257, DOI 10.1016/j.ccl.2017.12.007; Schwartz GG, 2018, NEW ENGL J MED, V379, P2097, DOI 10.1056/NEJMoa1801174; Soppert J, 2020, ADV DRUG DELIVER REV, V159, P4, DOI 10.1016/j.addr.2020.07.019; Stancu C, 2001, J CELL MOL MED, V5, P378, DOI 10.1111/j.1582-4934.2001.tb00172.x	23	0	0	0	2	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	FEB	2021	46	2					HS2	HS11					10	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	QU8YE	WOS:000627563600003					2022-04-28	
J	Sayre, TJ; Sucher, AJ				Sayre, T. J.; Sucher, Allana J.			Cardiovascular Impact of Coronavirus Disease 2019 (COVID-19)	US PHARMACIST			English	Article								Coronavirus disease 2019 (COVID-19) is an infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although COVID-19 primarily affects the respiratory system, it can also cause cardiovascular complications. Patients with pre-existing cardiovascular comorbidities are at risk for greater severity of illness and mortality. The cardiovascular effects of medications that may be used to treat COVID-19, as well as the impact of medications used for underlying cardiovascular conditions, are important considerations. Pharmacists should be aware of the potential cardiovascular impact of COVID-19.	[Sayre, T. J.; Sucher, Allana J.] Regis Univ, Sch Pharm, Pharm Practice, Denver, CO 80221 USA		Sayre, TJ (通讯作者)，Regis Univ, Sch Pharm, Pharm Practice, Denver, CO 80221 USA.		Lin, Chen/AFV-2163-2022					0	0	0	0	0	JOBSON PUBLISHING LLC	NEW YORK	100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA	0148-4818	2331-3501		US PHARM	US Pharm.	FEB	2021	46	2					17	20					4	Pharmacology & Pharmacy	Emerging Sources Citation Index (ESCI)	Pharmacology & Pharmacy	QU8YE	WOS:000627563600007					2022-04-28	
